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Summary
The small (S), medium (M), and large (L) surface antigens of Hepatitis B virus 
(HBV) are found in the virion envelope. They are initially synthesised in infected 
cells as multispanning transmembrane proteins of the endoplasmic reticulum (ER). 
These proteins perform many roles in the life cycle of the virus. Specifically, they 
play a crucial role in initiating the infection through virus attachment and entry into 
the target cells, and subsequently in the assembly and morphogenesis of the HBV 
virion. The surface antigens mediate these processes through interaction with each 
other, with HBV core and viral nucleic acid, and with host cell proteins. The major 
aim of this study was to investigate the protein-protein interactions of the HBV 
structural proteins in order to enhance our understanding of the mechanisms 
involved in these processes. To carry out this work, an extensive array of specific 
reagents was initially generated in house and characterised. These include 
monoclonal and polyclonal antibodies (MAbs and PAbs, respectively) to the preSl 
domain of the HBV L protein, and novel cell lines derived from primary human 
hepatocytes. Additional reagents were obtained from elsewhere. Furthermore, the 
genes encoding the HBV surface antigens and core were cloned and expressed 
using a recombinant vaccinia virus and bacterial systems. Using specific antibodies, 
the heterologous expression of the HBV proteins was confirmed in several assays.
HBV displays a strong tropism for human hepatocytes and cannot be propagated 
efficiently in cell culture. However, under certain conditions, the virus can replicate 
in cell lines of hepatic origin. Most hepatocyte cell lines in existence are derived 
from tumours, thus are likely to display aberrant gene expression in comparison 
with healthy hepatocytes. The failure of the virus to replicate efficiently in cell 
culture may be due to the lack of certain hepatocyte-specific functions in the cells. 
In this study, two hepatocyte cell lines, H5 and H I6 were generated in house from 
healthy liver tissue and were examined for expression of certain proteins known to 
be associated with hepatocyte phenotype. The results suggested that cell lines H5 
and HI 6 are likely to have retained at least some of the hepatocyte gene expression, 
and have not reverted to a fibroblast phenotype. Both cell lines H5 and H I6, as well 
as established cell lines (such as HepG2) were used for the study of the protein- 
protein interactions of the HBV structural antigens.
A detailed antigenic characterisation of the anti-L MAbs showed that all recognised 
a linear epitope on the preSl domain of the L protein. Interestingly, a previously 
uncharacterised anti-S MAb, 6B1, specific for a conformation-sensitive epitope in S, 
recognised S and M proteins, but not L in immunoprecipitation and 
immunofluorescence assays. These results provide the first biochemical evidence 
for the existence of important structural differences in the S moiety of L from that 
in M and S. Such differences have not been predicted in existing models of HBV 
surface antigen topology. The significance of a difference in the topology or 
conformation of the S domain of L in comparison with that of HBsAg is discussed.
The intracellular distribution of the HBV proteins expressed in this study was in 
keeping with previously published data. Recent studies show that amino acid 
peptides corresponding to regions within L and S bind HBV core in in vitro assays. 
However, to-date these interactions have not been demonstrated in cell culture. In 
this study, the interaction of the surface antigens with the core protein was 
investigated. Confocal microscopy analysis showed that the core protein when 
expressed singly localised throughout the cytoplasm and the nucleus. However, in 
the presence of the L protein the intracellular distribution of core changed to a 
tightly defined perinuclear region where L is normally localised, indicating co­
localisation of core with the L protein. Furthermore, the core protein also co­
localised with a secreted form of L (Lx) protein. In confocal microscopy assays, 
the L (or Lx) protein co-localised with core was readily detected by three out of 
four of our anti-L MAbs. However, one MAb, RC28, failed to recognise L co­
localised with core. This indicated that the amino acid residues in the epitope of 
preSl recognised by MAb RC28 may play a critical role in L-core interaction. 
Alternatively, the failure of MAb RC28 to recognise L bound to core may be due to 
conformational changes in the preS 1 domain of L induced by the interaction. In 
contrast with L (and Lx), the M and S proteins failed to affect the cellular 
distribution of core. The failure of core to co-localise with M or S in the confocal 
microscopy assay is not consistent with the published in vitro binding data. It is 
likely that L is fulfilling a scaffolding role in the virion morphogenesis process, 
where there is a small contribution to the L-core binding from the S domain of L. It 
is furthermore likely that S is unable to bind sufficiently strongly to the core to
facilitate an intracellular redistribution, pointing to a minor role, if any, of S in the 
morphogenesis process. Taken together, this data adds considerably to the existing 
body of literature, and enhances our understanding of the virion morphogenesis 
process.
The HBV L protein has been implicated in binding via its preSl domain to a cell 
surface receptor. To further understand the mechanism of the attachment of the L 
protein to cells, the preSl domain was expressed in bacteria and purified. This 
protein was investigated for its ability to bind hepatocytes by flow cytometry. A 
specific and inhibitable binding of the preSl domain of HBV L protein to HepG2 
and H5 cell lines, but not other non-human or non-hepatocyte cell lines, was 
demonstrated. This indicated that the preSl domain recognised a human 
hepatocyte-specific receptor(s). Interestingly, the preSl domain bound to H5 cells 
much more efficiently than to HepG2 and the binding was subject to inhibition by 
the peptide corresponding to amino acid 21-27 of the preSl domain, which has 
been implicated in receptor recognition. Thus, the flow cytometry assay developed 
in this study and the availability of cell lines such as H5 should aid in future studies 
to identify and clone the receptor(s) for preS 1.
Table of contents
Page
ACKNOWLEDGEMENTS i
SUMMARY ii
TABLE OF CONTENTS v
LIST OF FIGURES AND TABLES viii
ABBREVIATIONS x
Chapter 1 Introduction. 1
1.1 Genome organisation. 2
1.2 Polypeptides encoded by HBV. 3
1.2.1 The core and pre-core proteins. 3
1.2.3 The X Protein. 5
1.2.3 The surface antigens. 6
1.2.4 The polymerase. 10
1.3 Virion Morphogenesis. 11
1.4 Existing in vitro systems for the propagation of HBV. 13
1.5 Putative receptors for HBV and mechanisms of uptake. 15
1.5.1 Receptors for L protein. 15
1.5.2 Receptors for the M protein. 18
1.5.3 Receptors for S protein. 18
1.5.4. Receptors for Duck Hepatitis B Virus. 20
1.6 Project aims. 23
Chapter 2 Materials and Methods. 24
Radiochemicals. 24
Solutions. 24
Chemicals and reagents. 24
2.1 Bacterial strains. 25
2.2 Expression and purification of the preS 1 domain. 26
2.3 Nucleic acid manipulations. 26
2.4 Electrophoresis of nucleic acids. 27
2.5 Sodium-dodecyl sulphate polyacrylamide gel electrophoresis. 27
2.6 Western blotting. 28
2.7 Immunoprecipitations. 29
2.8 Preparation of samples for Cryo-Electron Microscopy. 30
2.9 Scanning electron microscopy. 31
2.10 Generation of Polyclonal antibodies. 31
2.11 Generation of monoclonal antibodies. 32
2.12 Purification of MAb RC28. 33
2.13 Production of peptides representing the preS 1 domain. 34
2.14 Epitope mapping of monoclonal antibodies. 34
2.15 Cell culture. 35
2.16 Purification of vLx. 35
2.17 Generation of the hepatocyte-derived cell lines. 36
2.18 Cloning of HBV structural genes. 36
2.19 Generation of the recombinant vaccinia viruses. 3 8
2.20 Confocal microscopy. 39
2.21 Fluorescence-Activated Cell Sorting. 40
v
Chapter 3 Generation and Characterisation of reagents. 42
3.1 Expression and purification of the preSl domain. 42
3.2 Generation and characterisation of recombinant vaccinia 44
viruses expressing HBV structural proteins.
3.2.1 Expression of L, Lx, M, S and core in cells. 44
3.3 Generation and Characterisation of Antisera. 46
3.3.1 Polyclonal Antisera 142 and 143. 46
3.3.2. Monoclonal antibodies. 47
3.3.3. Monoclonal Antibody 6B1. 49
3.3.4. Isotype determination. 50
3.4 Peptide characterisation. 50
3.5. Epitope Mapping of MAbs. 51
3.6 Purification of MAb RC28. 52
3.7 Preparation and Characterisation of Proteins for 
Ligand-Binding Assays. 53
3.8 Discussion. 54
Chapter 4 Generation and partial characterisation of novel
hepatocyte-derived cell lines. 56
4.1 Analysis of novel and established cell lines for expression
of hepatocyte-speciflc proteins. 58
4.1.1. Cytokeratins 8 and 18. 58
4.1.2 Albumin. 58
4.1.3. Alpha-fetoprotein. 59
4.1.4. Alpha (1 )-antitrypsin. 59
4.1.5. Apolipoprotein-la. 60
4.1.2. Annexin V. 61
4.2 Discussion. 62
Chapter 5 Investigations into the structure of the surface
antigens of HBV. 65
5.1 Intracellular localisation of HBV surface antigens. 66
5.2 Evaluation of anti-S MAbs for antigen recognition. 67
5.3 Co-expression of L and S. 68
5.4 Analysis of the interactions between L, Lx, M and S
by immunoprecipitation. 70
5.5 Discussion. 71
Chapter 6 Investigation of the interaction between HBV core
and L proteins. 75
6.1 Intracellular localisation of HBV core protein. 76
6.2 Co-expression of L and core. 76
6.3 Co-expression of Lx and core. 78
6.4 Co-expression of Core with M and S. 79
6.5 Discussion. 79
vi
Chapter 7 Ligand binding assays. 84
7.1. Binding of preS 1 domain to hepatocytes. 84
7.2. Binding of HepB3 and Lx protein to hepatocytes. 87
7.3 Discussion. 89
Chapter 8 Conclusions. 91
Appendix 1 Antisera 95
Appendix 2 Sequence information 96
Bibliography. 98
vii
List of Figures. Follows page
Figure 1.1. Organisation of the HBV genome. 2
Figure 1.2. Morphology of the virion and sub-viral particles. 3
Figure 1.3. Putative model of spatial arrangement of HBsAg 
envelope proteins. 3
Figure 2.1. Plasmid constructs used in this study. 38
Figure 3.1. Expression and purification of HBV preSl domain
from E. Coli. 43
Figure 3.2. Verification of the identity of the purified
protein as the preS 1 domain fusion protein. 43
Figure 3.3. Characterisation of HBV structural antigens. 45
Figure 3.4. Characterisation of HBV structural antigens. 45
Figure 3.5. Characterisation of PAbs 142 and 143 by Western
immunoblotting. 46
Figure 3.6. Characterisation of the PAbs 142 and 143 by
Immunoprecipitation. 47
Figure 3.7. Characterisation of the PAb 142 by
immunofluorescence. 47
Figure 3.8. Characterisation of PAb 143 in immunofluorescence 
assays. 47
Figure 3.9. Characterisation of MAbs RC9, RC28, RC109 and 
RC152 by immunoblot. 48
Figure 3.10. Immunoprecipitation of L and Lx by a cocktail 
of monoclonal antisera. 48
Figure 3.11. Characterisation of MAbs RC9 and RC28 by 
immunofluorescence. 48
Figure 3.12. Characterisation of MAbs RC 109 and RC152 
in immunofluorescence assays. 48
Figure 3.13. Characterisation of MAb 6B1 by Immunoprecipitation 
of HBsAg. 49
Figure 3.14. Characterisation of MAb 6B1 by immunofluorescence. 49
Figure 3.15. Determination of molecular weights of the purified peptides. 50
Figure 3.16. Epitope mapping of MAbs RC 9, RC28, RC109,
RC152 and MAb 18/7 with inhibitory peptides. 51
Figure 3.17 G. Purification of MAb RC28 from serum-free medium. 52
Figure 3.18. Characterisation of proteins used in ligand-binding assays. 53
Figure 4.1 Analysis of expression of cellular markers in COS-7 cells. 62
Figure 4.2 Analysis of expression of cellular markers in HepG2 cells. 62
Figure 4.3Analysis of expression of cellular markers in H5 cells. 62
Figure 4.4 Analysis of expression of cellular markers in HI 6 cells. 62
Figure 4.5 Evaluation of novel and established cell lines for the 
expression of annexin V. 62
Figure 5.1. Characterisation of the intracellular distribution 
of L protein in HepG2 cells. 66
Figure 5.2. Colocalisation of S and M with intracellular membranes. 66
Figure 5.3 Recognition of HBV surface antigens by MAbs directed 
against HBsAg. 67
Figure 5.4 Recognition of M and S by MAb 6B1. 68
Figure 5.5 Co-expression of L and S in HepG2 cells. 68
Figure 5.6 Co-expression of L and S in HepG2 cells. 68
Figure 5.7 Co-expression of Lx and S in HepG2 cells. 69
Figure 5.8 Co-expression of L and M in HepG2 cells. 69
Figure 5.9. Co-expression of Lx and M in HepG2 cells. 69
Figure 5.10 MAb 6B1 recognises S but not L or Lx by 
immunoprecipitation. 70
Figure 6.1 Colocalisation of core and L in HepG2 cells. 76
Figure 6.2 Colocalisation of core in H5 cells expressing core and L. 76
Figure 6.3 Colocalisation of core and L in HeLa cells. 76
Figure 6.4 Intracellular distribution of Core and L in H5 cells. 76
Figure 6.5 Intracellular distribution of Core and L in H5 cells. 76
Figure 6.6 Colocalisation of core and Lx in HepG2 cells. 78
Figure 6.7 Colocalisation of core and Lx in H5 cells. 78
Figure 6.8 Colocalisation of core and Lx in HeLa cells. 78
Figure 6.9 Intracellular distribution of Core and Lx in H5 cells. 78
Figure 6.10. Failure of recognition of L-core with RC28. 78
Figure 6.11 HepG2 cells expressing both core and M. 79
Figure 6.12 HepG2 cells expressing core and vHBsAg. 79
Figure 7.1 HBV preSl domain binding to HepG2 and BHK cells. 85
Figure 7.2 HBV preSl domain binding to non-hepatocyte cells. 86
Figure 7.3 Hepagene binding to HepG2, COS-7 and H5 cells. 87
Figure 7.4 Assessment of vLx protein binding to H5 cells. 87
Figure 7.5. Confocal-based assay to assess vLx binding to plasma 
membranes of HepG2, COS-7 and H5 cells. 88
Figure 7.6. Scanning Electron Microscopy-based assay to assess 
preSl domain binding to plasma membranes of COS-7 cells. 88
List of Tables. Follows page
Table 1. Peptide production, purification and characterisation. 50
Table 2. Summary of results for the expression of markers in
novel and established cell lines. 62
Abbreviations
Complementary DNA cDNA
Deoxyribonucleic acid DNA
Duck Hepatitis B Virus DHBV
Dulbecco’s Modified Eagle’s Medium DMEM
Endoplasmic Reticulum ER
Endoplasmic Reticulum-Golgi intermediate compartment ERGIC
Fetal Calf Serum FCS
Hepatitis B Virus HBV
Hepatitis C Virus HCV
Hepatocellular carcinoma HCC
Human Immunodeficieny Virus HIV
Immunoprecipitation IP
Kilobases kb
KiloDaltons kD
Messenger RNA mRNA
Microgram ug
Microlitre uL
Milligram mg
Millilitre mL
Molar M
Nanogram ng
Open Reading Frame ORF
Phosphate Buffered Saline PBS
Polyacrylamide Gel Electrophoresis PAGE
Polyethylene Glycol PEG
Polymerase Chain Reaction PCR
Ribonucleic Acid RNA
Sodium Dodecyl Sulphate SDS
Chapter One
Introduction
Human hepatitis B virus (HBV) is the prototypic member of the family 
Hepadnaviridae, which includes avian, primate and rodent hepatitis viruses. All 
hepadnaviruses share the property of restricted host range, a strong, but not exclusive, 
tropism for hepatocytes, and the ability to cause liver damage. HBV is a major 
human pathogen causing a chronic inflammatory liver disease often leading to the 
development of hepatocellular carcinoma (HCC). The clinical significance of HBV is 
easily demonstrated by the fact that more than 250 million people throughout the 
world are chronically infected. The portion of the population that is infected with 
HBV is exposed to a risk of developing HCC that is 200 times that seen in the 
uninfected population (Milich et al., 1994). Thus, HCC is one of the most frequently 
occurring cancers, with peak incidence where HBV infection is endemic. The overall 
risk of HCC increases with age: Asian patients have an average age of 50, whereas 
African patients have a shorter life expectancy, due to the higher incidence of HBV 
carriers in Africa, compounded with other factors such as the presence of aflatoxins in 
poorly preserved foodstuffs (Milich et al., 1994). Animal models have given useful 
data on the development of HCC in populations infected with Woodchuck hepatitis 
virus (WHV), Duck hepatitis B virus (DHBV) and Ground Squirrel hepatitis virus 
(GSHV). The woodchuck data reported a risk of 100% for development of HCC 
within three years of WHV infection, and data from ground squirrels has given a risk 
of 7% for HCC development. Human data has shown that in 80-90% of cases of 
HCC, HBV DNA is capable of insertion into the host chromosomal DNA (Chen et 
al., 1986) and is found in the liver tissue of patients (Dejean and de The, 1990). The 
ability of HBV to integrate its DNA into the host chromosomes is an important factor 
in the disease pathogenesis. It is not likely, however, that HBV is acutely 
transforming, due to the large lapse in time between infection and HCC.
1.1 Genome organisation
HBV has a relaxed circular partially double stranded DNA genome of approximately
3.2 kb (Fig. 1.1). The HBV genome consists of a complete long strand (termed the 
minus strand) of constant length with a free 3' terminus and a 5' terminus linked
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covalently to a small protein (TP). The short strand (positive strand) of DNA is 
incomplete and heterogeneous in length, varying between 15-60% of the length of the 
long strand (Fig. 1). The 5' ends of both S and L strands are base paired, assuring the 
relaxed circular form of the genome. There are also 11-base pair direct repeats 
(5TTCACCTCTGC) at the 5' ends, known as DR1 and DR2, which serve as a 
template for the synthesis of pregenomic RNA (Bartenschlager and Schaller, 1993). 
Important differences exist between the hepadnaviruses infecting different species. In 
comparison with the HBV, the avian hepadnaviruses possess no X gene, and no preS2 
gene. Primate hepadnaviruses have been isolated and found to share similar genomic 
organisation with HBV (Lanford et al., 1998).
The HBV replication cycle is poorly understood due to the lack of a suitable in-vitro 
culture system for examining the viral replication. However, some major steps have 
been characterised and these are briefly summarised. Following infection, the HBV 
genome is transported to the nucleus and converted to covalently closed circular 
(CCC) DNA to yield a double-stranded genome which serves as a template for 
transcription by the host cell RNA polymerase II. Transcription of the template gives 
rise to pregenomic mRNA and three sub-genomic mRNAs. The 3.5 kB pregenomic 
mRNA is produced with redundant ends and is used for the translation of the core 
protein and polymerase enzyme. Following transport of the pre-genomic mRNA and 
translation in the cytoplasm, selective encapsidation of the RNA into the nucleocapsid 
ensues, along with encapsidation of RNA polymerase. In the immature capsid, the
3.5 kB mRNA is reverse transcribed, to yield the minus strand. The RNA is degraded 
and the DNA strand is replicated, producing the second, shorter DNA strand. Early 
in the infection cycle, the cellular burden of viral DNA is amplified following the 
transportation of the mature nucleocapsid to the nucleus in order for replication to 
repeat. Viral surface proteins are produced at a later stage of the infection process, 
where subgenomic mRNAs are produced and translated. Nucleocapsids containing 
DNA genomes then acquire their outer envelope, probably by budding into the 
endoplasmic reticulum (ER) in areas where transmembrane HBsAg are inserted. The 
resulting Dane particles are then transported from the cell by normal pathways of 
vesicular transport. The particles are assembled and released without cell lysis, with 
no evidence of injury to host cells (Bruss et al., 1996a; Yen, 1993).
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Figure 1.1 Organisation of the HBV genome.
The physical, genetic and transcriptional map o f  HBV genome. The inner circles represent 
the viral DNA genome. The terminal redundancy is at the 5 ’ end o f  the minus strand. The 
open reading frames are depicted as open arrows. The P re-S i,  PreS-2 and S regions are for 
the HBsAg. TP is the terminal protein, followed by the polymerase and RNase H. The X is 
the transcribed region for the HBx protein, and the Pre-Core and C denote the Precore and 
Core protein, respectively. DR1 and DR2 are the direct repeats. The encapsidation signal is 
shown as 8 (Bartenschlager & Schaller, 1993).
There are two enhancers in HBV that are capable of upregulating transcription. The 
first enhancer (Enl) is capable of upregulating all four promoters, as shown by studies 
using plasmids or recircularised genomic DNA, by up to two orders of magnitude. 
Certain transcription factors found in hepatocytes (e.g. c/EBP, and another factor of 
unknown identity called HBLF) appear to bind to Enl (Chen et al., 1994; Garcia, 
et.al, 1993). A second enhancer (Enll) has the effect of upregulating the S promoter 
by approximately one order of magnitude. Identification of multiple transcription 
factors, HLF, FTF, HNF3 and E4BP4 binding to and controlling hepatitis B virus 
enhancer II has enhanced our understanding of the control of replication of HBV 
(Ishida et al., 2000; Li et al., 1995). A clearer understanding of the cellular factors 
that bind to the enhancers and influence the activity of the enhancer elements of HBV 
is likely to be of great importance in the delineation of the replicative mechanisms of 
HBV in the infected patient.
1.2 Polypeptides encoded by HBV
1.2.1 The core and pre-core proteins
Four promoters can be found in the HBV genome, giving rise to four major transcripts 
(see Fig. 1.1.) The core (C) promoter generates two transcripts, one of which is 
translated into a secreted protein (the misnamed precore protein, HBeAg) and one 
which generates the core protein (the nucleocapsid protein, HBcAg). The latter 
transcript also serves as a template for the translation of the polymerase protein, and 
as the pregenomic RNA that is packaged, reverse-transcribed and degraded. Thus, all 
the nucleocapsid components are the product of one RNA species (Yen, 1993). In 
order to produce these two transcripts from the core ORF, the elongating RNA 
polymerase II complex must ignore the polyadenylation signal once, but not the 
second time. The mechanism by which the polyadenylation signal is first ignored is 
not yet clear.
The hepatitis B virus core antigen (HBcAg) is a 21 kDa phosphoprotein of 183 or 185 
residues, depending on subtype, that is capable of self-assembly and forms the capsid 
that contains the nucleic acids and polymerase protein of HBV. The core particle has 
been structurally resolved and has been shown to exist in two species, one species 
exhibiting a triangulation number of T=3 (with 180 copies of HBcAg) the other
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Figure 1.2 Morphology of the virion and sub-viral particles.
The surface antigens are visible on the virion as LHBs (large HBV surface antigen) 
MHBs and SHBs are medium and small surface antigens, respectively. The core 
protein is present only in the virion. The sub-viral particles are abundant in patient 
serum and are composed chiefly o f HBsAgs with no other components (Gerlich et al., 
1993b). The filaments can be as long as 200 nm.
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Figure 1.3 Putative model of spatial arrangement of HBsAg envelope proteins.
The nature o f  the conformation o f  the proteins is apparent, and the transmembrane 
regions o f  the S protein are clearly shown. There are clear differences between the 
proposed structures o f  the S protein and the S domain o f  L protein. The rearrangement 
o f  the transmembrane regions at signal sequences I and II is shown with a comparison 
between S and L (from Gerlich et. al., 1993).
species exhibiting T=4 (240 copies) (Crowther et al., 1994). More recent work has 
shown, by cryoelectron microscopy, the structure of the core particle to a resolution of
7.5 Angstroms (Conway et al., 1998; Zlotnick et al., 1997). The core protein is 
known to dimerise and form the subunit component of the core particle. The crystal 
structure of the core particle has become available (Wynne et al, 1999), showing the 
assembly of the core homodimers at a resolution of 3.3 Angstroms.
The core protein has been the subject of much study in order to delineate the 
mechanisms involved in encapsidation and virion morphogenesis. The effect of N- 
terminal extensions on the behaviour of the core protein was investigated (Hui et al., 
1999) and it was shown that an extra 23 amino acids including a polyhistidine tag still 
enabled nucleocapsid assembly, but abrogated nucleocapsid envelopment. It is 
feasible that the additional N-terminal residues are interfering with the surface antigen 
binding residues on the tip of the core spike (residues 78-82). The 149 C-terminal 
residues of core are capable of self-assembly into nucleocapsids (Nassal, 1992b). The 
residues 150-183 are involved in binding nucleic acids and are rich in arginine 
residues (Nassal, 1992a). Furthermore, a C-terminal motif of SPRRR (Ser-Pro-Arg- 
Arg-Arg), while allowing assembly has been shown to be important in the 
preservation of competence for replication (Hui et al., 1999).
Structural studies have shown by peptide-difference mapping that the N-terminus of 
the core protein is visible by cryoelectron microscopy. The incorporation of an 
octapeptide at the N-terminus enabled the location of the N-terminus at the side of the 
spike, as the spike protrudes from the circumference of the spherical particle (Conway 
et al., 1998). The ability of core to assemble and tolerate significant insertions in the 
region of residues 78-82 has been exploited in efforts to design epitope delivery 
systems of potentially therapeutic value (Chambers et al., 1996).
The pre-core antigen (HBeAg) shares 149 residues involved in assembly of the core 
protein, but has an N-terminal extension of ten residues, which form the product from 
the propeptide which contains an extra 29 N-terminal residues. The pre-core protein is 
secreted from the cell, in marked contrast to core, and is in an unassembled form. The 
difference is the states of assembly between the core and pre-core is probably due to
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disulphide bonding of the residue cys-7 with cys61 (Nassal and Rieger, 1993). The 
pre-core protein has no apparent function but affords clinicians with a diagnostic tool.
1.2.3 The X Protein
The X protein (HBxAg) has not been thoroughly investigated yet, and its function 
remains largely unclear although it is believed to be a viral transactivating protein. 
The X protein is approximately 17 kDa in size and shares no topological features with 
other HBV proteins. In cultured cells, the X protein has been shown to exhibit 
transactivational behaviour on not only HBV promoters, but also class I MHC 
promoters, the c-myc promoter and the SV40 enhancer/early promoter (Su and Yee, 
1992). The X protein has been shown to be essential for the establishment of HBV 
infection in vivo but not for production of virions from cultured cells (Blum et al., 
1992). The intracellular degradation of X in infected cells has been shown to be rapid 
(Hu et al., 1999). Furthermore, it has been shown that X targets the proteasome 
complex and this represents a possible mechanism by which non-lysosomal protein 
degradation can be retarded in infected cells (Hu et al., 1999), thus, the X protein may 
attenuate the proteolytic processes employed by the host cell in the production of viral 
proteins. Clearly, there remains much to be learnt about the relevance and function of 
X protein in hepadnaviral infections.
The X protein is reported to perform many other functions including protein kinase 
activation (Wu et al., 1990), nucleotide diphosphate kinase activity (De-Medina and 
Shaul, 1994), and ATPase activity (de-Medina et al., 1994). However, the relevance 
of any of these functions to in vivo activity of the X protein remains unclear. It is 
interesting to note that the X gene is preserved in chromosomally integrated genomes 
of HBV, perhaps pointing to a role in establishing chronic infections. The X gene 
appears to support viral replication by transcriptional activation, it is dispensable, in 
vitro, which may suggest that L can overlap its function, with L protein exerting its 
transactivational effect early in the infection process, prior to the appearance of X 
(Hildt et al., 1996). Furthermore, the X protein acts on the infected cells by reducing 
cell proliferation (Sirma et al., 1999). Mutants of HBx are unable to prevent 
proliferation of infected hepatocytes, they are associated with increased risk of HCC 
(Sirma et al., 1999).
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The X gene is absent from the avian hepadnaviruses, but there are X genes in other 
mammalian hepadnaviruses such as WHBV and GSHBV, which further confuses the 
issues concerning the role of the X gene in HBV. The role of X protein remains 
unclear and is clearly in need of much study to elucidate its function, if any, in 
hepadnaviral infections.
1.2.3 The surface antigens
There are three envelope proteins in the HBV: Small (S), medium (M) and large (L) 
proteins, which constitute three forms of the HBsAg (Fig. 1.2). These three proteins 
are encoded from the env ORF. Upstream from env is a TATA box which contains a 
promoter (PS1) which is responsible for directing the transcription of a 2.4 kB 
subgenomic mRNA (Fig. 1.1). Full translation of the ORF yields the L or preSl 
protein (390 amino acids). The start sites for the M and S proteins are contained in­
frame in the ORF. PS2, a second promoter is present in the ORF but has no TATA 
box and directs the transcription of 2.1 kB mRNAs. The 2.1 kB mRNAs possess
tViheterogeneous 5’ ends. At the 120th codon (or the 109 depending on subtype) on 
the slightly longer transcript is an AUG which is used for the production of the M 
protein (281 amino acids). Some transcripts have the 5’ end downstream of this 
AUG, so the protein S (226 amino acids) is expressed. This S-domain is a polypeptide 
of 226 amino acids. Close to the N-terminus of the S protein is a signal sequence that 
inserts into the endoplasmic reticulum (ER) and causes translocation of downstream 
sequences. The signal sequence has a hydrophobic region at amino acids 8-22, and 
models (see Fig. 1.3) have predicted this region to be embedded in the membrane 
because a second signal sequence is found and this is also hydrophobic at amino acids 
80-98 (Bruss et al., 1996a). The hydrophilic regions of the S protein remain 
cytoplasmic but a large proportion of the protein is inserted into the ER. A 
hydrophilic region is presented at the surface of the virion, and this is presumably 
stabilised by the disulphide bridges that are present in abundance in the S protein. 
Postranslational modification of the S protein is apparent, but this is uniform with 
respect to all forms of HBsAg. The S protein is only partially N-glycosylated at the 
Asn 146, thus giving rise to two bands during sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) corresponding to a protein at 24 kDa 
and a glycoprotein at 27 kDa. Further studies are necessary in order to obtain a 
clearer picture concerning the structure and functions of the S protein. The abundance
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of cysteine residues in the S protein leads to disulphide bridging: 4 cysteine residues 
are present in the cytosolic loop, 1 in signal II, 8 in the luminal loop and 1 at the C- 
terminal (Gerlich, et.al., 1993). The effects of the disulphide bridging on the tertiary 
structure of the S protein can be seen in the proposed model in Fig. 1.3.
The preS2 domain is 55 amino acids long, and is located upstream of the S protein, 
forming the M protein. The pre-S2 region of the M protein is presented outside the 
mature virion (Gerlich, et. al, 1993) or in the lumen of the ER (Bruss et al., 1996a). 
The glycosylated form of M protein migrates as a 34 kDa band in SDS-PAGE. The 
partial resolution of the structure of the preS2 domain has been undertaken, and this 
has been examined as a fusion protein with the maltose-binding protein. The residues 
14-21 of the preS2 domain contain a B-cell stimulating epitope (Fei et al., 1995). The 
structure of some regions of the preS2 domain has been investigated (Saul et al., 
1997). The M protein has been found to be localised within the ER upon expression 
in mammalian cells (Hildt et al., 1993), but the function of M in the viral life cycle 
remains largely enigmatic (Le Seyec et al., 1998).
The preSl domain has been shown to contain no signal sequences or hydrophobic 
regions, but the anchorage and translocation of the L protein into the ER is achieved 
by the signal sequences in the S domain (Gerlich, et. al, 1993). The potential 
glycosylation site in the preS 1 domain of L is not used, even though some models 
suggests its use (Gerlich, et. al, 1993). The L protein is myristilated at gly2, and this 
fatty acid moiety has a profound effect on the in vitro infectivity of the virion (Bruss 
et al., 1996b). The new model of the L protein conformation suggests that half of the 
preS 1 domains are located in the inside of viral particles, interacting with HBcAg and 
providing a scaffolding function. The remaining proportion of the preSl are exposed 
at the surface of the virion (Bruss et al., 1996a). The dual topology of the L protein is 
a phenomenon that sets a precedent for viral proteins, and represents economical use 
of the genome for coding sufficient molecules for function with few genes.
The distribution of the surface proteins in the virion and in the sub-viral particles is of 
great interest and the subject of much study. The sub viral particle of about 20 nm 
(HBsAg) is the most common serum particle and has around 100 surface molecules, 
of which, two or less are L protein (Fig. 1.2). The M protein is equally distributed
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throughout all the forms of particle and is purported to compose 5% of the particles. 
The L protein is more abundant in the mature virion and the filamentous particle in 
comparison with the spherical subviral particles. The M protein is not necessary for 
complete virion formation or virus infectivity, but the S and L proteins are necessary 
for virion formation and infectivity (Ganem, 1991).
There are several features apparent in the sequence of the L protein in Fig. 1.3 (adw 
subtype). The preSl domain is contained in the amino acids 1-108, and in the preSl 
domain is a sequence 19-23 against which an antibody, MAb 18/7, has been raised 
(Gerlich, et. al, 1993) and this has aided many studies of the surface antigens 
(Germaschewski and Murray, 1995). The pre-Sl domain carries a sequence of amino 
acids from residues 21-47 which binds or interacts with a possible receptor on the 
surface of hepatocytes (Gerlich, et. al, 1993). Many studies have implicated various 
regions of the L protein in attachment to various cell surface components in efforts to 
determine the receptor or receptors for HBV.
Two protease cleavage sites are found near the start of the S domain: a V8-sensitive 
site at residue 165 and a chymotrypsin-sensitive site at residue 179. There is a 
potentially fusogenic peptide sequence at 169-181 and it has been suggested that this 
region is involved in the fusing of the viral and cellular membranes during the 
infection process (Lu, et. al., 1996; Rodriguez-Crespo et al., 1999). There are five 
possible sites for N-linked glycosylation on the L protein at positions 4, 112, 166, 222 
and 309. It is unclear whether all the potential sites are glycosylated but it is known 
that there is at least some degree of glycosylation (Gerlich, et. al, 1993).
There are different serotypes of HBV, determined by genetic variability at several 
positions on S. The group specific determinant, a, is present in all S material, along 
with two sets of usually mutually exclusive determinants, d or y  and w or r. The w 
determinant has been shown to have several variants, thereby widening the pool of 
variants of the HBV. Subtypes ayw, ayr, adr, adwl etc. are occasionally found in 
patients. The different subtypes are not known to have any biochemical, clinical or 
physiological differences attributable them, but they are useful markers for 
epidemiological studies.
Recent data have uncovered aspects of the functions of the L protein that implicate it 
in a number of activities besides the putative receptor-binding role. The L protein has 
been implicated as a transcriptional activator (Hildt et al., 1996). The L protein was 
investigated for transactivational activity after reports showed that the preS2 region of 
the M protein was sufficient for generation of a transcriptional activator function, 
providing evidence that the preS2 domain of both L and M proteins is capable of in 
vitro transactivation (Hildt et al., 1996). A difference in the localisation of the preS2 
region was shown to be important for the interaction of the M protein with the 
cytosolic binding partners. In the M protein, the N-terminal region of the M protein is 
oriented towards the lumen of the ER, whereas the transcriptionally active M protein 
has the N-terminus facing the cytoplasm. The authors then reasoned that the L protein 
might exhibit similar behaviour if the preS2 region was oriented in the direction of the 
cytoplasm. In cotransfection assays into HepG2 cells it was shown that the L protein 
elevated the level of the reporter CAT expression by 6 to 7-fold in the presence of M 
and S (Hildt, et. al, 1993; Hildt et al., 1996). The minimal promoters for the NF-kB 
and AP-1 genes were also activated by the presence of L protein.
The transcriptional activation ability of the L protein is in turn mediated by c-Raf-1 
kinase. The importance of the new information in this study is that the 
overproduction of L protein is capable of activating several kinase enzymes and 
activation of these enzymes might contribute to the development of HCC (Hildt and 
Hofschneider, 1998). Thus, from information gathered so far it seems that in addition 
to the structural role, the L protein is involved in transcriptional activation leading to 
changes in host cell gene expression and possibly enhancement of viral replication.
The glycosylation pattern of the HBV surface proteins is typical of other serum 
proteins produced in the liver. Mass spectra obtained by Liquid Secondary Ion Mass 
Spectroscopy (LSIMS) have shown that the oligosaccharide structures on the S appear 
to mimic those found on glycoproteins such as plasma fibronectin, a serum 
glycoprotein produced by the liver (Gillececastro et al., 1987). It is not surprising that 
the oligosaccharide residues are similar, as the viral proteins are produced and 
glycosylated in the liver before release. The relevance of the oligosaccharides to the 
adsorption of the virus to the target cell is not clear. It is reasonable to assume that if 
the oligosaccharides were involved in cell attachment, then this process is unlikely to
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be restricted to hepatocytes, as many cells endocytose the products of the liver. The 
specificity of HBV for hepatocytes and very few other types of cells suggest that the 
oligosaccharides are not likely to be involved in receptor binding.
1.2.4 The polymerase
The polymerase protein of HBV is known to have three functions: DNA-dependent 
DNA polymerase (DDDP), RNA-dependent DNA polymerase (RDDP) and RNAse
H. These activities of HBV polymerase are essential for viral replication. HBV 
polymerase has been successfully expressed in E. coli as a fusion protein in frame 
with maltose-binding protein (Jeong et al., 1996). A protein of 134 kDa was 
obtained, and was proteolytically cleaved into approximately 73 kDa of active 
fragment by proteinase K. Two activities of the polymerase were investigated and 
showed optima under conditions of 1 mM (DDDP) or 0.25 mM (RDDP) of MnC12, 
400 mM KC1, 37° C (DDDP) or 24° C (RDDP), and pH 7.0-7.7.
The HBV RNase H domain of HBV polymerase has been expressed as a maltose- 
binding protein-RNAse H fusion protein (MBP-RNase H) (Lee et al., 1997). The 
MBP-RNase H fusion protein (43 kDa MBP plus 17 kDa HBV RNase H domain) was 
proved to be RNase H by in vitro activity assays, inhibitor studies, and mutagenesis. 
The HBV RNase H domain represented the optimal RNase H activity in the presence 
of either 8 mM MgCL or 16 mM MnCL, with the pH optimum between 7.7 and 8.2. 
Mutation of highly conserved amino acids in the HBV RNase H domain diminished 
the RNase H activity. These authors suggest that the RNase H activity is separable 
from viral HBV polymerase enzymatic activities.
When polymerase is expressed in Xenopus oocytes upon injection of polymerase 
RNA (RT RNA), the polymerase assembles into a higher molecular weight complex 
with the characteristics of a ribonuclear protein (RNP) complex (Seifer and Standring, 
1995). The authors used results from in vitro RNA competition-binding experiments 
to suggest that RT RNA is preferentially packaged into this complex even though it 
lacks the viral encapsidation signal, epsilon, and viral nucleocapsid. The authors 
speculate that HBV RNP complexes containing polymerase and viral RNA may play
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a role in viral nucleocapsid assembly as the initial stages of virion morphogenesis, and 
may help to segregate HBV reverse transcription from the cellular environment.
A comprehensive understanding of the properties of the polymerase protein has been 
hampered by the inability of workers to propagate the virus in tissue culture. Thus, 
the advent of an in vitro propagation system for HBV should facilitate the 
understanding of the functions of the viral proteins, their relevance to the life cycle, 
and possibly the identification of suitable targets for therapy.
1.3 Virion Morphogenesis
Many processes are required to facilitate hepadnaviral morphogenesis. The 
association of the viral pregenomic RNA with the C-terminus (residues 150-183) of 
the core protein is the means by which the viral genome is encapsidated and held for 
reverse transcription by the polymerase enzyme (Zlotnick et al., 1997).
Existing models suggest the core and surface antigens associate as the assembled core 
passes into the lumen of the ER and obtains an envelope of the surface antigens 
(Bruss and Ganem, 1991; Bruss and Vieluf, 1995). The mechanism of envelopment 
of the nucleocapsid by the surface antigens has been the subject of much study. 
Numerous authors using different methods showed the demonstration of the 
scaffolding function of the L protein. The existence of an interaction between L and 
core was shown by the use of a random hexapeptide display library to identify the 
residues involved in binding the core protein (Dyson and Murray, 1995). Binding of 
the core particle to the L protein implies that the function of the cytoplasmically 
disposed loop of the L protein is a scaffolding function i.e. is responsible for 
associating the core particle with the envelope. The existence of a topological change 
in the L protein bound to core has been documented (Ostapchuk, et.al., 1994). The 
association of the L protein with the core particle has been studied by electron 
microscopy and has given useful information regarding the site of the interaction of 
the core and the L protein (Bottcher et al., 1998). The site of interaction of L and core 
has been identified as the tip of the core spike corresponding to amino acids 78-82 on 
the core protein. Furthermore, critical residues involved in the binding of L to core 
have been identified in the region between Arg 103 and Ser 124. The N-terminal 5 
residues of the preS2 domain of L have been implicated in the morphogenetic process
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(Le Seyec et al., 1998). These authors found that the deletion of the N-terminal 5 
residues did not support viral morphogenesis, however it remains unclear that these 
residues are absolutely required for assembly.
There has been shown a complex interaction between L and core using synthetic 
peptides. The association of L and core has been suggested to be mediated by two 
interaction sites on the L protein: one site on the preS 1 domain, and one site on the S 
domain (Poisson et al., 1997; Tan, et.al, 1999). Furthermore, these authors suggest a 
synergistic interaction with the two binding sites forming a strong interaction with the 
core protein. However, it remains unclear whether the presence of S alone is sufficient 
to recruit the core protein to the ER for encapsidation. It has not been shown in 
hepatocytes whether or not the relatively weak S-core bond is sufficiently strong to 
perform the scaffolding process, and allow the envelopment of the core particle with S 
in the absence of L.
The intracellular distribution of the core and precore proteins in the liver of patients 
with chronic HBV infections has been the subject of much study. 
Immunocytochemical studies have shown infected liver tissue cells expressing core 
antigen in the nucleus, and the pre-core protein was found to be distributed throughout 
the cytoplasm (Mondelli et al., 1986). Later work showed that it was a distinct 
possibility that the embedding protocols used in the sample preparation for 
immunocytochemistry were responsible for at least partial destruction of antigenicity 
of core in the cytoplasm of liver cells (Sansonno et al., 1988). The demonstration of 
core in the cytoplasm of transfected cells has also been achieved (Aiba et al., 1997). 
These authors show strong cytoplasmic staining from constructs expressing core 
alone, which contrasts well with the constructs expressing core and pre-core, which 
lead to a nuclear staining pattern. The intracellular interactions of core protein with 
the host cell have lead to the discovery of an interaction of core (and pre-core) with 
the extreme C-terminal region of human actin-binding protein (Huang, et. al, 2000).
The intracellular distribution of the surface antigens in infected liver cells has been 
investigated and has been shown to be variable in different patients (Chu and Liaw, 
1992). The differences observed by these authors were between the distribution 
patterns of L and M proteins, with a mixture of membranous and cytoplasmic
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distributions. The examination of the intracellular retention of L protein has yielded 
useful information regarding the processing and the retention of the mature protein. 
There has been a clear demonstration of the association of L with p53, a component of 
the anterograde protein transport pathway, the endoplasmic reticulum-golgi 
intermediate compartment (ERGIC) (Xu, et. al, 1997). Data from Xu, et. al has 
shown the formation of intracellular particles composed of L in the RER the ERGIC. 
The authors suggest that the L protein is retained in the ER and ERGIC by virtue of 
its interaction with calnexin. Furthermore, the retention of L within the ER has been 
demonstrated to lead to induction of the S promotor (Xu, et. al., 1997) with the effect 
of S production leading to secretion of the L and S proteins. The removal of the L 
protein from the ER by S results in lowering the oxidative stress in the ER, which in 
turn may prevent damage to the cell due to the accumulation of L (Xu, et. al, 1997). 
It is possible that the induction of physiological changes within infected host cells due 
to retention of L is one of the mechanisms of induction of hepatocellular carcinoma, 
as reasoned by many authors
1.4 Existing in vitro systems for the propagation of HBV.
Some attempts have been made to produce a productive infection in vitro of cell lines 
with HBV. However, most of these attempts have proven ineffective. Some 
researchers have infected human adult primary hepatocytes with HBV by using PEG 
and DMSO to enhance the entry of the virus. The efficiency of infection of the cell 
lines was measured by the amount of replicated HBV DNA in the cells. The 
environmental conditions for the maintenance of susceptibility to infection are 
stringent and involve incubation with 2% DMSO at the time of infection (Gripon, et. 
al, 1993). In this case, it is unlikely that the in vivo conditions of virus attachment 
and penetration resemble those used in this tissue culture system. Other researchers 
have found that the primary hepatocytes isolated from adult humans are competent for 
infection with HBV as determined by the de novo synthesis of viral proteins and the 
appearance of single-stranded viral DNA (a precursor to the mature virion) (Galle et 
al, 1994). However, with time, these cells lose the ability to produce the virus, and 
this is probably due to the loss of certain hepatocyte-specific functions. Moreover, 
only a fraction of the hepatocytes showed a susceptibility for infection, so this 
propagation system is far from ideal for use as an in vitro source of HBV, or for
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studying the early replicative steps of HBV. It has been shown that an established 
hepatoblastoma cell line, HepG2, is capable of supporting viral replication and virus 
particle synthesis following transfection with cloned HBV DNA (Sells, et. al, 1987). 
The authors identified 22 nm particles purported to correspond to S by the use of 
electron microscopy. Particles similar to Dane particles were also identified. 
However, as with the primary hepatocytes, this system is inefficient and furthermore, 
HepG2 cells are resistant to infection by the progeny virus. Other reports have 
suggested that non-hepatocyte cell lines may be used for propagation of 
hepadnaviruses (Galun et al., 1992), adding confusion to this difficult field.
Reports of the infection of peripheral blood mononucleocytes (PBMCs) have lead to 
many researchers trying to establish in vitro HBV infections in PBMCs, but these 
have remained unfruitful. (Kock et al., 1996) demonstrated that the association of 
HBV DNA and RNA with PBMCs, however, only the relaxed circular form (RC 
DNA) of the DNA was seen, and not the CCC DNA that is the replicative 
intermediate during active infection. The data presented shows clearly there is CCC 
DNA present and detectable in the liver of infected patients, but not in PBMCs (Kock 
et al., 1996). The association of HBV RC DNA with the PBMCs is explainable by 
adsorption and entry of the virus, but not infection. It is possible that the delivery of 
the viral genome to the nucleus is not facilitated in PBMCs, or it may be possible that 
the expression of gene products from the HBV genome is hindered by the lack of 
liver-specific gene expression factors, resulting in the inability of the HBV genome to 
replicate or synthesise viral products. However, the association of HBV with 
PBMCs, even in the absence of indications of active replication, suggests that one or 
more of the mechanisms involved in viral adsorption and entry are employed, but that 
productive infection remains to be established. The infection of the peripheral blood 
cells by HBV remains unclear due to difficulties in discerning the adsorbed virus from 
infection (Kock et al., 1996).
It is likely that the absence of an efficient propagation system for HBV (and Hepatitis 
C Virus) is due at least in part to the unavailability of cell lines permissive for active 
replication by these viruses.
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1.5 Putative receptors for HBV and mechanisms of uptake.
1.5.1 Receptors for L protein
The L protein has been found to bind to the asialoglycoprotein receptor (ASGPR) on 
the surface of hepatocytes (Treichel et al., 1994). The ASGPR is responsible for the 
endocytosis of N-galactose-containing glycoproteins into the hepatocyte. The 
ASGPR was isolated from plasma membrane preparations derived from fresh human 
livers by affinity chromatography and desalting, and bound an I-labelled 
asialoglycoprotein (asialoorosmucoid), thus demonstrating the biological activity of 
the isolated protein. Human hepatoma cell lines, HepG2 and Huh7, were also used to 
express ASGPR. The techniques used to study the interactions of HBV with ASGPR 
and the plasma membranes were radioimmunoassay and solid phase enzyme 
immunoassay. The results of radioimmunoassays in which HBV was incubated with 
the plasma membranes showed binding of HBV to the membranes in the absence of 
competing ligands. However, in the presence of the competing ligand asialofetuin, 
the binding was completely inhibited. The HBV interacted with the ASGPR with and 
without the presence of the competing ligand, but with the competing ligand the 
binding was reduced by 90%. Moreover, the binding of HBV to the ASGPR was 
completely inhibited, in a dose dependent manner, by the addition of an anti-preSl 
antibody (MAI8/7) (Treichel et al., 1994). Interestingly, addition of an anti-preS2 
antibody (Q19/10) had no effect on the binding. The blocking of the HBV interaction 
by the anti-preSl antibody indicates that the preSl region is responsible for the 
binding of HBV to the ASGPR (Treichel et al., 1994). However, the idea that HBV 
would bind to ASGPR in the presence of other ligands possessing higher affinities 
due to their greater degree of glycosylation than the relatively low degree of 
glycosylation of the HBV preSl is not compelling. The glycosylation of the preSl 
region remains a contentious issue and needs further study. The presence of ASGPR 
is exclusive to hepatocytes and may lend weight to the idea of organotropism, but the 
picture is still no clearer because other cell types not expressing the ASGPR, such as 
peripheral blood lymphocytes, can be infected. Generally, the ASGPR component is 
no longer considered as a cellular receptor for HBV.
The preSl domain has been strongly implicated in cellular attachment of the virus. 
(Neurath et al., 1986) examined areas of the preSl and preS2 domains and found a
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region that was recognised by specifically directed antibodies and anti-HBV serum. 
In this study, a commercially available S was used in preference to natural HBV 
particles. The authors state that the preliminary results from using natural HBV 
particles were very similar to the data obtained from the commercial S. This paper 
gives a great deal of information regarding the potential binding sites on HBV and has 
lead to important developments over the last decade. Interactions of S with 
hepatocytes were studied by using HepG2 cells and HBsAg supported on cellulose. 
The HepG2 cells were found to bind to the HBsAg on the cellulose in the absence of 
competition, whereas the addition of specific antibodies inhibited the cell binding. 
The authors then treated the HBsAg-cellulose with pepsin to remove the preS 
sequences and leave the presumably intact S domain exposed for attachment. 
However, the removal of the preS domains resulted in no attachment of the HepG2 
cells. Thus, it was reasonable to conclude that the S domain alone was devoid of 
attachment sites for the HepG2 cells. Attachment of the HepG2 cells to the HBsAg 
was inhibited by preparations of the HepG2 plasma membranes containing crudely 
purified cell receptor. It was found that three monoclonal antibodies recognising 
epitopes in the amino acids 12-32, 32-53 and 120-145 of the preS reduced virus 
attachment to HepG2 cells by 70%, 94% and 40% respectively. These findings led 
the authors to construct a region corresponding to 21-47 of preSl that overlapped the 
12-32 and 32-53 region. Antibodies to the 21-47 region successfully prevented 
attachment of the HepG2 cells to the HBsAg. Further evidence that the amino acids 
region 21-47 of preSl is involved in cell attachment came when a synthetic peptide 
corresponding to the 21-47, but not the 12-32 and 120-145, block virus attachment to 
cells. The results give strong evidence for the existence of a dominant binding site for 
the HepG2 cells on the preSl region of the HBV surface protein, and that this site is 
within the region of preSl (21-47). Furthermore, the binding site is well mimicked by 
a synthetic peptide analogous to amino acids 21-47 (Neurath et al., 1986).
The insertion of the N-terminus of the preSl domain into the membrane is modulated 
by the attachment of myristic acid at glycine 2 (Bruss et al., 1996b). These authors 
have shown that the myristilation at Gly 2 is essential for the maintenance of 
infectivity of HBV in vivo. The glycine 2 was changed by a point mutation to alanine, 
and the DNA was then cotransfected into HepG2 cells. This change to alanine 
resulted in a loss of in vitro infectivity of the progeny virus, but the presentation of the
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preSl domain on the virion surface, and the particle morphology were not adversely 
affected. It is reasonable to assume that the myristate moiety is responsible for 
anchorage of the preSl into the membrane and preserving the presentation of the 
preSl domain and allowing the receptor binding region to be properly displayed in 
order to be infective, as illustrated by the putative conformation (Gerlich, et. al, 
1993), (see Fig. 1.3). The non-myristilated protein was still located on the surface of 
the virion as demonstrated by immunoprecipitation using anti-preSl monoclonal 
antibodies. This evidence gives further support for the role of preS 1 in the infection 
process and strongly implicates the preS 1 domain as a receptor protein. However, in 
the absence of any X-ray crystallographic data to support a model of the structure of 
the L, M and S proteins, the presentation of these proteins at the virion surface 
remains uncertain.
More recent data has shown that the amino acids 21-47 of the preSl domain may not 
be the only region involved in the binding of HBV to the hepatocyte. An 80 kDa 
protein (p80) has been found to specifically bind to surface proteins of primary 
hepatocytes and hepG2 cells (Ryu et al., 2000). Using a pull-down assay, the authors 
showed that the glutathione-S-transferase-(GST)-preSl domain fusion protein 
specifically interacted with a 80 kDa protein present in a biotinylated preparation of 
plasma membranes. This interaction was completely inhibited by the addition of 
increasing concentrations of free preSl on the assay. The specificity of the binding of 
GST-preSl to p80 was studied to elucidate the regions of the preSl domain involved 
in the binding to p80. Truncation and deletion mutants of the preSl domain were 
generated and purified from bacterial cell lysate as GST fusion proteins and used in 
pull-down assays. Interestingly, two regions of the preSl domain were identified as 
critical in the binding of p80 in pull-down experiments; these regions were amino 
acids 12-20 and 82-90. The ability of HBV particles to bind this protein was shown by 
immunoprecipitation of p80 from cell lysates, giving good evidence that the in vitro 
interaction between the preSl domain and p80 represents the interactions in vivo 
interactions with the host cell. A most interesting observation concerning the tissue 
and species specificity of p80 came from pull-down experiments using extrahepatic 
tissues such as skin, cervical epithelium, kidney and peripheral blood 
mononucleocytes: p80 could be pulled down from cell lysates of all those tissues. 
The inability of the GST-preSl domain to pull-down p80 from lysates of human
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fibroblasts was noted, but furthermore, it was shown that a primary rat hepatocyte 
culture expressed a cell surface protein of 80 kDa that was bound to the preSl 
domain. The possibility that p80 could be Hsc70, a chaperone protein, known to 
interact with L (Loffler-Mary, et. al, 1997), was dismissed by the use of a 
monoclonal antibody against Hsc70 failing to recognise p80. Given the hepatotropic 
nature of HBV whether p80 is a “true” receptor for HBV preSl is debatable as p80 
appears to be widely distributed in human tissues and is also found in other species.
1.5.2 Receptors for the M protein.
The preS2 region of the M protein has been implicated in binding in a number of 
studies. Most of these studies have focused on the interaction of the polymerised 
human serum albumin (pHSA) with the preS2 region (Dash, et. al., 1990; Michel et 
al., 1984). The studies are overshadowed by the assumption that the glutaraldehyde- 
linked pHSA (G-pHSA) used in the studies is similar to the pHSA found in vivo. The 
preS2 component 120-145 has been shown to contain the epitope for pHSA binding 
(Dash, et. al., 1990). Dash et al have shown that there are two classes of binding site 
for native pHSA on HepG2 cells, with the sites having equilibrium dissociation 
constants of 16 ± 9.6 pmol/L and 1019 ± 172 pmol/L. The glutaraldehyde-linked 
pHSA binding sites were not blocked by the introduction of the monomeric HSA 
suggesting that there are separate sites for the binding of G-pHSA and HSA. 
However, the introduction of anti-preS antibodies in competition experiments showed 
that the antibodies block binding of preS2 peptide and HBV to primary hepatocytes 
by 40% and 70%, respectively. This is reasonable evidence to suggest that there is 
involvement of the preS2 region in attachment of HBV to the hepatocyte, but is also 
evidence to show that the preS2 region is not solely and completely responsible for 
the initial attachment of the HBV to the hepatocyte. Furthermore, preS2 is not 
essential for virus infectivity, making it an unlikely candidate for cellular attachment.
1.5.3 Receptors for S protein.
There is evidence for the involvement of the S protein in the attachment of HBV to 
the hepatocyte (de Bruin et al., 1995; de Bruin et al., 1996; Gong et al., 1996; Hertogs 
et al., 1994; Hertogs et al., 1993). The authors have shown that S bound to endonexin 
II (also known as annexin V) present in human liver membrane preparations, and that
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the immunisation of rabbits with native or recombinant human liver endonexin II 
results in the production of antibodies that are reactive with S. The development of 
antibodies that are anti-idiotypic for S is good evidence for suggesting that there is a 
receptor-ligand relationship between the S and human liver endonexin II. Rabbit 
antibodies against rat liver endonexin II which is known to have 90% homology with 
the human liver endonexin II, did not react with S, thus confirming the specificity of 
the antibodies produced by the immunisation of the rabbits. The authors excluded the 
possibility of contamination. The anti-idiotypic antibody was found to react only with 
S and exhibited no reactivity with preS 1 or preS2. The authors further investigated 
the interaction between S and annexin V and proceeded to generate a rat 
hepatoblastoma cell line expressing human annexin V which has been shown to be 
infectable by HBV (Gong et al., 1999).
The S was also found to be able to bind to apolipoprotein H (apo H) in vitro (Mehdi et 
al., 1994). Mature apo H is a protein found on plasma membranes and in serum, and 
consists of 326 residues. The S was able to bind to the apo H which was in an altered 
form compared with that which is found in the serum of humans (Mehdi, et. al, 
1996). It was speculated that the apo H was bound to S, and then bound to the 
hepatocytes via a specific receptor for the apo H, thus allowing the virus entry into the 
cell. However, HBV from the sera of patients failed to associate with apo H. Thus, 
faced with no evidence of S associating with apo H in patient serum, it was not a 
compelling hypothesis that the apo H receptor was responsible for the uptake of the 
HBV with the apo H molecule into the hepatocyte.
It has been suggested that S may be important in the entry of the virus after 
attachment has taken place. The cell line HepG2 was used in investigations of a 
potential fusogenic region of S. Entry of enveloped viruses often requires fusion of 
the envelope with the cellular membrane, allowing passage of the viral genome into a 
suitable compartment of the cell. HBV can attach the HepG2 cell surface via preSl 
but is unable to enter the cell line and initiate infection. (Lu, et. al., 1996) have shown 
that protease treatment of the HBV virion has profound effects upon its ability to 
infect HepG2 cells in vitro. Cleavage of the M and L proteins with V8 staphylococcal 
protease has resulted in exposure of a region of the S protein that is capable of fusing 
with the host cell membrane. Interestingly, another protease, chymotrypsin, cleaves
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the S protein at a site close to the V8 site, but does not induce the presentation of the 
fusogenic region. The removal of the preS regions was confirmed by the failure of 
antibodies specific to preSl and preS2 to bind to the protease treated virions. A 
conformation-dependent antibody C20/02 was used against the S after protease 
treatment and this showed no difference in binding to the protease treated virion. 
Thus, it is reasonable to assume that the conformation of S was not adversely affected 
by the removal of the preS 1 and preS2 regions. Upstream of the potentially fusogenic 
region is a PEST sequence (Lu et al, 1996). The PEST sequence is a region rich in P, 
E or D, S and T residues. The appearance of a PEST sequence is commonplace in 
many proteins that are rapidly degraded within the cell (Lu, et. al., 1996). It seems 
likely that a fusogenic region is involved in the in vivo entry of the virus to the host 
cell, but this is probably only one step of the entry process, and will come after the 
initial attachment at the cellular receptor site.
Non-specific, pre-S-independent, binding of HBV sub-viral particles to HepG2 cells 
after treatment of the particles with proteases has been demonstrated (Lu, et. al., 
1996). Treatment of the viral particles with staphylococcal V8 or porcine 
chymotrypsin resulted in infection of the HepG2 cells. The cleavage sites for 
staphylococcal V8 and porcine chymotrypsin are close to a potentially fusogenic 
region of the S domain, therefore the authors propose that the removal of the preSl 
and preS2 domains results in an exposed or active fusogenic domain that is necessary 
for the integration of the viral envelope with the plasma membrane of the host cell. 
This work has shown that the cleavage of the surface antigens of HBV at the protease 
sensitive site results in the ability of the virus to infect (Lu, et. al., 1996), therefore 
indicating that the proteolytic cleavage of the surface antigens is an important process 
in the natural infection pathway.
1.5.4. Receptors for Duck Hepatitis B Virus.
Some workers have made considerable progress on the elucidation of the entry 
process of the hepadnaviruses by studying the entry processes of DHBV. There are 
many advantages to using the Duck as a model for the identification of receptors for 
the hepadnaviruses (such as availability of primary hepatocytes). Early work on the 
infection process of DBHV has lead to some interesting observations. The infection
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process of DHBV involves the endocytosis of the virus, but this endocytic 
compartment is not an acidic compartment, and therefore no acid-dependent cleavage 
of proteins is required in the fusion process of the infection (Kock et al., 1996). The 
authors used lysosomotropic reagents such as sodium azide and 2-Deoxy-D-glucose 
to reduce the available energy in the normally acidic lysosome, therefore preventing 
the formation of acidic conditions. Under these conditions, it was still possible for 
DHBV to infect the cells. The detection of the DHBV DNA by sensitive RT-PCR 
allowed efficient determination of infection without gene expression; such gene 
expression would be disrupted by the use of sodium azide and 2-Deoxy-D-glucose.
Receptor-binding experiments have revealed a 120 kDa protein (p i20), able to bind 
the preS protein, which is only expressed in tissues infectable with DHBV (Li, et. al, 
1996). The authors used preparations of metabolically labelled primary duck 
hepatocytes and the GST-preS of DHBV for these assays. The association of p i20 
with the preS is apparent, but interestingly, the binding of preS truncation mutants to 
p i20 revealed a region at residues 98-102 that were critical for the interaction of preS 
with p i20 (Li, et. al., 1996). Contained within the 98-102 region is a motif that was 
found to be the p i 20-binding motif: the Phe-Arg-Arg motif. The pi 20 was shown to 
be available at the surface of the primary hepatocytes by cell surface labelling with 
biotin and subsequent pull-down using the GST-preS protein and associated 
truncation mutants. Pull-down experiments with cell lysates from other tissues 
showed that only liver, kidney and pancreas cells expressed the p i20 that bound the 
preS. This is in keeping with the known tropism of DHBV (Halpem et al., 1983). Li 
and co-workers postulate that the 120 kDa protein may represent a candidate for the 
second receptor for the DHBV, and suggest that this may be involved in the 
restriction of the host range of DHBV (Li, et. al., 1999).
Recently, the primary receptor for DHBV has been identified and characterised by 
work involving a number of groups. A protein of approximately 170 kDa was found 
to be responsible for the binding of the large surface antigen of DHBV on primary 
hepatocytes (Tong, et. al., 1995). This work showed that there was a likely receptor 
candidate for the initial stages of the infection process. Further work revealed the 
identity of a 180 kDa protein (p i80) involved in the plasma membrane binding of 
DHBV. The identity of the preS-binding protein p i80, is carboxypeptidase D (CPD),
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a golgi-resident protein that is also present on the plasma membrane in small amounts 
(Urban et al., 1998). The initiation of infection by DHBV preS was studied and there 
was found to be a region of 85 residues in the preS of DHBV that are critical for the 
interaction of preS with CPD (Urban et al., 1998). The authors showed that it was 
possible to inhibit the infection of primary duck hepatocytes with DHBV by 
competition with free DHBV preS in a dose-dependent manner. Furthermore it was 
also possible to inhibit the infection with free HHBV preS in a dose-dependent, 
manner (Breiner, et. al, 1998). Further work demonstrated the inhibition of infection 
of primary duck hepatocytes with DHBV with soluble CPD (Breiner, et. al., 1998). 
However, the overexpression of CPD in non-permissive cell lines did not lead to 
permissivity of infection (Breiner, et. al, 1998). The functional characterisation of 
CPD was undertaken and three domains of the CPD were found to be present. The 
domains A and B of CPD were shown to exhibit carboxypeptidase activity, and the C 
domain contains the preS-binding site (Eng et al., 1998). The process of attachment 
of the preS to CPD has been investigated and the association constants of the preS- 
CPD complex have been determined at 2.2x107 M '1 at 37°C (Urban, et. al., 1999). 
The association rate of preS and CPD has been determined at 4.0x104 M '1 S '1, and the 
dissociation rate has been determined to be 1.9x1 O'3 S '1. These constants and rates 
indicate that there is a very high affinity of preS to CPD. The DHBV preS region 
found to be responsible for maximal binding of CPD lies within an 85 residue stretch 
(corresponding to amino acids 30-115) covering about half of the length of the preS 
domain of DHBV. The authors showed specific dose-dependent inhibition of binding 
of DHBV by the addition of preS polypeptides produced in E. coll. Internal deletions 
in the amino acids 30-115 region of the preS domain result in a markedly reduced 
ability of the polypeptides to inhibit infection of the primary hepatocytes with DHBV. 
Internal deletions in the preS that were located outside of the 30-115 region had little 
or no effect on the ability of the preS polypeptide mutant to inhibit infection. The 
authors then proceeded to establish that the affinity of the recombinant preS 
polypeptides for CPD is similar to the affinity of the DHBV L protein for CPD 
(Urban et al., 1998). CPD also demonstrated the ability to bind the preS from HHBV, 
suggesting that the CPD may be involved as a common component of the avian 
hepadnavirus-receptor complexes. Homologous CPDs from other species have been 
identified and cloned and this family of proteins are found to be type I transmembrane
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proteins located on internal and plasma membranes (McGwire et al., 1997). An 
obvious avenue of investigation has been the evaluation of human CPD as a potential 
HBV receptor, and many researchers have investigated this with none reporting 
interactions between HBV and human CPD.
Project aims.
The overall aims of this project were; (1) to generate reagents such as MAbs, PAbs, 
cell lines and recombinant viruses to study the expression of these proteins and 
provide reagents for further research; (2) investigation of the behaviour and structure 
of the L and S proteins with novel immunological reagents, in order to obtain further 
information on the conformational nature of the surface antigens; (3) investigation of 
the interaction of the surface antigens with the core proteins when expressed 
intracellularly to delineate the mechanisms of hepadnaviral morphogenesis, and ; (4) 
to investigate the binding of the preSl domain to the plasma membranes of 
hepatocytes and other cells in order to provide new information on the specificity of 
binding and the host range of HBV.
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Chapter 2
MATERIALS AND METHODS
Radiochemicals
S L-methionine was obtained from Amersham at a specific activity of 10 pCi/pL. 
Solutions
PBSA: 170 mM NaCl; 3.4 mM KC1; 10 mM Na2HP04; 1.8 mM KH2P 0 4; pH7.2. 
PBSC: PBSA with CaCl2.2H20  and MgCl2.6H20  at lg/L.
PBST: PBSA plus 0.05% Tween-20.
FPBS: PBSC; 2% FCS; 0.05% sodium azide.
Glycine-SDS buffer: 14.4 g glycine; 3.75 g Tris in 1 L distilled water.
10X TBE: 1.25 M Tris; 0.4 M boric acid; 27 mM EDTA.
TE: 10 mM Tris-HCl; 1 mM EDTA pH 8.0.
Towbin’s buffer: 100 mL methanol; 14.4 g glycine; 3.75 g Tris in 1 L water.
Zweig’s buffer: 10% glycerol; 0.1 M Tris-HCl; 0.5% NP-40; 0.5% Na-Deoxycholate; 
protease inhibitors (Complete protease inhibitors Boehringer Mannheim); in distilled 
water.
Chemicals and reagents
Laboratory chemicals were purchased from Sigma Chemicals or BDH Chemicals, UK 
unless otherwise stated.
Amersham Life Science: Rainbow protein markers RPN 756 
Beecham Research: ampicillin (Penbritin)
Bio-Rad: ammonium persulphate (APS), acrylamide (27.5%) crosslinker, N,N,N’,N’, 
tetramethylethylenediamine (TEMED), coomassie brilliant blue.
Boehringer Mannheim: protease inhibitors (EDTA-free).
Gibco BRL: IPTG
Marvel: dried skim milk
Prolabo: ethanol, glycerol, methanol.
UKC Chemical Laboratories: Citifluor.
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2.1 Bacterial strains
The E.coli strains DH5a, TGI and JM109 were employed for the growth and 
maintenance of plasmid DNA. The growth medium for these bacteria was LB broth 
(Lauria-Bertani medium, 10 g NaCl, 10 g Bactopeptone, 5 g yeast extract in 1 L water 
at pH 7.5). The E.coli strain M l5 carrying the plasmid pREP4 (Invitrogen) was used 
for the expression of recombinant proteins. For expression, these bacteria were grown 
in 2YT broth (5 g NaCl, 16 g Bactopeptone, 10 g yeast extract in 1 L water at pH 7.5). 
Agar plates were made in 90 mm diameter dishes with the inclusion of about 25 mL 
LB-agar (LB broth with 1.5% agar). Antibiotic supplementation was as follows: for 
Ampr cultures, 50 pg/ml, for Kanr cultures 25 pg/ml.
For the preparation of electrocompetent E.coli cells, 100 mL 2YT broth was 
inoculated with an overnight culture at a dilution of 1:50 and the bacteria allowed to 
grow until they reached an OD600 of about 0.6. The culture was cooled on ice for 30 
minutes and centrifuged at 2500 rpm in a Sorval RT6000B centrifuge for 15 minutes. 
The supernatant was decanted, and the cells were carefully resuspended in distilled 
water and recentrifuged. The cells were resuspended in water a further two times and 
finally the cells were resuspended in 2 mL water containing 10% glycerol, and 
immediately frozen in liquid nitrogen. The cells were stored in 40 pL aliquots at -  
70°C.
Transformation of the electrocompetent cells was done by the addition of 5 pL of a 
ligation mixture, or 0.5 pg of DNA, into the 40 pL aliquot of freshly thawed cells. 
The cells were mixed with the DNA for 1 minute on ice, then electroporated in a Bio- 
Rad electroporation cuvette at 200 Volts and immediately transferred into 1 mL of L 
broth without antibiotics and incubated with shaking for 1 hour at 37°C. The cells 
were then plated onto LB agar plates containing the appropriate antibiotics and 
incubated overnight at 37°C. Individual colonies were picked and analysed for the 
presence of the plasmid.
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2.2 Expression and purification of the preSl domain.
A single colony of E.coli M l5 (pREP4) cells harbouring the plasmid pQESl was 
inoculated into 10 mL 2YT containing amp/kan and incubated with shaking at 37°C 
overnight. The 10 mL culture was then added to 500 mL of pre-warmed 2YT broth 
with amp/kan and incubated with shaking at 37°C until the OD450 had reached 0.3. To 
induce expression IPTG was added to a final concentration of 1 mM and the culture 
was incubated for a further 3 hours. The bacteria were pelleted at 8,000 r.p.m. in a 
SORVAL RCB centrifuge for 15 minutes at 4°C and the supernatant decanted. The 
pellets were resuspended in TN buffer (10 mM Tris-HCl, 150 mM NaCl, pH7.5) and 
freeze-thawed three times in a dry ice/methanol bath. The bacteria were then lysed 
with a sonic probe for bursts of 15 seconds with immediate incubation on ice. The 
resultant cell lysate was pelleted in a SS34 rotor at 15,000 r.p.m. in a SORVAL RCB 
centrifuge for 30 minutes at 4°C. The supernatant carrying soluble proteins was 
removed and incubated with Ni-NTA resin (equilibrated in TN buffer) for one hour at 
4°C. The slurry was then dispensed into a Bio-Rad 5 cm disposable column and 
washed with 3 column volumes of TN buffer. The column was then washed with 3 
column volumes of TN buffer containing 20 mM imidazole (Sigma) to remove 
proteins bound non-specifically to the resin. The preSl protein was eluted from the 
column with 2 column volumes of TN buffer containing 250 mM imidazole. The 
eluted protein was dialysed against PBSA at 4°C for three changes in DIALYZE-A- 
SLIDES (Pierce Warriner) with a molecular weight cut-off of 10 kDa. The dialysed 
protein was further concentrated by centrifugation at 2,500 r.p.m. for 2 hours at 4°C 
using an Amicon concentrator with a molecular weight cut-off of 10 kDa in a 
SORVAL bench top centrifuge. Final protein concentration was determined with the 
Bio-rad protein determination kit. The protein solutions were aliquoted and stored at 
-20°C until required.
2.3 Nucleic acid manipulations.
Restriction enzyme digestion of DNA was carried out according to the manufacturers 
instructions. The buffering systems were either the Boehringer Mannheim system 
(buffers A, B, H, L, M) or the New England Biolabs buffer system (buffers 1, 2, 3, 4). 
For diagnostic analysis, the reaction volumes of 20 pL generally contained 1 pg DNA
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and 1 unit of the restriction enzyme in IX buffer. For the isolation of specific 
fragments, the amount of DNA used in the digestion was about 20 pg.
Blunt ending of DNA containing 5’ overhangs was achieved with the incubation of 
the digestion mixture with dNTPs and 2 units Large Klenow fragment of DNA 
polymerase I. The blunt ending reaction was left for 30 minutes at 37°C.
The removal of 5’ phosphate groups from digested vectors was performed using 
alkaline phosphatase in order to prevent re-circularisation of the vectors with 
complementary ends. The addition of 1 unit of calf intestinal phosphatase to the 
digestion mixture ensured the removal of the phosphate groups. The extraction of 
nucleic acids from reaction mixtures was done by using the nucleic acid extraction 
kits (Qiagen) according to the manufacturer’s instructions. Ligation of appropriately 
ended insert and vector DNA fragments was done by incubation of a 5:1 respective 
ratio of target/vector DNA in a reaction volume of 20 pL with IX ligation buffer and 
2 units of T4 DNA ligase at room temperature overnight.
2.4 Electrophoresis of nucleic acids.
Resolution of nucleic acids was achieved by the use of agarose gels at a concentration 
of 1% w/v, containing 1 pg/mL ethidium bromide (EtBr). Gels approximately 1 cm 
thick were poured into the gel moulds and, once set, immersed in 1% TBE buffer with 
EtBr in the Bio-Rad gel tank system. The DNA samples were mixed in DNA loading 
buffer to make a final volume of 20 pL. The gels were run at 100 V until the dye 
front had migrated to the end of the gel. DNA fragments were visualised with a short­
wave UV light and images captured by The Imager (Appligene). If required, the band 
of DNA was retrieved from agarose gels by excision of the band of interest and 
subsequent purification performed using the Gel Extraction kit (Qiagen) according to 
the manufacturer’s instructions.
2.5 Sodium-dodecvl sulphate polyacrylamide gel electrophoresis (SDS-PAGEL
SDS-PAGE was performed with the Mini-Protean II kits from Bio-Rad. Resolving 
gels were poured to a height of 5 cm between two glass plates and were overlaid with 
water until polymerisation was complete. After washing with distilled water, the
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resolving gels were overlaid with the stacking gels and left to polymerise with a track 
marker comb inserted in the top of the gel. Samples for electrophoresis were mixed 
with final sample buffer (FSB) and boiled for 2 minutes before loading. Gels were 
run in the holding tank in glycine-SDS buffer at 120 V until the FSB dye reached the 
bottom of the gel. The resolving gels used in this work were at a concentration of 9%, 
10% or 12% acrylamide. TEMED and APS were used as the catalysts for the 
polymerisation of the acrylamide. The fractionated proteins were visualised by 
staining with coomassie brilliant blue (Bio-Rad), autoradiography, or Western 
blotting.
2.6 Western blotting.
Electroelution of proteins from SDS-PAGE gels was done by using the Western Blot 
kit supplied with the Mini-Protean II kits. The nitrocellulose transfer membranes 
(Hybond ECL) were obtained from Amersham and were cut to size before transfer. 
Transfer of proteins from the gels was done in Towbin’s Buffer at 90 V for one hour 
with the inclusion of an icepack in the tank to prevent overheating. Following 
transfer, the ECL membranes were removed from the tank and quickly immersed in a 
90 mm Petri dish containing PBST with 5% milk powder, for blocking of non-specific 
binding sites, for at least 30 minutes followed by a further incubation with a fresh 
solution of 5% marvel added for a further 30 minutes. The membranes were then 
washed three times in PBST to remove the milk powder and were the probed with 
antisera. Primary antibodies were diluted in PBST/BSA (PBST containing 2% BSA) 
into a total volume of 5 mL and were added to the membranes with gentle agitation 
for 60-90 minutes. Residual primary antibodies were washed off with three washes of 
PBST and the appropriately diluted secondary antibodies added in PBST/BSA for one 
hour with gentle agitation. Three 15 minute washes with PBST were used to remove 
residual secondary antibodies, and the membranes were incubated for 2  minutes in a 
mixture of equal volumes of ECL Enhanced Chemiluminescence reagents 
(Amersham). The membranes were sandwiched between two sheets of transparent 
film and the chemiluminescence was detected with Kodak X-OMAT film by exposure 
to the membranes for varying lengths of time.
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2.7 Immunoprecipitations.
Cells were grown in 24-well plates to about 60% confluence, and were then infected 
with the relevant recombinant vaccinia viruses (rVVs). For radiolabelling of proteins, 
cells were washed with PBSA at 5 hours post-infection and incubated in methionine- 
free Eagles Medium containing 50 pCi/mL 35S-Methionine for 18 hours. After 24h, 
the culture supernatant was aspirated and clarified at 13,000 r.p.m. in a benchtop 
centrifuge to remove cellular debris. The clarified supernatant was then transferred to 
an eppendorf tube, added to an equal volume of Zweig’s buffer and stored at -20°C. 
Cell monolayers were washed three times with PBSA and the cells were dislodged 
and pelleted by brief centrifugation to pellet the cells. The cells were resuspended in 
200 pL of Zweig’s buffer and incubated on ice for 30 minutes to allow lysis. The cell 
lysates were centrifuged at 15,000 r.p.m. in a benchtop centrifuge to pellet the nuclei. 
The lysates were transferred to fresh tubes and stored at -20°C. The cell lysates were 
used in 50 pL volumes. To immunoprecipitate proteins, 5 pL of rabbit polyclonal 
antisera, 50 pL of hybridoma supernatant, or 10 pL of ascites fluid were added to the 
cell lysates or cell medium. The samples were incubated at 4°C overnight with 
shaking to form the antigen-antibody complexes. Immune complexes formed with 
rabbit polyclonal antisera were mixed with 50% slurry of protein-A-Sepharose, 
equilibrated in Zweig's buffer and incubated for 2 hours at 4°C with shaking. The 
protein-A-Sepharose was washed three times in Zweig’s buffer and once in 0.5 M 
lithium chloride in 20 mM Tris at pH 7.5. The protein-A-Sepharose was resuspended 
in 50 pL of final sample buffer and boiled for 2 minutes before loading on SDS- 
PAGE gels.
For immunoprecipitations using mouse monoclonal antibodies, a bridging antisera, 
rabbit anti-mouse IgG, was added to the protein-A-Sepharose slurry for 30 minutes at 
4°C. The use of the bridging antisera enables efficient recruitment of the mouse IgG 
molecules which have a lower affinity for protein A in comparison with rabbit IgGs. 
Unbound bridging antisera was removed by washing and 50 pL of 50% slurry was 
added to the samples for 2 hours at 4°C. The samples were prepared for SDS-PAGE 
as described above.
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2.8 Preparation of samples for Crvo-Electron Microscopy.
Cells were grown in 6 -well plates to about 60% confluence and infected at a m.o.i. of 
5 p.f.u. per cell for each rW . The cells were incubated after infection for 24 hours, 
washed three times with PBSA and removed from the wells by a rubber policeman. 
The cells were suspended in 400 pL of PBSA, placed in Beem Capsules, and 
centrifuged in a benchtop centrifuge at 1,200 r.p.m. for 4 minutes at room temperature 
(RT) to pellet the cells. The supernatant was removed from the pellet and 500 pL of 
2.5% glutaraldehyde (EM grade, double distilled, TAAB, Aldermaston, UK) was 
carefully added to the pellet for fixation of the cells. The fixing pellet was stored at 
4°C for at least one day. The Glutaraldehyde was carefully removed and the Beem 
capsule was filled with a 4% w/v solution of gelatin (TAAB) in PBSA at 37°C. The 
pellet was stored at 37°C for 3 hours to allow the cells to become permeated with the 
gelatin, and then the samples were transferred to 4°C overnight to solidify the gelatin. 
The Beem capsules were sectioned with a razor blade to expose the cell pellet. The 
pellet was carefully removed from the capsule and the excess gelatin was removed 
from the cell pellet. The pellet was cut into small blocks of about 1 mm2 by hand, and 
placed in a solution of 2.3 M sucrose for two days at 4°C for cryoprotection. Samples 
were removed from the sucrose and manipulated on aluminium stubs, then plunge- 
frozen in liquid nitrogen. The stubs were inserted into the chuck of a microtome and 
sectioned to give 70 nM sections. The microtome components were constantly cooled 
with liquid nitrogen throughout the sectioning procedure. The sections were 
transferred to grids (nickel, copper or gold) and floated in water to remove excess 
sucrose. The grids were incubated in primary antibody by flotation on a drop of 
PBSA with the appropriately diluted antibodies for 3 hours at RT. Transferring the 
grids sequentially to three drops of PBSA washed off the residual primary antibodies. 
Incubation with the secondary antibodies was done by flotation in a drop of PBSA 
containing 1:50 dilutions of an appropriate anti-IgG-gold conjugate (Nanoprobes Ltd) 
for one hour at RT. Sequential transfer to three drops of PBSA washed off the 
residual secondary antibodies. Following washing, the samples were treated with 
Nanovan (vanadium acetate, Nanoprobes Ltd) to negatively stain the proteins. The 
use of Nanovan enables enhanced resolution of proteins by transmission EM and gave 
clearer results than uranium acetate due to the smaller ionic radius of the vanadium.
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The stained samples were placed in a specimen holder and analysed in a JEM 100S 
electron microscope.
2.9 Scanning electron microscopy.
Cells were plated on glass coverslips in 24-well plates and grown in DMEM at 37°C 
for three days to reach a confluence of 60-70%. The cells were cooled for one hour to 
4°C in DMEM. The cells were labelled with approximately 1 pg of ligand (where 
applicable) in DMEM for 30 minutes at 4°C, followed by three washes with fresh 
medium. A mixture of MAbs RC9, RC28 and RC152 was diluted in DMEM and the 
cells were incubated in this mixture for 30 minutes at 4°C, followed by three washes 
with fresh medium. Secondary antibody (anti-mouse IgG-Gold conjugate with a 10 
nm gold particle) was diluted in DMEM and added to the coverslips for 30 minutes at 
4°C. The residual secondary antibodies were washed off with three washes with 
DMEM and the samples were then fixed by the addition of 2.5% glutaraldehyde (EM 
grade, double distilled, TAAB, Aldermaston, UK) in PBSA to the wells. The samples 
were stored at 4°C overnight. The glutaraldehyde was removed, and the cells washed 
twice with distilled water. The cells were then osmicated by the addition of 1 mL 1% 
osmium tetroxide in distilled water at RT for one hour. The coverslips were washed 
and dehydrated in 30%, 50%, 70%, 90% and finally 100% ethanol. In order to ensure 
complete removal of water from the cells the samples were placed in acetone to 
displace the ethanol and were then inserted into a critical point drying chamber and 
the acetone displaced with liquid carbon dioxide, which was then volatilised. The 
samples were degassed overnight at room temperature. Scanning electron microscopy 
was performed with a JOEL Scanning Electron Microscope.
2.10 Generation of Polyclonal antibodies.
Two female NZW rabbits (numbers 142 and 143) were used to generate polyclonal 
antisera against the preSl domain. Pre-immune serum was taken from these rabbits 
prior to injection with antigen. This serum was clarified by centrifugation at 1000 
RPM in a Beckman RT6000B centrifuge, then aliquotted into 1 mL volumes and 
stored at -20°C. The two rabbits were injected intramuscularly with 100 pg quantities 
of purified preSl domain at 14 day intervals. The first injections were augmented 
with 50% Freund’s complete adjuvant, the subsequent injections were augmented
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with incomplete Freund’s adjuvant. Test bleeds were taken after five injections of 
antigen had been completed, and the antibody response to preSl was assessed by 
ELISA. Test bleeds from both rabbits showed high antibody titres following five 
single injections. Serum from rabbit 142 was harvested, whereas rabbit 143 was 
injected with antigen a further five times, and the plasma then harvested and clarified. 
The resultant sera were aliquoted and stored at -20°C. Sera from 142 and 143 were 
assayed for activity in Western blotting, immunofluorescence and 
immunoprecipitations.
2.11 Generation of monoclonal antibodies.
The Author gratefully acknowledges the guidance and supervision of Dr Susan 
Graham during the generation of the monoclonal antisera described here.
The inbred strain of BALB/c mice (Harlan Orlac Ltd., Oxon. England) was used. 
Five Balb/C mice were subcutaneously injected with 20 pg of preSl domain in 50% 
Freund’s complete adjuvant with a final injection volume of 100 pi. Three weeks 
after the first injection, subsequent injections were of 20 pg of preSl in incomplete 
Freund’s adjuvant were administered. This procedure was repeated twice more at two­
weekly intervals. Test bleeds were taken from all mice and assayed by ELISA against 
the antigen to establish the degree of response from the mice. Two mice with the 
highest titre of antisera against the preSl domain were selected and boosted with a 
intraperitoneal injection containing 100 pg of preSl domain. Seven days after 
boosting, splenectomies were performed and lymphocytes were removed from the 
spleen by repeated irrigation in PBSA using a G19 sterile needle (Sherwood Medical). 
The spleen cells were then pelleted at low speed in a 50 mL centrifuge tube, and a 
viable count was performed. NSO (ECACC 85110503) murine myeloma cells were 
used as the fusion partner for the generation of hybridoma cell lines. These cells are 
non-invasive, non-metastatic, non-secreting, non-light chain-synthesising 
plasmacytoma cells subcloned from the non-metastatic SP2/0 cell line. They were 
grown in NSO growth medium and were split 1:2 three days before the fusion to 
ensure that they were in logarithmic phase growth before each fusion. The SP2/0- 
derived cells were resuspended from the incubation flask by shaking and pelleted in a 
50 mL centrifuge tube. A viable count was performed. The pelleted cells were
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resuspended in 1 mL of serum-free medium. The spleen-derived lymphocytes were 
thoroughly mixed with a suspension of the SP2/0-derived cells in a ratio of 1:5 and 
incubated at 37°C. The fusion of cells was induced by the drop-wise addition of 1 mL 
of 50% polyethylene glycol (PEG1500). The mixture was mixed by gentle aspiration. 
After 1 minute of incubation at 37°C, 1 mL of serum-free medium (SFM, DMEM 
with no added components) was added over a period of 1 minute. A further 1 mL of 
SFM was added over a one minute period. A further 2 mL was added over 1 minute 
and, finally, 4 mL was added over a period of 1 min. The cell suspension was the 
made up to 40 mL with SFM and centrifuged at 1,200 r.p.m. for 10 minutes to fuse 
the cells. The cells were resuspended and diluted into 100 mL of HAT medium and 
200 pL aliquots of the suspension were plated in 96-well tissue culture dishes. The 
96-well plates were incubated at 37°C in a 5% CO2 atmosphere and the wells were 
periodically examined for hybridoma colony growth. Supernatants from wells 
containing colonies were tested for anti-preSl antibody by ELISA. Colonies found to 
be secreting antibodies were subcultured to 24 well plates. Frozen stocks of antibody- 
secreting hybridomas were generated from the 24 well plates by resuspension of the 
colony, followed by dilution of the aspirated colony into 1 mL of HAT medium 
containing 10% DMSO. The cells were then gradually frozen overnight in cryovials 
(Sarstedt) at -70°C in a controlled-temperature reduction vessel. Long-term storage 
of cultures was done in Linde racks cooled with liquid nitrogen. Viable colonies were 
subcultured to T25 flasks for evaluation of the hybridoma supernatants. Hybridoma 
supernatants from the T25 flasks were assayed for activity of antibodies in Western 
blots, immunofluorescence and immunoprecipitation. Cultures found to be positive in 
any of the above assays were cultured in T175 flasks to harvest the supernatant. The 
resultant antibody preparations were then isotyped with the use of a Mouse Antibody 
Isotyping Kit (Sigma Chemical Co.) according to the manufacturer’s instructions.
2.12 Purification of MAb RC28.
The hybridoma supernatants from MAbs RC9, RC28, RC109, and RC152 were 
examined for activity in FACS assays. It was noted that RC28 was active in FACS 
assays, where the others were not, therefore milligram quantities of RC28 were 
purified. The culture of RC28 was grown in serum free hybridoma medium (Gibco) 
in T 175 flasks until the cells appeared crenated. The medium was aspirated from the
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flasks and clarified by centrifugation at 3,000 r.p.m. in a Sorvall RT6000B benchtop 
centrifuge for 5 minutes at RT. The clarified supernatant was dialysed against 20 mM 
sodium phosphate, pH7.0 for four changes. The dialysed supernatant (approximately 
900 mL) was filtered through 0.22 M me mbranes and passed through a protein G- 
Superose column (Pharmacia) connected to a LKB FPLC Akta instrument at a flow 
rate of 1 mL per minute at RT. The column was washed with 20 mM sodium 
phosphate for one hour and the antibody was then eluted in 0.5 mL fractions with 200 
mM glycine, pH2.7. The eluate was collected in 0.5 mL aliquots in tubes containing 
50 pL of 1M Tris-HCl buffer at pH9.0 in order to ensure neutralisation of the pH. 
The fractions were stored at 4°C until further use.
2.13 Production of peptides representing the preSl domain.
Peptides were synthesised using an automated peptide synthesiser. Following 
synthesis, peptides were eluted from the column matrix and lyophilised. Further 
purification of the peptides was done by high performance liquid chromatography 
(HPLC) LKB octadecyl silica HPLC column (Shandon Ltd, UK) coupled to a HPLC 
system (LKB, UK). The peptides were purified to about 95% purity and were 
lyophilised, weighed, and then redissolved at a concentration of 1 mg/mL in distilled 
water. The peptides were dispensed in 1 mg aliquots in glass vials and lyophilised. 
The peptides were analysed with a Lasermat mass spectrometer to ascertain the 
molecular weight of the purified species. The use of two standard peptides (kindly 
supplied by Dr. H. Marsden) of known molecular mass enabled calibration of the 
Mass Spectrometer for the purposes of molecular mass determination of the peptides 
described here. Further information pertaining to these peptides is shown in table 1.
2.14 Epitope mapping of monoclonal antibodies.
ELISA plates (96-well Immulon II) were coated overnight at RT with 125 pg of 
preSl domain in 100 pL of PBSA. The next day the plates were washed three times 
with PBST and blocked with 200 pL of 2% BSA in PBSA for one hour at RT. The 
plates were washed three times with PBST and to each well 90 pL of a known 
concentration of a peptide corresponding to a known region of the preSl domain was 
added. The peptides were added at 10, 100 and 1000 times the concentration of preSl 
used to coat the plate. A blank positive control was used, where 90uL of PBSA was
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added. Finally, 10 pL of hybridoma supernatant of each MAb generated here was 
added to the 90 pL of inhibitory peptide, and the plates were agitated to ensure 
mixing. The peptide-MAb mixture was left for 2 hours at RT and then removed by 
washing three times in PBST. The secondary reagent, anti-mouse-HRP conjugate 
was used at a dilution of 1:1000 for two hours. Following washing three times with 
PBST, the colour was developed with ABTS in hydrogen peroxide, and the colour 
measured at 405 nM after 30 minutes.
2.15 Cell culture.
All cell lines, unless otherwise stated, were cultured in Dulbecco’s modified essential 
medium (DMEM) supplemented with 10% FCS (fetal calf serum, Gibco), 1% non- 
essential amino acids (Gibco) 100 units/mL penicillin/streptomycin and 10 mM 
glutamine (Gibco).
Baby Hamster Kidney (BHK-C13) cells were grown in Gibco BHK medium 
supplemented with 5% new-bom calf serum, 10 mM glutamine, 100 units/ml and 1% 
non-essential amino acids. Hybridoma cells were grown in DMEM supplemented 
with 10% FCS, 4% HAT (hypoxanthine aminopterin, Gibco), 0.1% Gentamycin 
(Gibco) and lOmM glutamine (HAT Medium). Tissue culture plastics were obtained 
from Nunc, Bibby, Costar and Falcon.
2.16 Purification of vLx.
BHK cells were cultured in roller bottles to about 60% confluence, then were infected 
at a m.o.i. of 0.1 p.f.u/cell with WR or vLx, and the infections were allowed to 
proceed until complete cytopathic effect (c.p.e.) was observed. The medium from the 
infected cells was harvested and clarified at 3,000 r.p.m. in a benchtop centrifuge, 
then the supernatant was overlaid on a 40% w/v sucrose cushion and centrifuged at
18,000 rpm in a AH629 rotor (SORVAL) at 4°C for 4 hours. The pellet was 
resuspended in PBSA and centrifuged through a 15-30% continuous sucrose gradient 
for 2 hours at 35,000 rpm in a TST41 rotor (SORVAL). The gradients were 
fractionated and analysed by Western blot for the presence of Lx. Fractions 
containing the Lx protein were bulked and stored at -20°C, as were the corresponding
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fractions from WR-infected samples. The bulked samples were analysed for the 
presence of Lx by Western blot with MAb RC28.
2.17 Generation of the hepatocvte-derived cell lines.
The generation of immortalised cell lines with the phenotype of hepatocytes has been 
an area of much study in recent years. The generation of immortalised cell lines from 
primary hepatocytes was undertaken in this laboratory in order to study the 
mechanism of infection and the replication of the hepatotropic viruses, HBV and 
HCV. Primary human hepatocytes were obtained commercially (from BioWhittacker, 
UK) in the form of monolayers in a 6 -well plate. The transformed hepatocyte cell 
lines were derived from primary human hepatocytes by transduction with a mouse 
Moloney Leukaemia virus expressing the E6  and E7 proteins from Human 
Pappilloma virus type 16. Following infection, the cultures were incubated at 37°C in 
DMEM and subcultured. Frozen stocks of the cell lines were generated and 
cryopreserved. This work was carried out by Dr. A. Patel and viable cell lines were 
made available to the author for experimentation. The cultures were grown in DMEM 
(see section 2.15) or Defined Medium (Runge et al., 2000). These novel cell lines 
were investigated partially for hepatocyte phenotype by probing the plasma 
membrane and the intracellular matrix for the presence of cytokeratins 8  and 18. 
Furthermore, the cell lines were probed with antibodies reactive against human 
albumin, apolipoprotein 1A, alpha-fetoprotein, antitrypsin, and annexin V (see 
Chapter 4).
2.18 Cloning of HBV structural genes
The genes encoding the HBV structural proteins were cloned immediately 
downstream from a strong synthetic late vaccinia virus promoter into the transfer 
vector pMJ601 (Davison and Moss, 1990) as described below. Plasma from an HBV 
seropositive patient was donated from the laboratory of Dr. W. F. Carman. The 
portion of the HBV genome encoding the L protein was amplified by the polymerase 
chain reaction (PCR) by Dr. A. Owsianka in our lab. The resulting PCR product 
carrying the L open reading frame (ORF) was cleaved with Aflll and Hindlll and 
inserted together with an oligonucleotide linker with Sail to Hindlll ends and carrying
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sequences encoding a secretory signal sequence of a major secretory protein of 
vaccinia virus (Patel et al., 1990) (Patel, Subaksharpe, and Stow, 1992) into Sail to 
//mdlll-cleaved pMJ601. The resulting plasmid, pMJLx, carried the HBV L ORF 
fused in-frame to the vaccinia virus secretory signal sequence at its 5’ end (Fig. 2.1). 
To construct, pMJL, the L ORF from pMJLx was digested with the restriction 
enzymes Aflll and Hindlll and cloned into Aflll to //mdlll-cleaved pMJ601. To clone 
the HBV M gene, the nucleotide sequences encoding M ORF (amino acids 131 to 
411) was cleaved from pMJL with Bsu36l, the ends made blunt using the Klenow 
fragment of E. coli polymerase I, and cleaved with Hindlll. This ifaw36I/blunt to 
Hindlll fragment was extracted from agarose gel and cloned into Smal to Hindlll- 
cleaved pMJ601 to form pMJM (Fig.2.1). The S gene was subcloned from plasmid 
pRK5/HBsAg (obtained from Dr. W. F. Carman’s lab) on a Nrul to Hindlll fragment 
into Smal to //mdlll-cleaved pMJ601 to form pMJHBsAg. The HBV core gene was 
subcloned from plasmid p5D (obtained from Dr W. F. Carman’s lab) on a Nrul to 
Hindlll fragment into Smal to //mdlll-cleaved pMJ601 to form pMJ5D (Fig.2.1). 
The HBV preSl domain encoding amino acids 1 to 108 of the L protein was cloned 
by PCR amplification using pMJLx as a template. The PCR product was cleaved with 
BamHl to Hindlll and cloned into the bacterial expression vector pQE30 (Qiagen). 
The resulting plasmid, pQESl, carries sequences encoding the amino acids 
MRGSHHHHHHGS followed by residues 1 to 108 representing the HBV preSl 
domain. The entire nucleotide sequence encoding the Lx ORF in pMJLx, and the 6  
histidine-tagged preSl domain in pQESl was determined by the dideoxynucleotide 
chain termination method (Sanger et. al., 1997) and the nucleotide sequence of the Lx 
gene is shown in Appendix 2.
All the constructs described were derived following ligation and transformation of 
appropriate DNA into the E. coli DH5a strain. The transformed bacteria were 
transferred to 1 mL of 2YT broth and incubated with shaking for 1 hour at 37°C, then 
were plated onto L broth Agar supplemented with 100 pg/mL penicillin, and were 
incubated overnight at 37°C. The plates were examined the next day for colonies and 
twelve colonies were picked and grown in 2 mL 2YT broth containing 100 pg/mL 
penicillin for 5 hours. Bacteria from the twelve cultures were pelleted in a benchtop 
centrifuge and the plasmid DNA extracted by the alkaline lysis method and restriction
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analysis was performed to identify colonies carrying the appropriate construct. Large- 
scale cultures of the positive colonies were grown to produce plasmids using a 
commercial plasmid extraction kit (Qiagen, UK). This plasmid DNA was used to 
generate recombinant vaccinia virus (see below).
It should be noted that the plasmids pMJLx, pMJHBsAg, pMJ5D, and pQESl were 
constructed by Dr. A. H. Patel. The plasmids pMJL and pMJM were generated by the 
author.
2.19 Generation of the recombinant vaccinia viruses.
BHK cells were grown in 50 mm dishes and infected with wild-type (wt) Western 
Reserve (WR) at a m.o.i. of 0.05 p.f.u. per cell in 300 pi of maintenance medium. 
The cells were incubated with the inoculum for 1 hour at 37°C to allow the adsorption 
of the virus. Following adsorption, the cells were transfected with the appropriate 
plasmids by lipofection. A mixture of 100 pL of Optimem (Gibco BRL) and 12 pL 
Lipofectase was added to a solution containing 5 pg of plasmid DNA (vector pMJ601 
with the appropriate inserted ORF) in 90 pL of Optimem, and mixed gently. The 
solution was incubated at RT for 10 minutes, whereafter a further 2 mL of Optimem 
was added. The WR-infected monolayer was washed twice in Optimem and the 
lipofection solution was added to the monolayer and incubated at 37°C for 5 hours. 
The lipofection solution was aspirated and the cells were incubated in maintenance 
medium for 2-3 days until the c.p.e. was complete. The cells were harvested, freeze- 
thawed twice and sonicated to release the progeny virus. Aliquots of the lysate was 
diluted to give IX, 10"1, 10‘2 dilutions, and these were added to a monolayers of 
HuTK‘ cells (human thymidine kinase negative) in 50 mm dishes, in a final volume of 
300 pL, for a period of 1 hour at 37°C. The monolayers were overlaid with 2 mL of 
maintenance medium containing 1% low-melting point agarose and 25 pg/mL BudR. 
The medium was set, then overlaid with 1 mL of maintenance medium to prevent 
dehydration of the agarose. The cells were incubated for 2 days, and then the liquid 
medium was removed and replaced with 2 mL of maintenance medium (containing 
1% low-melting point agarose, 25 pg/mL BudR and 250 pg/mL X-gal). The cells 
were incubated overnight at 37°C and examined the next day for blue plaques. Blue 
plaques were picked and replated onto BHK monolayers four times to plaque purify
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the recombinant virus. Following four rounds of plaque purification of the rW s , the 
plaques were added to a T25 culture flask containing BHK cells, and incubated at 
37°C until a c.p.e. was observed. Cells were removed and freeze-thawed twice, then 
sonicated to release the progeny viruses. To generate stocks of rVVs, 6  roller bottles 
of BHK cells were infected at a m.o.i of 1:300 and incubated at 37°C until c.p.e. was 
complete. The cells were harvested by disruption with glass beads and were 
centrifuged at 3,000 r.p.m. in a Sorval RT6000B. The pellet was resuspended in 8  mL 
of Tris-HCl, pH9.0 on ice and was homogenised by 20 strokes in a Dounce 
homogeniser. The homogenate was pelleted at 2,000 r.p.m. for 10 minutes at 4°C, 
and the supernatant was collected. The pellet was resuspended in 8 mL of Tris-HCL, 
pH9.0 on ice and recentrifuged. The supernatants were combined and incubated with 
0.1% trypsin at 37°C for 30 minutes with frequent vortexing. The supernatant was 
diluted to a final volume of 36 mL and two 18 mL aliquots were layered onto 18 mL 
of 36% w/v sucrose in 10 mM Tris-HCl pH9.0, in AH629 rotor tubes. The samples 
were centrifuged at 13,500 r.p.m. for 80 minutes at 4°C, then the pellet was 
resuspended in 2 mL 1 mM Tris-HCl pH9.0. The titre of the rW s  was determined by 
plating ten-fold dilutions of the stock onto BHK monolayers, incubating at 37°C for 
one hour, then overlaying with CMC medium. After three days incubation, 2 mL of 
Giemsa’s stain was overlaid on the monolayer and incubated at RT for 3 hours. The 
stain was washed off in running water, and the plates left to dry at RT. The plates 
were examined with an optical microscope for CPE and the titre of the viral stocks 
was calculated. Stocks of virus were stored at -70°C.
2.20 Confocal microscopy.
Samples for analysis by confocal microscopy were prepared on 13 mm glass 
coverslips in 24 well plates. Cells were grown on the coverslips to 50-60% 
confluence prior to experimental procedures. Cells were infected with rW s  at a 
m.o.i. of 0.5 PFU per cell in 100 pi of DMEM for 1 hour at 37°C with periodic 
agitation to ensure coverage of the cells by the virus suspension. The cells were then 
washed with PBS A to remove any unbound virus and were incubated in DMEM at 
37°C for 24 hours to allow expression of the proteins. Samples for analysis of plasma 
membrane-bound proteins were washed in PBS three times and were then fixed in 2% 
paraformaldehyde and stored at 4°C until further use. Labelling of these samples with
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antibodies was done by incubating the cells with the appropriate dilution of primary, 
then secondary antibodies in PBSA in volumes of 200 pL. Cells to be analysed for 
intracellular expression and localisation of proteins were washed on the coverslips 
three times in PBSA, then stored in ethanol at -20°C for at least 20 minutes, usually 
overnight. The samples were then washed in PBSA and then permeablised with 
PBST for 30 minutes at RT. Labelling of permeablised samples with antibodies was 
done in 200 pL volumes of PBST. The labelled samples were mounted on glass slides 
with a drop of Citifluor anti-fade reagent, and the slides were sealed with Nail 
varnish. Confocal analysis was performed using a Zeiss Laser Scanning Microscope 
with LSM5150 software.
2.21 Fluorescence-Activated Cell Sorting.
Cells were grown to near-confluence in T175 flasks. Cell monolayers were washed 
three times with PBSA and the monolayers were incubated in 10 mL of dissociation 
buffer at 37°C for approximately 30 minutes or until the monolayers became loose 
and the cells were no longer in large clumps. The dissociated cells were washed in 
PBSC twice and centrifuged at 1,000 r.p.m. at 4°C for 2 minutes. The pelleted cells 
from each T175 flask were thoroughly resuspended in 2 mL FPBS. Cells were 
dispensed in 100 pL aliquots (containing approximately lx l0 6 cells per aliquot) to 12 
mL tubes for subsequent labelling with ligands and antisera. Where cells were 
labelled with ligands, the ligands were typically added in volumes of 20 pL at a 
concentration of 1 mg/mL and incubated on ice for 30 minutes. Unbound ligands were 
removed by filling the tube with FPBS and centrifugation of the suspended cells at
1,000 r.p.m. for 2 minutes in a Sorval RT6000B centrifuge. The FPBS was aspirated 
and the cells resuspended in fresh FPBS and the washing repeated. The cells were 
resuspended in 100 pL of FPBS and labelled with primary antibody. Purified 
antibody RC28 was used at a concentration of 1 mg/mL, and 1 pL was added to each 
aliquot of cells requiring labelling. The cells were incubated in primary antibody for 
30 minutes at 4°C and were then washed twice and resuspended in FPBS as 
previously described. The fluorescent labelling of cells was achieved by addition of 1 
pL of anti-IgG-FITC (Sigma) per aliquot of cells resulting in a 1:100 dilution of the 
secondary antibody. The cells were incubated in secondary antibody for 30 minutes 
at 4°C and were washed twice and resuspended in a final volume of 0.7 mL.
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Fluorescence quantitation and analysis was achieved by passing the cells through a 
Becton Dickinson FACScan instrument with CellQuest software.
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Chapter 3
Generation and Characterisation of Reagents
The generation of reagents was undertaken as part of this work. There was a paucity 
of reagents for HBV research in this laboratory prior to the author starting work, 
therefore the initial stages of the work were centred around creation and 
characterisation of reagents for Hepatitis B Virus research. Reagents generated here 
include recombinant vaccinia viruses expressing L, Lx, M, S and core proteins, a 
bacterially produced 6 -hsitidine tagged (6 xHis) preSl domain, monoclonal and 
polyclonal antisera directed against L protein and cell lines derived from primary 
human hepatocytes. Furthermore, some reagents were obtained from other institutes 
and companies, and were used in this work; a monoclonal antibody 6 B 1 , directed 
against S (C. McCaughey QUB, Belfast); polyclonal antisera against core protein 
(DAKO, UK); monoclonal antibody to preS2 (Heermann et al., 1987) antibodies to 
cellular markers (see appendix 1); and HepB3 protein (Medeva, UK). The generation 
and characterisation of reagents is described in this chapter. These reagents were used 
to carry out the aims and objectives of this thesis.
3.1 Expression and purification of the preSl domain
The gene encoding the preSl domain of HBV (adw subtype) surface antigen was 
fused in-frame to the nucleotide sequence coding for the amino acids MRGS followed 
by six histidine residues and two extra amino acids (GS) in the plasmid pQE30 
(QIAGEN, UK). The resulting plasmid, pQESl, was transformed into E.coli M l5 
(pREP4) for protein expression. The expressed product was expected to carry the 
amino acids sequence MRGSHHHHHHGS followed by the N-terminal 108 amino 
acids of the preSl domain with an estimated molecular mass of 14 kDa. A single 
colony each of E.coli strain Ml 5 [pREP4] carrying the plasmid pQE30 or pQESl was 
grown in 2YT broth in the presence or absence of IPTG. Five hours after addition of 
IPTG, the cell extracts were analysed by SDS-PAGE either directly or following 
affinity chromatography on Ni-NTA resin. Figure 3.1 shows the expression of the 
preSl domain in E. Coli and its subsequent purification. As expected, a 14 kDa band 
was seen in IPTG-induced, but not in uninduced, culture of cells carrying pQESl 
(Fig. 3.1, lanes C and D, respectively). This band was not present in induced or
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uninduced cultures of cells carrying the plasmid vector pQE30 (Fig. 3.1, lanes A and 
B). This indicated that the band in lane C from the induced cells carrying pQESl may 
contain the expressed HBV preSl domain. To test if this protein was expressed in a 
soluble form, IPTG-induced cultures of cells carrying pQESl were lysed following 
two rounds of freeze thawing and sonication. The total lysate was then spun for 30 
minutes at 15,000 r.p.m. and the supernatant carrying soluble proteins analysed on 
SDS-PAGE. As shown in Fig. 3.1 lane G, the clarified lysate indeed contained the 14 
kDa protein indicating that at least some of the expressed protein is produced in a 
soluble form. To purify this protein, the clarified lysate was incubated with Ni-NTA 
slurry on a mixer for 1 h at RT, following which it was transferred to a 5 mL 
disposable chromatography column. The column was wash extensively with TN 
buffer and the bound proteins were eluted from Ni-NTA in 250 mM imidazole in TN 
buffer. Analysis of the eluted proteins by SDS-PAGE showed the presence of a band 
at 14 kDa (Fig. 3.1, lanes E and F). The 14 kDa band is the only band visible at the 
limits of optical detection by coomassie blue staining in SDS-PAGE, indicating that 
the purification was highly effective.
The identity of the preSl domain from lane E in Fig. 3.1 was verified by Western 
immunoblotting of this sample of protein using a monoclonal antibody directed 
against the MRGS-6xHis tag (Qiagen, UK) or the HBV preS 1 domain. As shown in 
Fig. 3.2A, the anti-his MAb recognised the 14 kDa protein in the total extract of 
IPTG-induced cells carrying pQESl (lanes B and C) and in the protein fraction eluted 
from the Ni-NTA column (lane A). As expected, the anti- his MAb failed to recognise 
a 14 kDa product in the extracts of pQE30-carrying cells (Fig. 3.2A, lanes D and E). 
To show that the his-tagged product was the preSl domain, another Western blot was 
performed using a monoclonal antibody MAb 18/7 that is known to recognise the 
preSl domain (Heermann et al., 1984). As seen in Fig. 3.2B, the MAb 18/7 identified 
the protein of the same molecular weight as the protein recognised by the anti-His 
MAb. These results, taken together with those shown in Fig. 3.1 show that the preSl 
domain is expressed in reasonable quantities in bacteria, that this protein is 
recoverable in a soluble form, and that it can be purified by single-step affinity 
chromatography to near homogeneity.
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Figure 3.1 Expression and purification of HBV preSl domain from E. Coli.
E.coli strain M l5 (pREP4) carrying pQE30 (lanes A and B) or pQESl (lanes C to G) was 
grown in the absence (-) or presence (+) of IPTG. Following incubation at 37°C for 5 hours, 
cells were harvested and analysed on a 12.5% SDS-PAGE either directly (lanes A-D) or 
after lysis and affinity chromatography (lanes E+F) on a Ni-NTA column. The fractionated 
proteins were visualised with coomassie brilliant blue.
Lane A+B: Total extract of cells carrying pQE30.
Lane C+D: Total extract of cells carrying pQESl.
Lane E+F: proteins from E. coli expressing pQESl eluted with 250 mM and 20 mM 
imidazole, respectively.
Lane G: soluble cell lysate from cells expressing pQESl.
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Figure 3.2A and B: Verification of the identity of the purified protein as the preSl 
domain fusion protein.
The induction of the bacteria with IPTG leads to the expression of protein species migrating 
at 14 kDa that are reactive with antisera against known epitopes. The purified protein eluted 
in 250 mM imidazole (lane A, panels A and B) was probed with anti-MRGS-6xHis MAb
(3.2A), or MAb 18/7 (3.2B). The lysate from cells carrying pQESl (lanes B and C)
following induction with IPTG (+) or in the absence of IPTG (-), and the lysate from cells 
carrying the pQE30 plasmid (lanes 4 and 5) following induction with IPTG (+) or in the 
absence of IPTG (-) were probed with anti-MRGS 6xHis and Mab 18/7 to confirm the 
identity of the proteins.
Lane A: purified protein from Ni-NTA eluted in 250 mM imidazole.
Lanes B and C: Total extract of cells carrying pQESl.
Lanes D and E: Total extract of cells carrying pQE30.
3.2 Generation and characterisation of recombinant vaccinia viruses expressing 
HBV structural proteins.
The genes encoding HBV structural proteins L, M, S, and core were inserted into the 
thymidine kinase locus of vaccinia virus strain WR (see Materials and Methods). 
Briefly, the L gene was PCR amplified by Dr A. Owsianka from a patient serum and 
cloned immediately downstream from a strong synthetic late vaccinia virus promoter 
into the transfer vector pMJ601 (Davison and Moss, 1990). The nucleotide sequence 
of the Lx gene was determined and it’s amino acids sequence deduced and is shown 
in Appendix 2. As expected, the amino acids sequence of the Lx gene was almost 
identical to the published sequences of L protein of adw subtypes. However, several 
variant amino acids were present in the Lx sequence (see Appendix 2). It is not clear 
whether these changes have occurred due to PCR errors or represent the patient 
serotype. The ORFs encoding L and M and the preSl domain were subsequently 
subcloned from the plasmid pMJLx into appropriate vectors as described in the 
Materials and Methods. The genes encoding S and core were subcloned into pMJ601 
from constructs obtained from Dr. W. F. Carman. The pMJ-based constructs were 
used to generate recombinant vaccinia viruses (rW s) vL, vLx, vM, vS and v5D (as 
described in Materials and Methods).
3.2.1 Expression of L, Lx, M, S and core in mammalian cells.
The initial characterisation of the proteins expressed by the rW s  was performed by 
Western immuno blotting and confocal microscopy using antibodies specific to viral 
antigens. BHK cells were mock infected or infected with wt vaccinia virus strain WR 
or the rW s. At 24 h post-infection, the medium was collected, cells washed twice 
with PBS and lysed in lysis buffer (see Materials and Methods). The medium and cell 
lysate of infected cells were then subjected to SDS-PAGE and the fractionated 
proteins were electrotransferred to Hybond ECL membranes. The membranes were 
subjected to Western immunoblotting using an anti-preSl MAb 18/7 or an anti-core 
MAb 2A23 As shown in Fig. 3.4A, the MAb 18/7 specifically recognised a 42 kDa 
product in the lysate of cells infected with vL or vLx, but not with strain WR or 
mock-infected controls. Furthermore, this MAb also recognised the same sized 
product in the medium of cells infected with vLx, but not with WR, or mock infected 
control (Fig. 3.4A). These results show both vL and vLx express the L protein of 
expected molecular weight. Furthermore, in agreement with observation made by
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others, the L protein is not secreted into the medium. However, secretion of L protein 
can be achieved if the protein is fused to a secretory signal peptide (see Fig. 3.3A, 
lane Lx, SN).
As expected, Western immunoblot using anti-core MAb 2A23 showed that this MAb 
specifically recognised a 22 kDa core protein in cells infected with v5D, but not with 
WR-infected or mock-infected cells (Fig. 3.4B). The ECL membranes were also 
probed with available antibodies to the M and S protein of HBV. Unfortunately, 
neither of these antibodies recognised the appropriate protein in Western blots (data 
not shown). However, the expression of M and S by vM and vS, respectively, was 
confirmed by immunofluorescence assay (see below).
To facilitate confocal analysis of the structural proteins, HepG2 cells were infected 
with the recombinant vaccinia viruses vL, vLx, vM, vS or v5D on coverslips, 
incubated for a further 24 hours at 37°C and fixed 24 hours post-infection in methanol 
at -20°C. After washing, the fixed cells were incubated with anti-preSl MAb 18/7, 
anti-M MAb 2-2fl2 (kindly supplied by Professor W. H. Gerlich, Institute of Medical 
Virology, Giessen, Germany; (Heermann et al., 1984), anti-S MAbs H I66 and H53 
(Abbott Laboratories; obtained from Dr W. F. Carman’s lab), or a polyclonal 
antiserum raised against HBV core (DAKO, UK). Following washing, the cells were 
then incubated with anti-mouse IgG-FITC or anti-rabbit IgG-TRITC conjugate as 
appropriate for 1 h at RT. After washing the coverslips were mounted on glass slides 
and cells examined under confocal microscope. As shown in Fig. 3.4, cells infected 
with vL and vLx produced a protein that was recognised by MAb 18/7 (panel A and 
B). Similarly, MAb 2-2fl2, MAb H I66, or polyclonal anti-core anti-serum recognised 
the HBV M (panel C), S (panel D), or core (panel E), respectively, in cells infected 
with appropriate rW s  (Fig. 3.4). All the expression products encoded for by the rW s  
reacted with the antisera directed against that particular protein, thus providing 
evidence that the encoded HBV protein was reactive with antisera known to react 
specifically with a particular HBV antigen. A detailed characterisation of expressed 
protein is described in chapters 5, 6 and 7.
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Figure 3.3. Characterisation of HBV structural antigens.
HepG2 cells on glass coverslips in 24-well plates were infected at an m.o.i. of 0.5 p.f.u./cell with 
vL (Panel A), vLx (panel B), vM (panel C), vHBsAg (panel D), and v5D (panel E). At 24 hours 
post-infection, the cells were fixed in methanol at -20°C, then permeablised in PBST. The cells 
were probed with MAb 18/7 (panels A and B), MAb 2-12f2 (panel C), MAb H166 (panel D) and a 
polyclonal antiserum against core (DAKO, UK, panel E).
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Figure 3.4. Characterisation of HBV structural antigens.
BHK cells were mock-infected, or infected with WR, vLx, vL or v5D at a m.o.i. of 10 p.f.u./cell. 
At 24 hours post-infection, the supernatants were clarified, and the cells were harvested and lysed 
with final sample buffer and subjected to 10% SDS-PAGE. The fractionated proteins were 
transferred to Hybond ECL membranes and probed with MAb 18/7 (panel A) at a 1:1000 
dilution, or MAb 2A23 (panel B) at a 1:500 dilution. The bound antibodies were detected with 
1:1000 diluted anti-mouse-IgG-HRP followed by chemiluminescence with ECL reagents.
3.3 Generation and Characterisation of Antisera.
Polyclonal and monoclonal antibodies were generated by immunisation of rabbits and 
mice respectively, with the purified preSl domain described in section 3.1. The 
characterisation of the rabbit polyclonal antibodies (PAbs) generated here was 
performed by the author and is described in the following sections.
3.3.1 Polyclonal Antisera 142 and 143.
Two rabbits, numbers 142 and 143, were repeatedly immunised with the preSl 
domain in order to obtain polyclonal antisera reactive against the L protein of HBV. 
Following the immunisation protocol (described in Materials and Methods), the 
rabbits were exsanguinated and the serum clarified by centrifugation, aliquotted and 
stored at -20°C.
The rabbit-derived antisera raised against the preSl domain were evaluated for 
activity in the following assays: Western blot, immunoprecipitation and 
immunofluorescence. For Western blotting, HepG2 cells were infected at an m.o.i. of 
10 p.f.u./cell with vaccinia virus strain WR or the recombinant vaccinia virus 
expressing Lx (vLx). At 24 h post infection, the cells were lysed in SDS-PAGE 
denaturation buffer. The extracts were electroblotted on to Hybond ECL membrane 
following resolution of proteins by SDS-PAGE, and probed with PAb 142 or 143 as 
shown in Figs. 3.5A and B. Both antisera reacted specifically to a 46 kDa band in 
vLx-infected cells but not in cells infected with the wt vaccinia strain WR. The pre- 
immune sera taken from each rabbit prior to the start of the immunisation (see 
Materials and Methods) regimes were tested shortly after acquisition and were found 
to be unable to immunoprecipitate or recognise vLx protein in Western immunoblot 
(data not shown), thus confirming the specificity of PAbs 142 and 143 to HBV L 
protein.
To test the reactivity of PAbs 142 and 143 in immunoprecipitation assay, HepG2 cells 
were either mock-infected or infected with the wt vaccinia strain WR, or recombinant 
vaccinia viruses vLx, or vL and the cells radiolabelled with 35S-methionine from 5 h 
to 18 h post-infection. The infected cells were washed twice with PBS and lysed in 
Zweig’s buffer. The lysates were clarified and the labelled proteins
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Figure 3.5. Characterisation of the PAbs 142 and 143 by Western immunoblotting.
BHK cells were infected with the wild-type vaccinia virus strain WR or the recombinant vaccinia 
virus expressing the Lx protein (vLx) at a m.o.i. of 10 p.f.u./cell. At 24 hours post-infection, the 
cells were harvested and lysed with final sample buffer and the lysate subjected to 10% SDS- 
PAGE. The fractionated proteins were transferred to Hybond ECL membranes and probed with 
PAb 142 (panel A) or PAb 143 (panel B) at a 1:1000 dilution. The bound antibodies were 
detected with 1:1000 diluted protein-A-sepharose followed by chemiluminescence with ECL 
reagents.
immunoprecipitated using PAb 142 or 143. As shown in Fig. 3.6 A and B, both 
antisera precipitated a protein of approximately 46 kDa from cells infected with vLx 
and vL. The absence of any significant bands at the appropriate molecular weight in 
the mock-infected cells or WR-infected cells at around the 46 kDa position on the 
autoradiograph indicated that these antisera can specifically immunoprecipitate the L 
protein with minimal reactivity to cellular or vaccinia virus proteins (Fig. 3.6 A and 
B). To test the reactivity of PAbs 142 and 143 in immunofluorescence assays, HepG2 
cells, mock-infected or infected with vaccinia strain WR or vLx, were probed with 
immune or pre-immune PAb 142 and 143. The antisera were evaluated at titres of 
1:500, 1:1000, 1:2000 and 1:4000 for these assays. The results shown in Figs. 3.7 and 
3.8 were obtained with a titre of 1:1000. This titre offered the best contrast between 
the infected and non-infected cells in the vLx-infected samples. As shown in Panel A 
of Figs. 3.7 and 3.8, both polyclonal antisera specifically recognised the vLx protein. 
The absence of any reactivity in the panels B and C of Figs. 3.7 and 3.8 indicated 
minimal reactivity to any cellular or vaccinia virus proteins. Furthermore, the 
respective pre-immune sera from rabbits 142 and 143 failed to react with the vLx- 
expressing cells (Panel D, Figs. 3.7 and 3.8) again indicating strongly that the 
reactivity is specific to the L protein.
Taken together, these results indicate that the polyclonal antisera 142 and 143 are 
capable of specifically recognising the L protein in the described assays, with minimal 
recognition of cellular or vaccinia proteins.
3.3.2. Monoclonal antibodies
A batch of five Balb/c mice were immunised with the purified preSl domain 
described in section 3.1. Following repeated boosting of the mice with antigen, the 
spleen cells were removed and fused with the sp2/0 cell line as described in Materials 
and Methods. Following growth of colonies in 96-well plates, the supernatants from 
the wells were analysed by ELISA to identify colonies producing immunoglobulins 
reactive to the preS 1 domain. Hybridoma supernatants giving ELISA-positive results 
were screened for reactivity to the bacterially expressed preSl domain in Western 
blotting assays. Hybridoma supernatants showing positive reactivity in Western blots 
against the preSl domain were screened for reactivity against the vLx protein in 
Western blotting assays (data not shown). The aim of this discriminatory assay was
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Figure 3.6. Characterisation of the PAbs 142 and 143 by Immunoprecipitation.
HepG2 cells were mock-infected, infected with the wild-type WR strain vaccinia virus or 
the recombinant vaccinia virus expressing the Lx protein (vLx), or vL, at a m.o.i. of 10 
p.f.u. per cell. At 5 hours post-infection, the infected cells were radiolabelled with 35's 
methionine. At 18 hours post-labelling, the cells were lysed, clarified and subjected to 
immunoprecipitation with PAb 142 (panel A) or PAb 143 (panel B). The immune 
complexes were subjected to 10% SDS-PAGE and the radiolabelled proteins detected by 
autoradiography.
Lane MI: Mock-infected cell extract.
Lane WR: WR-infected cell extract.
Lane vLx: vLx-infected cell extract.
Lane vL: vL-infected cell extract.
Figure 3.7. Characterisation of the PAb 142 by immunofluorescence.
HepG2 cells on glass coverslips in 24-well plates were infected at a low m.o.i. with the 
recombinant vaccinia virus expressing the Lx protein (vLx, Panel A and D) mock-infected (MI, 
Panel B) or wild-type (WR, Panel C). At 24 hours post-infection, the cells were fixed in 
methanol at -20°C, then permeablised in PBST. The cells were probed with a 1:1000 dilution of 
PAb 142 (panels A, B and C) or pre-immune serum (panel D) from rabbit 142. The 
immunolabelled cells were detected with a 1:1000 dilution of anti-rabbit-FITC with a NIKON- 
Microphot microscope.
Figure 3.8. Characterisation of PAbl43 in immunofluorescence assays.
HepG2 cells on glass coverslips in 24-well plates were infected at a low m.o.i. with the 
recombinant vaccinia virus expressing the Lx protein (vLx, Panels A and D) mock-infected (MI, 
Panel B) or wild-type (WR, Panel C). At 24 hours post-infection, the cells were fixed in methanol 
at -20°C, then permeablised in PBST. The cells were probed with a 1:1000 dilution of PAb 143 
(panels A, B and C) or pre-immune serum (panel D) from rabbit 143. The immunolabelled cells 
were detected with a 1:1000 dilution of anti-rabbit-FITC with a NIKON-Microphot microscope.
to establish which of the cultures were secreting antibodies that were reactive to the 
preSl domain of L, not against the MRGS-6xHis tag. Using this approach, four MAbs 
were identified which reacted specifically to HBV L protein. The reactivity of these 
MAbs (RC9, RC28, RC109 and RC152) is shown in Figs. 3.9 A to D, with a 
negligible background in the WR or mock-infected cells.
The ability of the four monoclonal antibodies RC9, RC28, RC109 and RC152 to 
immunoprecipitate L protein was examined. Briefly, HeLa cells were infected with 
WR, vLx, vL viruses, or were mock-infected. The cells were incubated with 
methionine-deficient medium supplemented with 35S-methionine five hours post 
infection, and incubated overnight. The next day, the cells were detergent-solublised 
and the clarified extract (see Materials and Methods) used in immunoprecipitation 
assays. In initial experiments, very poor reactivity was observed of the monoclonal 
antibodies generated here, when tested singly (not shown). However, a cocktail of all 
four antibodies was able to immunoprecipitate the Lx and the L protein from cells 
infected with vLx and vL, respectively (Fig. 3.10). There was little reactivity of this 
mixture of antibodies with proteins in mock- or vaccinia virus strain WR-infected 
cells (Fig. 3.10) indicating the specificity of these MAbs to HBV L protein. It has 
been reported that a combination of monoclonal antibodies directed against a 
particular protein can be used to greater effect in immunoprecipitations than one 
monoclonal antibody alone (Ehrlich and Moyle, 1986). Certainly, in this case it is 
evident that a co-operative effect is observable with immunoprecipitation being 
effectively enabled with a combination of monoclonal antibodies. It is not clear why 
the MAbs failed to immunoprecipitate the L protein when tested individually. It is 
possible that the conditions (e.g. lysis buffer) employed for immunoprecipitation 
assays in this work were not optimal for the individual antibodies to 
immunoprecipitate the L protein.
Hybridoma supernatants RC9, RC28, RC109, or RC152 were examined in an 
immunofluorescence assay for reactivity against the Lx protein in vLx-infected HeLa 
cells. As shown in Figs. 3.11 and 3.12, all four MAbs reacted with the Lx protein in 
vLx-infected cells (panels A and D), but there was no discernible fluorescence in the 
WR-infected and mock-infected cells (panels B, C, E, and F) indicating that these 
antisera are reacting specifically to HBV L in immunofluorescence assays. These
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Figure 3.9. Characterisation of MAbs RC9, RC28, RC109 and RC152 by immunoblot.
HepG2 cells were infected at a m.o.i. of 10 p.f.u/cell with WR (lanel), vLx (lane 3) or were 
mock-infected (lane 2). At 24 hours post-infection, the cells were lysed in final sample buffer 
and the lysate subjected to 12.5% SDS-PAGE. The fractionated proteins were transferred to 
Hybond ECL membranes and were then probed with 1:1000 dilution of RC9 ( panel A), 
RC28 (panel B), RC109 (panel C) or RC152 (panel D). The bound antibodies were detected 
by anti-mouse-IgG-HRP followed by chemiluminescence with ECL reagents.
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Figure 3.10. Immunoprecipitation of L and Lx by a cocktail of monoclonal antisera.
HepG2 cells were mock-infected (lane 1) or infected at m.o.i. of 10 p.f.u./cell with WR (lane 2), 
vLx (lane 3) or vL (lane 4). At five hours post-infection the cells were labelled with methionine- 
deficient medium supplemented with 35S-methionine. At 18 hours post-infection, the cells were 
harvested and lysed. The cell lysate was subjected to immunoprecipitation with a cocktail of 
hybridoma supernatants from cultures RC9, RC28, RC109 and RC152. The immune complexes 
were analysed by 10% SDS-PAGE and the radiolabelled proteins were detected by 
autoradiography. The combination of antibodies results in effective immunoprecipitation of the 
large surface antigen, with minimal reactivity with cellular or vaccinia proteins.
vLx/vL
Figure 3.11. Characterisation of MAbs RC9 and RC28 by immunofluorescence.
HepG2 cells on glass coverslips in 24-well plates were infected at an m.o.i. of 0.5 p.f.u./cell with 
the recombinant vaccinia virus expressing the Lx protein (vLx, Panels A and D) mock-infected 
(MI, Panels B and E) or wild-type (WR, Panels C and F). At 24 hours post-infection, the cells 
were fixed in methanol at -20°C, then permeablised in PBST. The cells were probed with a 
1:1000 dilution of RC9 (panels A, B and C) or RC28 (panels D, E and F). The immunolabelled 
cells were detected with a 1:1000 dilution of anti-rabbit-FITC with a NIKON-Microphot 
microscope.
Figure 3.12. Characterisation of MAbs RC 109 and RC152 in immunofluorescence assays.
HepG2 cells on glass coverslips in 24-well plates were infected at an m.o.i. of 0.5 p.f.u./cell with 
the recombinant vaccinia virus expressing the Lx protein (vLx, Panels A and D) mock-infected 
(MI, Panels B and E) or wild-type (WR, Panels C and F). At 24 hours post-infection, the cells 
were fixed in methanol at -20°C, then permeablised in PBST. The cells were probed with a 
1:1000 dilution of RC109 (panels A, B and C) or RC152 (panels D, E and F). The 
immunolabelled cells were detected with a 1:1000 dilution of anti-rabbit-FITC with a NIKON- 
Microphot microscope.
supernatants were used at a titre of 1:1000 in these assays, and also at 1:1000 for any 
other immunofluorescence assay during this work. The reactivity of the MAbs RC9, 
RC28, RC109 and RC152 against the Lx protein (which lacks a MRGS-6x His tag) 
confirms that these antibodies are directed against the preS 1 domain of the L protein.
3.3.4. Monoclonal Antibody 6B1
A previously uncharacterised monoclonal antibody 6B1, raised against the Engeryx™ 
vaccine consisting of S, was kindly supplied by Dr. C. McCaughey of Queen's 
University, Belfast, UK. The MAb 6B1 was initially supplied as a hybridoma 
supernatant, and then as an ascites fluid, and was characterised by the author.
Initially, MAb 6B1 was tested in Western immunoblot for reactivity against S protein 
from cells infected with vS, but it consistently failed to show recognition (data not 
shown). This may have been due to amino acid differences between the S present in 
Engeryx™ preparation and that encoded by vS. Alternatively, it is possible that the 
MAb 6B1 recognises a conformational epitope in S. To ascertain if that is the case, 
MAb 6B1 was tested for its ability to specifically immunoprecipitate S. Radiolabelled 
proteins of HepG2 cells infected with vaccinia virus strain WR or vS were 
immunoprecipitated with MAb 6B1 and the immune complexes were analysed 
following SDS-PAGE. As shown in Fig. 3.13, MAb 6B1 specifically 
immunoprecipitated proteins of the characteristic double band at 25 and 27 kDa 
corresponding to the glycosylated and non-glycosylated forms of the S. These bands 
were not seen in the WR- or mock-infected cells, thus demonstrating the ability of 
MAb 6B1 to specifically immunoprecipitate S from clarified cell extract of S- 
expressing cells. This result was further confirmed in an immunofluorescence assay 
where S was clearly recognised by MAb 6B1 in HepG2 cells infected with vS (Fig. 
3.14, panel A), but showed little or no discernible fluorescence in the WR or mock- 
infected samples (panels B and C). Although the fluorescence in this figure seems 
weak, it should be noted that the immunofluorescent microscope (NIKON Microphot- 
SA) was used for all of these initial characterisation experiments. Later work done 
with the Zeiss Laser Scanning Confocal Microscope portrays more accurately the 
immunofluorescent labelling characteristics of the MAb 6B1.
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Figure 3.13. Characterisation of MAb 6B1 by Immunoprecipitation of HBsAg.
HepG2 cells were infected at m.o.i. of 10 p.f.u./cell with WR (lane 1), mock infected (lane 2) or 
vHBsAg (lane 3). At five hours post-infection the cells were labelled with methionine-deficient 
medium supplemented with 35S-methionine. At 18 hours post-infection, the cells were 
harvested and lysed. The cell lysate was subjected to immunoprecipitation with the ascites fluid 
from culture 6B1. The immune complexes were analysed by 10% SDS-PAGE and the 
radiolabelled proteins were detected by autoradiography. There is clearly effective
immunoprecipitation of the glycosylated and non-glycosylated forms of the surface antigen. 
There is minimal reactivity of the 6B1 ascites fluid with cellular or vaccinia proteins.
Figure 3.14. Characterisation of MAb 6B1 by immunofluorescence.
HepG2 cells on glass coverslips in 24-well plates were infected at an m.o.i. of 0.5 p.f.u./cell 
with vHBsAg, (Panel A) mock-infected (panel B) or WR (panel C). At 24 hours post­
infection, the cells were fixed in methanol at -20°C, then permeablised in PBST. The cells 
were probed with a 1:500 dilution of MAb 6B1. The immunolabelled cells were detected 
with a 1:1000 dilution of anti-rabbit-FITC with a NIKON-Microphot microscope.
Taken together, the above results show that the inability of MAb 6B1 to recognise S is 
not due to amino acid difference between the antigen used to immunise mice and that 
expressed by vS, but rather it recognises a conformation-dependent epitope in S.
3.3.5. Isotype determination
Assessment of the isotype of immunoglobulin expressed by each of MAbs RC9, 
RC28, RC109 and RC152 was performed using a commercially available mouse 
antibody testing kit (Sigma, UK), according to the manufacturer's instructions. All of 
the monoclonal antibodies were found to be of the IgGla subtype.
3.4 Peptide characterisation
The production of short peptides corresponding to overlapping regions of the preSl 
domain was undertaken in order to facilitate epitope mapping of the MAbs generated 
here. A series of eight peptides, mostly of 20 residues with an overlapping 5 residue 
region at the C-terminus corresponding to the N-terminal 5 residues of the next 
peptide in the series were synthesised and purified (see Materials and Methods).
Following purification of the peptides by reverse-phase High Performance Liquid 
Chromatography, the analysis of the molecular weight of the peptides was undertaken 
to ensure the correct fractions had been recovered. A typical example of one peptide 
being analysed in order to establish its molecular weight is portrayed in Fig. 3.15. 
Two control peptides of known molecular weight, corresponding to segments of the 
reverse transcriptase of human immunodeficiency virus were included in all samples 
to enable the calibration of the instrument and also to serve as internal controls 
throughout the course of the determination of multiple samples. The amino acid 
sequence of the overlapping peptides is shown in Table 1. The results from the 
analysis of the molecular weights of the peptides and the comparison of the expected 
and observed molecular weights are shown in Table 1. All of the peptides synthesised, 
purified and characterised here were of the expected molecular mass, and were 
soluble in water.
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Figure 3.15. Determination of molecular weights of the purified peptides
The molecular weight of purified peptides was assessed by comparison with two peptide standards 
of known molecular weight by using a Mass Spectrometer. Here, an example of one analysis of a 
newly synthesised and purified peptide (1123b) shows the observed molecular mass of 2386.0. 
The peak at 1560.8 mass units is due to the presence of an internal control peptide corresponding 
to a portion of the reverse transcriptase of HIV-1. The observed molecular weight of peptide 
1123b correlated well with the expected molecular mass of 2386.5. The molecular weights 
determined for the remainder of the series of peptides produced in this work were very close to 
the expected values (see table 1).
Peptide aa sequence M. Wt. solubility charge
1123a MGQNLSTSNPLGFLPDHQLD 2217.6 (2225.8) + -1
1123b DHQLDPAFRANTNNPDWDFN 2386.5 (2386.0) + -2
1123c TNNPDWDFNPKKDPWPEANK 1818.9(1824.0) + -2
1123d PKKDP WPE ANK V G V GAY GPG 2298.5 (2314.5) + -1
1123e AYGPGFTPPHGGLLGWSPQS 1880.2(1882.0) + +2
1123f WSPQSQGTLTTLPADPPPAS 1998.2 (2009.8) + -1
1123g PPPASTNRQS GRQPTPISPP 2090.3 (2362) + +2
1123h PISPPLRDSHPQA 1953.2(1952.9) + +2
21 -47 PLGFLPDHQLDP AFGANSTNPD WDFNP Y
Table 1 Peptide production, purification and characterisation.
The design and characterisation of the peptides is portrayed above. The molecular weights of the 
peptides obtained after HPLC purification is shown, the first of the figures being the expected 
molecular weight of the peptide as calculated from the amino acid composition, the figures in 
parenthesis are the observed molecular weights following determination by mass spectrometry. In 
most cases, the observed and expected values are within the limitations of the sensitivity of the 
instrument (10 mass units). The peptides were all soluble in distilled water. It should be noted 
that peptide 21-47 was produce’by Dr. A. Owsianka prior to the commencement of this work. The 
sequence for peptide 21-47 corresponds to the receptor binding region and is derived from data 
published by Gerlich et. al. 1993.
3.5. Epitope Mapping of MAbs
Epitope mapping of the monoclonal antibodies was performed so that the residues of 
the preSl domain each antibody is reactive with could be delineated. An ELISA- 
based peptide-inhibition-binding assay was used to competitively inhibit the binding 
of the antibody to the immobilised preSl domain with the peptide that contains the 
reactive residues (see Materials and Methods). Briefly, the wells of a 96-well 
Immulon II microtitre plate were coated with 125 ng of preSl domain. Unbound 
preSl domain was removed by washing with PBST buffer. Peptides 1123A to H 
were added to the wells in 0, 10, 100 and 1000-fold molar excess in volumes of 100 
pL for the inhibition assays. The MAbs RC9, RC28, RC109 or RC152 were incubated 
along with the peptides for two hours. The wells were washed with PBST and anti­
mouse IgG-HRP was added to the wells for one hour. The unbound secondary 
antibody was washed away with PBST and the chromogenic substrate was added and 
the intensity determined in an ELISA plate reader. The inhibition of recognition of 
preSl domain by MAbs RC9, RC28, RC109 and RC152 can be seen in Fig. 3.16 A to 
D. The inhibitory peptide responsible for abrogation of binding of MAbs RC9, RC28, 
RC109 and RC152 to preSl domain is identified as 1123B in all cases. The inhibition 
by lOOOx molar concentration of the inhibiting peptide 1123B resulted in almost 
complete abrogation of binding of the MAbs to the immobilised preSl domain. Aside 
from 1123B, no other peptides were capable of an inhibitory effect on the binding of 
the MAbs to the preS 1 domain, therefore, all of the MAbs are found to be reactive to 
residues contained within the positions 15-35 of the preSl domain. However, due to 
the overlapping design of the peptides, it could be suggested that the residues 15-20 
are not involved in binding the MAbs, as the peptide 1123A did not inhibit binding, 
and furthermore, the peptide 1123C (residues 30-45) did not inhibit binding. Thus, it 
could be suggested that the minimal epitopes for reactivity of the MAbs lie between 
the residues 20-30. Furthermore, the MAb 18/7 was assessed for reactivity to its 
epitope (Fig. 3.16E) by the same method of inhibition by increasing concentrations of 
inhibitory peptide and was also found to be reactive to the region of the preS 1 domain 
represented by the 1123B peptide. This is in agreement with (Heermann et al., 1984) 
data which mapped MAb 18/7 to the PAFRAN epitope.
51
2a
m©
4JCJ
SA
-DS-
©cn-D
c
B *
in
©
oucc«-Di-ow-D
<
10
— 1123e
— 1123f
Inhibitory peptide concentration (M)
1.4
1.2
1
0.8
0.6
0.4
0.2
0
0 10 100 1000
1123a 
1123b 
1123c 
1123d 
1123e 
1123f 
1123g 
1123h
Inhibitory peptide concentration (M)
Figure 3.16 A and B. Epitope mapping of MAbs RC 9, RC28, RC109, RC152 and MAb 
18/7 with inhibitory peptides.
96-well plates were coated with 125 ng of preSl domain, overnight at room temp. The next 
day, the wells were blocked with 2% BSA in PBSA. The monoclonal antisera RC9 (panel A), 
RC28 (B), RC109 (C), RC152 (D) and MAb 18/7 (E) were added to the wells in the absence of 
peptides 1123a-h, or in the presence of 10, 100 or lOOOx molar excess of peptides 1123a-h. The 
antisera were also incubate in the presence of 1 OOOx molar excess of peptides corresponding to 
epitopes not present on the preSl domain (panel F). The unbound complexes were washed 
from the plate and the bound antibodies detected by anti-mouse IgG-HRP and the chromogenic 
substrate ABTS.
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Figure 3.16 C and D. Epitope mapping of MAbs RC 9, RC28, RC109, RC152 
and MAb 18/7 with inhibitory peptides (continued).
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Figure 3.16 E and F. Epitope mapping of MAbs RC 9, RC28, RC109, RC152 
and MAb 18/7 with inhibitory peptides (continued).
For a further control study, four peptides were obtained from Dr. W. F. Carman’s 
laboratory, corresponding to the hydrophilic regions of the S. Each antibody mixed 
with a lOOOx molar concentration of the S peptides was tested for reactivity to the 
immobilised preSl domain. As expected, the peptides failed to block MAb 
recognition of preSl, indicating that the peptide 1123B-mediated inhibition of preSl 
recognition by MAbs RC9, Rc28, RC109, and RC152 not due to non-specific 
interactions with a peptide not representing a portion of the preSl domain (Fig. 
3.16F).
Taken together, these data show that the four MAbs generated and characterised here 
are reactive to regions in the preSl domain that are represented by the 1123B peptide. 
Thus, the four anti-preSl MAbs used in this study are reactive to linear epitopes of the 
preSl domain.
3.6 Purification of MAb RC28.
The MAb RC28 was purified in order to obtain a preparation of antibody that was free 
from contaminants such as bovine IgG. It was considered desirable to purify RC28 in 
order to obtain a pure monoclonal antibody to use in ligand-binding assays. It should 
be noted that the co-purification of bovine IgG with mouse IgG would possibly 
interfere in binding assays where the sensitivity of the assays could be crucial, 
therefore purification of RC28 from serum-free medium was undertaken.
Large-scale purification of the MAb RC28 from serum-free hybridoma medium 
(Gibco) was undertaken, and the purification profile is depicted in Fig. 3.17. Briefly, 
the serum-free supernatant was dialysed against 20 mM phosphate buffer then filtered 
before pumping onto a protein-G Superose column (Pharmacia), washing in 
phosphate buffer, and fractional elution by Glycine at pH 2.7 into tubes containing 
neutralisation buffer (see Materials and Methods). The elution of the MAb RC28 is 
apparent from the UV absorbency at 280 nm, at position C on Fig. 3.17. This 
antibody was dialysed against PBS A after neutralisation of the glycine with Tris-HCl 
buffer in order to minimise pH-dependent degradation of the immunoglobulin over 
time. This purified antibody preparation was used chiefly for flow cytometry-based 
ligand binding assays to investigate the binding of the preSl domain to plasma 
membranes (See chapter 7).
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Figure 3.17. Purification of MAb RC28 from serum-free medium.
H ybridom a cells o f  culture RC28 were grown in T175 flasks in serum -free m edium . A fter 10-14 
days o f  incubation, the m edium  was harvested and clarified, then dialysed against 20 mM  
phosphate buffer at pH7.0 then was pum ped on to a protein G colum n (Sigm a) starting at point 
A, the colum n was washed in 20 mM  phosphate buffer (point B) and the antibody was eluted 
in glycine at pH2.7 (point C). The M Ab was eluted in 1 mL aliquots and added to Tris-HCl at 
pH9.0 and m ixed thoroughly. The eluted M Ab was dialysed against three changes o f  PBSA at 4° 
C, and stored in 1 mL aliquots at 4°C.
3.7 Preparation and Characterisation of Proteins for Ligand-Binding Assays.
The use of ligands representing the surface proteins of viruses has been employed 
successfully by many researchers to elucidate mechanisms of viral entry and also in 
the identification of cellular receptors for viruses (Flint et al., 1999; Higginbottom et 
al., 2000). This section describes the preparation and characterisation of various 
proteins that were used later in binding assays. The preparation of a variety of ligands 
was undertaken in order to assess the binding of each ligand to the plasma membranes 
of cells, but also to provide more than one means of examining the ligand-cell 
interaction for HBV surface antigens. The ligand most often used in this work was 
the preSl domain described in section 3.1. This ligand was purified in milligram 
amounts and used in flow cytometry and other assays (see Chapter seven) to 
investigate the binding to cells. Another ligand, HepB3, was a kind gift from 
Medeva, UK. The HepB3 preparation consists of recombinant S particles carrying the 
amino acid 21-47 region of the preSl domain into one of the hydrophilic loops. The 
HepB3 is intended for vaccine use, but was evaluated here as a ligand in flow- 
cytometry assays.
The surface iodination using 125I of the preSl domain and the HepB3 preparation was 
undertaken in order to provide radiolabelled ligands for use in cell binding assays, and 
the autoradiograph profile of the labelled proteins was examined. This was to ensure 
that the iodination has worked and that the proteins had remained intact during this 
procedure. As shown in Fig. 3.18A, a major band of 21 kDa or 14 kDa of HepB3 
particle or preSl domain was seen, and there was no indication of apparent 
degradation of the proteins. The HepB3 preparation was used for iodination as 
supplied by the manufacturer, and is seen here in Fig. 3.18A to be composed of a 
number of proteins, two of which resemble the S dual bands thought to be the 
glycosylated and non-glycosylated form. The higher bands at around 40 kDa in Fig. 
3.18A are presumably the preSl 21-47-region-containing versions of the recombinant 
S that form part of the particle. The HepB3 preparation is expected to contain 
particles consisting of S alone or S carrying the preSl 21-47 amino acid region 
(personal communication, Medeva Pic).
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Figure 3.18. Characterisation of proteins used in ligand-binding assays.
Samples of the Hepagene protein (Medeva, UK) and the preSl domain were radiolabelled 
with 125I (see Chapter 2) and subjected to 10% SDS-PAGE to examine the integrity of the 
proteins (panel A). BHK cells were cultured in roller bottles to about 60% confluence, then 
were infected at a m.o.i. of 0.1 p.f.u/cell with WR or vLx, and the infections were allowed 
to proceed until complete c.p.e. was observed. The medium from the infected cells was 
harvested and clarified, then overlaid on a 40% w/v sucrose cushion and centrifuged at 
18000 rpm in a AH629 rotor (SORVAL) at 4°C for 4 hours. The pellet was resuspended in 
PBSA and centrifuged through a 15-30% continuous sucrose gradient for 2 hours at 35000 
rpm in a TST41 rotor (SORVAL). The gradients were fractionated and analysed by 
Western blot for the presence of Lx. Fractions containing the Lx protein were bulked and 
stored at -20°C, as were the corresponding fractions from WR-infected samples. The bulked 
samples were analysed for the presence of Lx by Western blot with MAb RC28 (panel B).
In addition to having radiolabelled ligand described above, it was also desirable to 
have a relatively pure form of the Lx protein. In order to obtain this preparation of the 
Lx protein, roller bottles containing BHK cells were infected at a high m.o.i. with Lx 
or WR and incubated until all cells exhibited c.p.e. The medium from the infected 
cells containing the secreted Lx protein was clarified and the secreted proteins 
centrifuged at 18,000 r.p.m. in a AH629 rotor onto a cushion of 40% w/v sucrose. 
The pelleted material was then centrifuged through a continuous gradient of 15-30% 
w/v sucrose and removed in 1 mL aliquots (see Materials and Methods) and analysed 
by Western blot for the presence of vLx. The demonstration of this protein by 
Western blot is necessary due to the low concentration of Lx in the preparation, and 
the relatively high amount of co-purifying proteins. The enriched preparation of vLx 
obtained for infected cell supernatant was shown to contain a protein reactive with the 
MAb RC28 at a molecular weight of 42 kDa (Fig. 3.18B). The centrifugation 
procedure provided a means of enrichment for Lx, but could not be described as an 
effective purification. The medium from cells infected with WR was treated in the 
same way as the vLx-infected cell medium in order to provide negative controls for 
binding experiments.
3.8 Discussion.
In order to achieve the aims and objectives of this project, several important reagents 
were generated. The structural components of HBV were expressed in bacterial and 
recombinant vaccinia virus system. The preS 1 domain was produced from a bacterial 
expression system, and was purified to near homogeneity by single-step affinity 
chromatography. The authenticity of the bacterially expressed preSl domain was 
confirmed in Western blot assay using a well-characterised monoclonal antibody, 
MAb 18/7. The purified preSl domain was used to (1) raise both polyclonal and 
monoclonal antibodies to the HBV L protein, and (2) map the epitopes recognised by 
the anti-preS 1 MAbs.
Both polyclonal antibodies generated reacted specifically to HBV L protein in 
Western blot, immunoprecipitation, and immunofluorescence assays. Similarly, the 
four anti-preS 1 monoclonal antibodies generated reacted specifically to L in both 
Western blot and immunofluorescence assays. However, the reactivity of the 
monoclonal antibodies in immunoprecipitation assays when used singly was
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disappointingly poor. In contrast, when used as a cocktail, they efficiently 
immunoprecipitated the L and Lx proteins with minimal reactivity with other cellular 
or viral proteins from cells infected with the appropriate recombinant vaccinia virus. 
To map the epitopes recognised by the anti-preS 1 MAbs, a series of eight peptides 
representing overlapping regions of the preSl domain were synthesised, purified and 
characterised. All four monoclonal antibodies were found to be of isotype IgGl, and 
the reactivity of all to the pre-Sl domain was blocked by the synthetic peptide 1123B 
representing amino acids 15-35. The peptides generated here were also tested for their 
ability to block preSl binding to putative cell surface receptor(s) (see Chapter 6).
The structural antigens (L, M, S, and core) of HBV were expressed in their full-length 
form using a recombinant vaccinia virus system. The recombinant vaccinia viruses 
were initially characterised for expression of appropriate HBV proteins using specific 
antibodies in both Western blot and immunofluorescence assays. The vaccinia virus- 
expressed structural antigens were also analysed with the anti-preS 1, -preS2, -S and 
anti-core monoclonal and polyclonal antisera generated here (for L and Lx) and/or 
those obtained from elsewhere. The molecular masses of the L, Lx, S, and core 
proteins were in agreement with those observed by others using similar expression 
systems (Xu, et. al, 1997). In contrast to L, the Lx protein was shown be secreted 
from expressing cells (see Fig. 3.3A). This is due to the gene encoding Lx carrying a 
heterologous secretion signal sequence. The monoclonal antibody, MAb 6B1, 
although generated elsewhere (Connal McCaughey, Queen’s University, Belfast) was 
characterised for the first time for reactivity against the small surface antigen. 
Interestingly, this MAb was found to be reactive with a conformational-specific 
epitope on S. To the author’s knowledge, there are no other conformation-dependent 
monoclonal antibodies in existence that are capable of distinguishing between the 
surface antigens of HBV. This novel reagent represents a valuable tool by which the 
structures of the surface antigens can be investigated. Further detailed 
characterisation of intracellular behaviour of these proteins using the antibodies 
described here is presented in Chapter 6. Taken together, the characterisation data 
prove that the reagents generated here are reactive to the HBV structural proteins. 
Furthermore, as shown in the following Chapters, they have proven extremely useful 
tools for pursuing the aims of this project.
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Chapter 4
Generation and partial characterisation of novel 
hepatocvte-derived cell lines
Hepatitis viruses such as HBV and HCV are refractory to growth in tissue culture, 
which has hampered advances in understanding virus-host interaction, replication, and 
pathogenesis. The generation of immortal cell lines that retain hepatocyte phenotype 
has remained an important aim not only for virologists, but also for cell biologists and 
toxicologists. There is an enormous scope for the use of cell lines that closely 
resemble the hepatocyte phenotype, as such cell lines could be considered as a proper 
host for carrying out functional analysis of HBV proteins, and moreover, they may 
support efficient replication of the virus.
Primary hepatocytes do not divide in culture, but they can be maintained for several 
weeks in maintenance medium in which it is necessary to include a number of 
reagents to retain the hepatocyte phenotype (Runge et al., 1999). The inclusion of 
certain growth factors, hormones (e.g. epidermal growth factor and hepatocyte growth 
factor) and dimethyl sulphoxide (DMSO) has been reported to assist in the retention 
of the hepatocyte phenotype, and withdrawal of DMSO from the medium has been 
documented to result in the appearance of a fibroblastic phenotype. Clearly, for 
hepatitis virologists interested in delineating the mechanisms involved in 
hepatocellular tropism, the retention of the hepatocyte phenotype in cultured cells is 
important: it is likely that fibroblasts will not express the liver-specific genes whose 
products are involved in the hepatocyte-specific processes. Furthermore, the omission 
of culture medium components that could interfere with viral entry (such as DMSO 
and polyethylene glycol) is desirable (Gripon et al., 1988). Therefore, the 
immortalisation of hepatocytes could be employed as a means of retaining the 
hepatocyte phenotype without the use of DMSO, and enabling the establishment of 
cultures from non-tumour cells. The hepatocyte cell lines HepG2, Huh7 and WRL68 
are derived from hepatoblastoma, hepatocellular carcinoma and fetal liver cancer, 
respectively. Thus, the expression of liver-specific genes in those tumour cell lines 
could be greatly different to that observed in cell lines derived from healthy
56
hepatocytes. These cell lines have been shown to replicate HBV and produce progeny 
virus when infected with HBV (Bchini et al., 1990) and/or when transfected with 
infectious viral DNA (Mabit et al., 1994), however, the efficiency of infection 
remains low and is subject to considerable variation.
Primary hepatocytes derived from normal human liver were immortalised by 
retrovirus-mediated transduction of human pappiloma virus type 16 E6 and E7 
transforming proteins (A. Patel, unpublished). Several cell lines were established 
which were able to grow both in serum-free, defined medium (see Materials and 
Methods) as well as serum containing medium. The cell lines were initially grown in 
defined medium lacking serum for ten passages and cryopreserved stocks were 
generated. It was found necessary to coat culture vessels with a preparation of 
collagen under serum-free conditions in order to provide the cells with an acceptable 
matrix for growth. However, when DMEM was used as the culture medium, there was 
no requirement for collagen coating of the growth surfaces of the culture vessels, and 
the coating step was omitted. The culture medium for the growth and maintenance of 
the novel hepatocytes during the studies performed here was changed from the 
defined medium to DMEM and the cultures propagated in the same manner as 
established cell lines HepG2 and COS-7. Two immortalised hepatocyte cell lines, H5 
and H I6, which were among the cell lines that were viable after many passages, were 
used in this study. These cell lines were assayed for some markers of hepatocyte 
phenotype, and were compared with the established hepatocyte cell line HepG2, and 
also compared with a non-human, non-hepatocyte cell line COS-7 (African Green 
Monkey kidney). Here, the generation and initial characterisation of the cell lines by 
immunofluorescent analysis with specific antisera to certain cell proteins is described. 
The antisera used for testing the cell lines are as follows: monoclonal antibodies to 
Cytokeratins 8 and 18, annexin V, albumin, alpha-fetoprotein, alpha-1-antitrypsin and 
apo-lipoprotein la. These were used as part of the initial characterisation of the cell 
lines because they were readily available to us, but it is important to point out that 
these markers are only a small proportion of the markers that are routinely used by 
hepatologists to characterise hepatocyte-specific gene expression.
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4.1 Analysis of novel and established cell lines for expression of hepatocvte-
specific proteins.
4.1.1. Cytokeratins 8 and 18.
The expression of cytokeratin 8 and 18 has been shown to be specific to a number of 
cell types, particularly liver and liver-derived tumours (Blaheta et al., 1998), however, 
there is an absence of cytokeratin 8 and 18 from fibroblasts (Tsuji et al., 1999). 
Therefore, the analysis of expression of the cytokeratins 8 and 18 affords a means of 
distinction between fibroblasts and hepatocytes. All the cell lines used in this study 
were evaluated for the expression of human cytokeratin 8 and cytokeratin 18. As 
shown in panels A, B, C and D, of Figs. 4.1, 4.2, and 4.3, monoclonal antibodies 
against human cytokeratin 8 and 18 show clearly the plasma membrane distribution 
and cytoplasmic expression of cytokeratins 8 and 18 in HepG2, H5 and H16 cell lines. 
The fluorescence from the H5 and H I6 cell lines compares well with the positive 
controls for the hepatocytes (HepG2). There is a small degree of plasma membrane 
fluorescence in some of the hepatocyte-derived cell lines. That the presence of both 
cytokeratins 8 and 18 is evident in the H5 and H I6 cell lines suggests that these cell 
lines have not reverted back to the fibroblast phenotype that occurs commonly in 
hepatocyte-derived cell lines (Gripon, et. al, 1993). As expected in COS-7 cells, no 
intracellular expression of cytokeratin 8 or 18 was seen, however, both antibodies 
reacted very weakly with plasma membrane proteins (Fig. 4.1, Panels A to D). It is 
not clear whether the antibodies were recognising COS-7-specific cytokeratin 8 and 
18 or they were binding non-specifically to cell membrane proteins (Fig. 4.4, Panels 
A to D). It is also possible that this weak signal may be due to autofluorescence.
4.1.2 Albumin.
HepG2, H5, H I6, and COS-7 cells were tested for albumin expression by confocal 
microscopy. Cells grown on glass coverslips were fixed, permeablised, probed with 
anti-human albumin MAb followed by FITC-conjugated anti-mouse IgG, and 
analysed by confocal microscopy. As shown in panel F of each of Figs. 4.1 to 4.4, no 
albumin expression on any of the cells tested, including HepG2 which are known to 
express albumin, (Molina et al., 1997) was detected. Given that HepG2 cells were 
negative for albumin expression, it would appear that the anti-albumin MAb or the
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assay chosen here to detect the expression of the albumin might be inappropriate. 
Therefore, the immunofluorescence results shown in panel F of Figs. 4.1, 4.2, 4.3 and 
4.4 are inconclusive. Further examination, of these cells is necessary, probably by 
analysis of albumin-mRNA to establish the absence or expression of albumin.
4.1.3. Alpha-fetoprotein.
Alpha-fetoprotein (AFP) is a useful clinical marker of HCC. It is known that 75% of 
HCC patients have serum levels of AFP in excess of 10 ng/mL (Johnson, 1999). The 
association of AFP with induction of the apoptotic pathway has been established in 
HepG2 cells (Semenkova et. al., 1997). The HepG2 culture is known to be positive 
for AFP (Semenkova et. al., 1997), and the location of AFP in the liver cell has been 
identified as the endoplasmic reticulum (Sato et al., 1998). It has been shown that 
there is a relationship between the effect of tumour necrosis factor (TNF) and the 
presence of AFP in HepG2 cells (Semenkova et al., 1997). The relationship between 
AFP and TNF seems complex in tissue culture: HepG2 cells are resistant to the effects 
of TNF while AFP is present in the culture medium. The possibility exists that the 
AFP is used by the cell to circumvent the cytotoxic effect of TNF, allowing tumour 
growth to proceed. Furthermore, it has been shown that in vitro addition of AFP 
results in promotion of growth of hepatoma cell lines (Wang and Xie, 1998), strongly 
indicating a role for AFP in cell proliferation/tumourogenicity. The differentiation 
between AFP produced in normal tissues and AFP produced in tumours of hepatic 
tissues is achievable by the exploitation of the differences in the carbohydrate side 
groups on the AFP (Johnson et al., 1999). The expression of AFP was examined by 
immunofluorescence assay in the cell lines HepG2, H5, H I6, and COS-7. As shown 
in panel G of Figs. 4.1, 4.2, 4.3, and 4.4 each, AFP was found to be expressed in 
HepG2 cells, but not in H5, H I6, and COS-7 cells. The AFP expression in HepG2 
cells is in agreement with previously published results (Semenkova et. al., 1997).
4.1.4. Alpha (l)-antitrypsin.
Alpha (1)-Antitrypsin (A-l-AT) is a 54 kDa plasma glycoprotein that constitutes the 
principal inhibitor of neutrophil elastase in tissue fluids (Molmenti, et al., 1993). 
Neutrophil elastase is a serine protease that is responsible for tissue degradation at 
sites of inflammation in infected tissues. A-l-AT has been considered a prototype for
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liver-derived acute phase proteins in that its concentration in plasma increases three- 
to fourfold during the host response to inflammation/tissue injury (Hafeez et al, 
1992). Acute-phase proteins are associated with the host response to viral infection 
and are part of a response to the induction of inflammatory cytokines. The presence 
of A-l-AT correlated well with HBV infection in one study (Ohmachi et al., 1994), 
where 81% of HBV-infected patients had A-l-AT in their liver as opposed to only 
11% of HCV patients. Expression of A-l-AT has been detected in other tissues 
besides the liver such as enterocytes and the colon-derived cell line Caco2 (Molmenti 
et al., 1993).
In the panels labelled H in Figs. 4.1, 4.2, 4.3 and 4.4, the immunofluorescent analysis 
of the expression of A-l-AT in all of the cell lines studied here is shown. The 
fluorescence was strongest in the HepG2 cells (Fig.4.1, panel H) presumably because 
the HepG2 cells are derived from a hepatic tumour. The presence of A-l-AT in 
HepG2 cells is in agreement with published data (Hafeez et al., 1992), and A-l-AT 
expression in inflamed and injured tissues is documented (Busachi et al., 1986), as is 
the existence of A-l-AT in cell lines derived from HCC (He et al., 1984). In 
comparison with the HepG2 cell line, both H5 and H16 (panel H of Figs. 4.2 and 4.3, 
respectively) were negative for A-l-AT as determined by the immunofluorescence 
assay performed here.
4.1.5. Apolipoprotein-la.
Levels of plasma apolipoprotein-la (Apo-la) vary greatly in humans. More than one 
hundred different alleles of Apo-la have been identified so far, possibly resulting in 
proteins with different folding characteristics or different levels of carbohydrate 
trimming in the near-mature protein (White et al., 1997). It has been suggested that 
these differences in folding or glycan composition may account for the wide 
differences in levels of plasma Apo-la observed in humans (White et al., 1997). 
Apolipoprotein la is involved in the regulation of lipid metabolism, an important 
function of the liver. The interaction of the C-terminal domains of Apo la with lipids 
has been recently analysed (Laccotripe et al., 1997) and has given useful information 
regarding the structure-function relationship between the numerous alpha helices of 
the protein and its lipid ligands. The interactions of Apo-la with lipopolysaccharide 
have also been studied (Massamiri et al., 1997), enabling the elucidation of some of
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the steps in the metabolism of lipids and other processes, such as the egress of 
cholesterol from the cell. The association of Apo-la with phophatidylcholine enables 
the formation of lipid disks. The structure of these lipid disks is purported to aid in 
the protection of the hydrophobic lipid tails of Apo-la from the aquatic environment 
(Phillips et al., 1997). The localisation of Apo-la, and Apo-B has been examined in 
hepatocytes (Panin et al., 1997), and these proteins are found in highest 
concentrations in the nucleus. The localisation of radiolabelled high-density lipid 
(HDL) and low-density lipid (LDL) with the Apo-la, Apo-B and Apo-E would 
suggest that these proteins are involved in the import of lipids into the cell nucleus 
(Panin et al., 1997).
The immunofluorescence results from HepG2 cells (Fig. 4.1, panel I) were strongly 
positive for the presence of Apo-la. This is not unexpected as Apo-la expression in 
HepG2 cells has been shown previously (Cianflone et al., 1994). Both our hepatocyte 
cell lines, H5 and H I6, also expressed Apo-la as shown by strong fluorescence when 
probed with anti-apo-la MAb (Fig. 4.2 and 4.3, panel I, respectively). In comparison, 
the COS-7 cells probed with the anti-human Apo-la MAb (Fig. 4.4, panel I) showed a 
very weak level of fluorescence that is probably due to autofluorescence.
4.1.2. Annexin V.
Annexin V is a 32 kDa calcium-binding protein that is anchored in lipid membranes. 
The presence of annexin V has been reported in many cell types such as human 
foreskin fibroblasts (Barwise and Walker, 1996), chondrocytes (vonderMark and 
Mollenhauer, 1997), cardiac cells (Luckcuck et al., 1997) and hepatocytes (Hertogs et 
al., 1993). Annexin V has also been reported to reside within the cytoplasm and 
nuclei of cultured cells (Sun et al., 1992). An important role of annexin V is to 
facilitate the Ca2+ influx into cytoplasmic vesicles, therefore allowing mineralisation 
of structures requiring calcium, such as bone. Annexin V has been purported to be a 
receptor for HBV S protein (Gong et al., 1999). To test for annexin V expression, 
cells were fixed, permeablised, and analysed by confocal microscopy using an anti­
human annexin MAb. As shown in panel E each of Figs. 4.1 to 4.4, a weak 
fluorescence was observed in H5 and H7, but not on HepG2 and COS-7 cells. Flow 
cytometry was used to facilitate quantitative analysis of the expression of annexin V 
on the plasma membrane of these cells. As shown in Fig. 4.5, panel A, the HepG2
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Figure 4.1 Analysis of expression of cellular markers in COS-7 cells.
COS-7 cells were grown on glass coverslips in DMEM for 3 days, then were fixed with 2% 
paraformaldehyde for plasma membrane staining, or permeablised with methanol at -20°C for 
intracellular staining. The coverslips were incubated with appropriate antisera as follows: A: 
anti-cytokeratin 8 in non-permeablised cells. B: anti-cytokeratin 8 in permeablised cells. C: 
anti-cytokeratin 18 in non-permeablised cells. D: anti-cytokeratin 18 in permeablised cells. E: 
anti-annexin V in permeablised cells. F : anti-human albumin in permeablised cells.
Figure 4.1 Continued. Analysis of expression of cellular m arkers in COS-7 cells .
G: anti-alpha-fetoprotein in permeablised cells. H: anti-human antitrypsin in permeablised cells 
I: anti- apo-lipoprotein Al in permeablised cells.
Figure 4.2 Analysis of expression of cellular markers in HepG2 cells.
HepG2 cells were grown on glass coverslips in DMEM for 3 days, then were fixed with 2% 
paraformaldehyde for plasma membrane staining, or permeablised with methanol at -20°C for 
intracellular staining. The coverslips were incubated with appropriate antisera as follows: A: 
anti-cytokeratin 8 in non-permeablised cells. B: anti-cytokeratin 8 in permeablised cells. C: 
anti-cytokeratin 18 in non permeablised cells. D: anti-cytokeratin 18 in permeablised cells. E: 
anti-annexin V in permeablised cells. F : anti-human albumin in permeablised cells.
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Figure 4.2 Continued. Analysis of expression of cellular m arkers in HepG2 cells .
G: Alpha-fetoprotein in permeablised cells 
H: Antitrypsin in permeablised cells 
I: Apo-lipoprotein A1 in permeablised cells.
Figure 4.3Analysis of expression of cellular markers in H5 cells.
H5 cells were grown on glass coverslips in DMEM for 3 days, then were fixed with 2% 
paraformaldehyde for plasma membrane staining, or permeablised with methanol at -20°C for 
intracellular staining. The coverslips were incubated with appropriate antisera as follows: A: anti- 
cytokeratin 8 in non-permeablised cells. B: anti-cytokeratin 8 in permeablised cells. C: anti- 
cytokeratin 18 in non permeablised cells. D: anti-cytokeratin 18 in permeablised cells. E: anti- 
annexin V in permeablised cells. F : anti-human albumin in permeablised cells.
Figure 4.3 Continued. Analysis of expression of cellular markers in H5 cells .
G: anti-alpha-fetoprotein in permeablised cells.
H: anti-human antitrypsin in permeablised cells 
I: anti- apo-lipoprotein A1 in permeablised cells.
EFigure 4.4 Analysis of expression of cellular markers in H16 cells.
H I6 cells were grown on glass coverslips in DMEM for 3 days, then were fixed with 2% 
paraformaldehyde for plasma membrane staining, or permeablised with methanol at -20°C for 
intracellular staining. The coverslips were incubated with appropriate antisera as follows: A: anti- 
cytokeratin 8 in non permeablised cells. B: anti-cytokeratin 8 in permeablised cells. C: anti- 
cytokeratin 18 in non-permeablised cells. D: anti-cytokeratin 18 in permeablised cells. E: anti- 
annexin V in permeablised cells. F: anti-human albumin in permeablised cells.
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Figure 4.4 Continued. Analysis of expression of cellular m arkers in H16 cells .
G: Alpha-fetoprotein in permeablised cells 
H: Antitrypsin in permeablised cells 
I: Apo-lipoprotein A1 in permeablised cells.
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Figure 4.5 Evaluation of novel and established cell lines for the expression of annexin V
HepG2, H5, H16 and COS-7 cells were analysed for the plasm a m em brane expression o f  
annexin V by flow cytom etry. The cells were grown in T175 flasks to near confluence and 
were then dissociated from m onolayers. Follow ing w ashing, the cells w ere incubated with 
isotype control M Ab, the anti-hum an annexin V M Ab, or no M Ab. The bound antibodies 
were then detected using anti-m ouse-IgG -FITC in a BD FA CScan.
Panel A: HepG2 cells.
Panel B: H5 cells.
Panel C: H16 cells.
Panel D: COS-7 cells.
Isotype Ctrl
Annexin V
FL1-H -->
Table 2 Summary of results for the expression of markers in novel and 
established cell lines
COS-7 HepG2 H5 H16
Cytokeratin 8 - +++ +++ +++
Cytokeratin 18 - +++ +++ +++
Annexin V + ++ ++ ++
Albumin - - - -
Apolipoprotein A - + ++ ++
Antitrypsin - ++ - -
Alpha-fetoprotein - ++ - -
Cell lines were tested for expression of marker proteins by immunofluorescence and 
flow cytometry. This table summarises the results obtained. It should be noted that 
the results obtained from the Anti-Albumin antibody are inconclusive due to the 
absence of fluorescence in the positive control, HepG2.
cells expressed Annexin V on the plasma membranes. There was a large increase in 
fluorescence in the majority of the cells (shown as the long broken line) in 
comparison with the isotype control (shown as the punctate line). There was minimal 
uptake of the isotype MAb control on the plasma membrane of the HepG2 cells, as 
can be seen by the very small increase in fluorescent intensity of the isotype MAb 
control in comparison with the unstained cells. This small difference in fluorescent 
intensity indicated that the binding of the IgGl molecule directed against Annexin V 
is not an artefact due to the presence of IgG receptors on the plasma membrane of the 
HepG2 cells. Unlike HepG2 cells, there was a significant shift in fluorescence on H5 
cells and to a lesser extent on H I6 cells due to the isotype MAb control, indicating 
that the isotype control or the anti-mouse IgG-FITC conjugate binds to the plasma 
membrane (Fig. 4.5, panels B and C, respectively). However, like HepG2 cells, both 
H5 and H I6 cells exhibited a distinct increase in fluorescence (in comparison with the 
isotype control) when probed with the anti-annexin V MAb indicating expression of 
this protein on the cell surface (Fig. 4.5 panels B and C). The binding of the isotype 
control MAb to the plasma membrane of the cells is probably due to the presence of 
receptors for the Fc region of IgG molecules, on the plasma membrane. Interestingly, 
the COS-7 cells used as a supposedly negative control for these experiments showed 
an increase in fluorescence when probed with the anti-annexin V MAb (Fig. 4.5, 
panel D). However, the increase in fluorescence due to anti-annexin V MAb did not 
appear as great as that obtained from the other cell lines studied here.
4.2 Discussion.
The cell lines partially characterised here have been generated as part of an ongoing 
programme of reagent generation to obtain suitable systems for the study of the 
mechanisms of hepatotropism exhibited by HBV (and HCV). Although the data 
presented in this chapter do not fulfil the requirements of a comprehensive 
characterisation for these cell lines, they do offer some insights into the nature of 
these cells and indicates that they may be worthwhile reagents for the study of HBV 
(and HCV) replication and tropism.
The results discussed here have been summarised in Table 4.1. The demonstration of 
the expression of the cytokeratins 8 and 18 in the novel cell lines indicated that the 
reversion of these hepatocyte-derived cell lines to fibroblasts has not occurred. This
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evidence, while no guarantee of hepatocytic phenotype, suggests that the cell lines H5 
and H16 may have retained hepatocytic characteristics. Furthermore, these cell lines 
were analysed for expression of the products assayed here after about 30 passages in 
DMEM in normal tissue culture conditions. The retention of the expression of 
cytokeratins 8 and 18 after this time is encouraging and leads the author to suggest 
that these cell lines may be of use in work where the phenotype of the cells used 
should be as close as possible to that of a primary hepatocyte, with the added 
advantage of being a stable and proliferative cell line.
The expression of Annexin V on these hepatocytes is worthy of study when seen in 
the context of the literature concerning the binding of the small surface antigen of 
HBV to hepatocytes. The association of Annexin V with S has been documented 
(Hertogs et al., 1994). Furthermore, the presence of Annexin V has been suggested as 
a determining factor for infection of cells by HBV (Gong et al., 1996). Clearly, in the 
primary characterisation of these novel cell lines that are intended to be used for viral 
entry studies, the demonstration of expression of Annexin V is of great importance.
The absence of AFP in the H5 and H I6 cell lines in comparison with HepG2 is in 
keeping with the origin of these cell lines: the primary hepatocytes from which these 
cells were derived were negative for HBV, HCV, HIV1, HIV2 and HCMV, and were 
taken from a recently deceased but healthy individual. The absence of AFP from H5 
and H I6 indicates the cells are from uninjured tissue and would imply the cells are 
unlikely to be expressing acute-phase proteins due to infection or injury. Likewise, 
the absence of A-l-AT from the novel cell lines provides further evidence for the 
healthy state of the liver tissue from which the primary hepatocytes were isolated.
The expression of Apo-la in the novel cell lines is evidence to suggest that these cells 
have retained at least some of the hepatocytic phenotype. Taken together, the data 
obtained here provides a good basis to suggest that these cell lines are stable in the 
short term, are immortalised, express some liver-specific proteins and have not 
reverted to a fibroblast-like phenotype. That H5 and H I6 are growing in DMEM with 
minimal supplementation, with the absence of factors such as DMSO and 
dexamethasone, and still retain markers such as these cytokeratins, indicates that these 
cell lines may be useful tools in the delineation of the infection process of
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hepatotropic viruses. The infection of established cell lines with HBV, in many cases, 
has required the presence of polyethylene glycol (PEG) and DMSO in the culture 
medium (Gripon et al, 1993). The inclusion of PEG and DMSO in the culture 
medium is unwanted, as it would complicate the interpretation of results from the 
point of view of studying the mechanisms of virus attachment and entry into the target 
cells. The presence of PEG and DMSO could result in disruption of the plasma 
membrane of the hepatocytes allowing viral entry which does not necessarily mimic 
the process occurring in vivo (Gripon et al, 1993).
It is recognised by the author that the analysis carried out here for marker proteins in 
these novel cell lines is only a small portion of the required characterisation for novel 
cell lines. A more comprehensive analysis would include examination of the mRNA 
transcripts for all of the proteins analysed here, and for other proteins such as 
cytokeratin 19, cytochrome p450, albumin, hepatocyte nuclear factors one, two, three 
and four (HNF -I, -II -III and -IV), phosphoenolpyruvate carboxykinase-2 (PCK2) 
and other serum proteins in cell lines grown both in serum-free and normal growth 
medium. It is intended, as part of the future work of this laboratory, to characterise 
these and other novel cell lines for expression of these liver specific marker proteins, 
and to examine the ability of these cell lines to support the in vitro infection processes 
and replication of HBV (and HCV).
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Chapter 5
Investigations into the structure of the surface antigens of HBV
The intracellular behaviour of the surface antigens of HBV is of interest to HBV 
virologists, because by associating with the nucleocapsid they play a crucial role in 
the hepadnaviral morphogenesis process, and also in the morphogenesis of sub-viral 
particles. The ability to distinguish between the surface antigens when co-expressed 
in the same cell would be a valuable tool for studying the intracellular behaviour of 
the surface antigens. For example, reagents that could identify M and/or S proteins 
without detecting the respective domains on the L protein in co-expressing cells 
would be of great value in evaluating the role of these protein in viral particle 
assembly and morphogenesis. Additionally, the structure of the surface antigens 
remains unresolved. The work described in this chapter was undertaken as a study of 
the structure and intracellular behaviour of the surface antigens.
There is little information available concerning the structure of the HBV surface 
antigens. There are difficulties associated with the determination of structures of 
proteins that are embedded in a lipid bilayer which prevent crystallisation of the 
proteins and therefore X-ray crystallography can not be utilised to resolve the 
structure. Another way to gain insight into the tertiary structure of proteins embedded 
in a lipid bilayer is to probe the proteins with monoclonal antibodies that are directed 
against linear and conformational epitopes. The ability of the antibodies to recognise 
linear or conformational epitopes of the protein can be exploited to yield information 
concerning the folding and maturation of proteins.
Computer-generated models have been generated for the structure of S (Peterson, 
1987; Sonveaux et al, 1995; Stirk et a\ 1992), but there is very little information 
regarding the prediction of the structure of the L protein. The are features of the L 
protein which are likely to have influence on the structure of L such as insertion of the 
PreSl region into the lipid membrane (Ou and Rutter, 1987; Persing et al, 1987; 
Prange et al, 1991), but there remains little biochemical or immunological 
information regarding the arrangement of the transmembrane helices, and the packing 
of the surface antigens when oligomerised.
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Here, the behaviour of the surface antigens when expressed singly or upon co­
expression was examined using both polyclonal and monoclonal antibodies to various 
HBV surface antigens described in Chapter 3. The antibodies were tested for their 
ability to distinguish between the surface antigens, and to study the antigenicity of 
these proteins.
5.1 Intracellular localisation of HBV surface antigens.
Recent work has shown that L protein, when expressed in a heterologous system, is 
retained in the ER, and co-localising with p53, a protein known to be enriched in the 
ER-Golgi intermediate compartment or ERGIC (Xu et al, 1997). Therefore the 
evaluation of the L encoded by rVV vL and vLx was undertaken by confocal 
microscopy in order to assess its intracellular distribution and to afford comparison 
with previously published data. HepG2 cells were infected with r W  vL or vLx and 
fixed after 24 h. The cells were probed with anti-preSl antiserum PAbl43 and anti- 
p53 MAb and the bound primary antibodies detected by appropriate secondary 
reagents described in the legend to Fig. 5.1 A and B. The L protein was found to 
localise predominantly in the perinuclear compartment (Fig. 5.1 A, panel A), whereas 
the p53 protein appeared to be localised as large spots again in the perinuclear area, 
although some weak staining was also seen throughout the cytoplasm (panel B). 
Superimposition of the two images showed that the spot of p53 colocalised or co- 
compartmentalisation with the L protein (visible as the yellow colour in panel C), 
which is consistent with the findings of others (Xu et al., 1997).
In contrast to L, the distribution of Lx is markedly different to that of L in cells 
infected with vLx in that it was spread evenly throughout the cytoplasm possibly in 
keeping with its secretory nature (Fig. 5.IB, panel A). As shown in Fig. 5.1 A (Panel 
B), the p53 protein localised as mainly as spots in the perinuclear region, and this 
localisation was co-incident with at least a portion of Lx (Fig. 5. IB, panel C). This 
intracellular distribution of Lx and its co-localisation with p53 is in agreement with 
previously published data obtained using a secretory form of L similar to Lx (Xu et 
al., 1997).
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The intracellular distribution of M or S was analysed by double immunofluorescent 
staining and confocal microscopy. HepG2 cells were infected with r W  vM or vS, 
and fixed after 24 h. Anti-M MAb 2-12F2 or anti-S MAb 6B1 were used as primary 
antibodies in conjunction with the lectin concanavalin A (ConA) conjugated to FITC. 
Con A is used as a marker for intracellular membranes. As shown in Fig. 5.2, the 
staining for both S and M was distributed throughout the cytoplasm (panels A and D, 
respectively), as was that for ConA (panels B and E). The localisations of ConA and S 
or ConA and M were coincident when the respective images were merged (panel C 
and F), indicating that these proteins are associated with intracellular membranes. 
These proteins are known to be secreted but do not bud through the plasma 
membrane, rather, they are secreted through the exocytic pathway. It is important to 
note that such a distribution of L or Lx was not evident -  L was retained in the 
ER/ERGIC, whereas Lx was more evenly distributed in the cytoplasm of cells (Fig.
5.1 A and B).
5.2 Evaluation of anti-S MAbs for antigen recognition.
HepG2 cells were infected with rVV expressing L, Lx, M, and S. Following 
incubation for 24 h, the cells were fixed, permeablised and probed with a panel of 
monoclonal antibodies directed against S. As shown in Fig. 5.3 A to D, all the MAbs 
tested recognised not only S, but also M, L, and Lx proteins. In all cases, the 
reactivity of the MAbs to the mock-infected and WR-infected negative controls was 
minimal. It is important to note that the intracellular distribution of M and S was 
quite distinct from that of L and Lx when probed with all the anti-S MAbs tested here 
(Fig. 5.3 A to D, panels C to F). Both M and S localised in a matrix-like pattern with 
internal membranes (as confirmed in Fig. 5.2) in the cytoplasm of the cell, as opposed 
to L or Lx which have a more even cytoplasmic distribution. The observation that the 
anti-S MAbs tested here are capable of recognising the M, L and Lx proteins when 
expressed in this recombinant vaccinia virus system confirms the difficulty in 
distinguishing between the surface antigens in co-expressing cells. Whereas it is 
possible to distinguish the L protein from the M or S proteins by the use of antisera 
directed against the preSl domain (see Fig. 5.5), it is difficult to discriminate the S 
protein from the L protein due to the inclusion of the S domain in the L protein. The 
anti-S MAbs H35, H I66, H10 and RF7 are all directed against linear epitopes found 
on the S protein (for data on H35 and H I66 see Chen et. al, 1996). The epitopes on S
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Fig. 5.1A Characterisation of the intracellular distribution of L protein in HepG2 cells.
HepG2 cells on glass coverslips in 24-well plates were infected at a low m .o.i. w ith  vL. At 24 
hours post-infection, the cells were fixed in m ethanol at -20°C, then perm eablised in PBST. The 
cells were probed with PAb 143 (anti-L) and M Ab (anti-ER G IC  p53) for two hours at room  
tem perature, then were washed in PBST. The coverslips were incubated w ith anti-m ouse FITC 
and A nti-R abbit Cy5, and the coverslips were m ounted and exam ined by Confocal m icroscopy. 
Panel A: C ells expressing vL stained with Pab 143 and anti-rabbit IgG -cy5, coloured red.
Panel B: p53 protein stained w ith anti-p53 M Ab and anti-m ouse IgG -FITC.
Panel C: M erge. W hite arrow  indicates area o f  colocalisation o f  L and p53.
The intracellular distribution o f  the L protein is reasonably well associated w ith  the p53 m arker for 
the ER G IC com partm ent w hen expressed in FlepG2 cells.
Fig. 5.IB Characterisation of the intracellular distribution of the Lx protein in HepG2 cells.
HepG2 cells on glass coverslips in 24-well plates were infected at an m.o.i. of 0.5 p.f.u./cell with 
vLx. At 24 hours post-infection, the cells were fixed in methanol at -20°C, then permeablised in 
PBST. The cells were probed with PAb 143 (anti-L) and MAb (anti-ERGIC p53) for two hours at 
room temperature, then were washed in PBST. The coverslips were incubated with anti-mouse FITC 
and Anti-Rabbit Cy5, and the coverslips were mounted and examined with by confocal microscopy. 
Panel A: Cells expressing vLx stained with PAb 143 and anti-rabbit IgG-cy5, coloured red.
Panel B: p53 protein stained with anti-p53 MAb and anti-mouse IgG-FITC.
Panel C: Merge. White arrow indicates area of colocalisation of Lx and p53.
The intracellular distribution of the Lx protein is more widespread than that observed with vL.
Fig. 5.2 Colocalisation of S and M with intracellular membranes in HepG2 cells.
HepG2 cells on glass coverslips in 24-well plates were infected at an m.o.i. of 0.5 p.f.u./cell 
with vHBsAg (panels A, B and C) or vM (panels D, E and F). At 24 hours post-infection, the 
cells were fixed in methanol at -20°C, then permeablised in PBST. The vHBsAg-infected cells 
were probed with MAb 6B1, and the vM-infected cells were probed with MAb 2-12F2, and 
then incubated with anti-mouse-Cy5. All cells were also probed with concanavalin-A-FITC. 
Panel A: vHBsAg infected cells stained with 6B1/1 and coloured red.
Panel B: Concanavalin-A-FITC conjugate coloured green.
Panel C: Merge.
Panel D: vM infected cells stained with MAb 2-12F2 and coloured red.
Panel E: Concanavalin-A-FITC conjugate coloured green.
Panel F: Merge.
Fig.^5.3 Recognition of HBV surface antigens by MAbs directed against HBsAg.
cells were grown on glass coverslips in 24-well plates to about 60% confluence. The cells 
were infected at a m.o.i. of 0.5 p.f.u per cell with vL, vLx, vM, vS, WR, or were mock-infected. 
At one hour post-infection, the cells were washed and incubated in DMEM for 24 hours. The 
coverslips were washed three times in PBS A and fixed in methanol at -20°C overnight. After 
fixing, the coverslips were washed twice with PBS A, then were permeablised by incubation with 
PBST for at least 30 minutes. The coverslips were incubated with one of four monoclonal 
antibodies directed against HBsAg for two hours in a volume of 200 pL. Unbound antibodies 
were removed by washing, and the coverslips were incubated in anti-mouse IgG-FITC for two 
hours. The unbound secondary antibodies were removed by washing and the coverslips were 
mounted and analysed with a Zeiss Laser Scanning Confocal microscope.
Figure 5.3A: Anti-HBsAg MAb H53 at a dilution of 1:100.
Panel A: Mock-infected cells.
Panel B: WR-infected cells.
Panel C: vL-infected cells.
Panel D: vLx-infected cells.
Panel E: vM-infected cells.
Panel F: vS-infected cells.
Fig. 5.3B: Anti-HBsAg MAb H166 at a dilution of 1:100.
Legend as for Figure 5.3A
Fig. 5.3C: Anti-HBsAg MAb H10 at a dilution of 1:100.
Legend as for Figure 5.3A
Fig. 5.3D: Anti-HBsAg MAb RF7 at a dilution of 1:100.
Legend as for Figure 5.3A
Fig 5.3A MAb H53 recognises all the HBV surface antigens.
Fig. 5.3B MAb H166 recognises all the HBV surface antigens.
BFigure 5.3C MAb H10 recognises all the HBV surface antigens.
Fig. 5.3D MAb RF7 recognises all the HBV surface antigens.
to which the RF7 and H10 MAbs are reactive remain unknown to the author. The use 
of the above antisera to study the behaviour of S in the presence of L or Lx would be 
inappropriate, due to the inability of any of these antisera to differentiate between the 
surface antigens. This work demonstrated the difficulty of examining the behaviour 
of these two proteins upon co-expression.
Another anti-S monoclonal antibody, MAb 6B1 was shown in Chapter 3 to be specific 
for a conformation-sensitive epitope on the S protein. This antibody was tested here 
for its ability to recognise L, Lx, M, as well as S proteins of HBV. HepG2 cells were 
infected with vL, vLx, vM or vS and fixed after 24 h. The cells were then probed with 
MAb 6B1 and analysed by confocal microscopy. As shown in Fig.5.4, this MAb 
recognised the S protein and the S domain of M (panels B and C), but interestingly, 
failed to recognise the S moiety on Lx (panel D) It was clear that MAb 6B1 is able to 
distinguish between the S protein and S domain present in L, and therefore it 
constitutes a valuable immunological reagent to study the properties of these proteins 
in expressing cells.
5.3 Co-expression of L and S
As shown in Fig. 5.1 A, the HBV L protein is co-localised with the ERGIC marker 
p53 indicating retention of this protein in the ER compartment of the cell. Since in 
MAb 6B1 we have a monoclonal antibody that discriminates between L and S, it was 
thought interesting to examine the intracellular behaviour of these proteins in co­
expressing cells. HepG2 cells were co-infected at low m.o.i. with vL and vS, fixed 
after 24 h, double immunolabelled with anti-preSl PAb 143 and anti-S MAb 6B1, and 
analysed by confocal microscopy. Figure 5.5 panel A, shows two cells infected with 
the rVVs; one of which had an even cytoplasmic distribution of L whereas in the 
other, it is akin to that seen in S-expressing cells (see Fig. 5.3, panels C to F). The 
later cell could also be stained by the anti-S MAb 6B1 (Fig. 5.5, panel B), indicating 
that this cells is co-infected with vL and vS. In contrast the S staining was not seen in 
the cell carrying an even cytoplasmic fluorescence shown in panel A, indicating that 
this cells is only infected with vL. This is confirmed by the inability of MAb 6B1 to 
recognise L in this cell. Superimposition of the two images showed that L and S co­
localised in the doubly infected cells (panel C). Also interestingly, the intracellular 
distribution of L when co-expressed with S changed dramatically - from the ERGIC
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compartment to the matrix-like membrane-associated localisation observed with S 
(Fig. 5.5). The clear difference in the fluorescent labelling of L and S was apparent in 
Fig. 5.5; the anti-preSl PAb labelled the L protein (coloured red) and the 6B1- 
labelled S protein, but not L (coloured green). The inability of the 6B1 antibody to 
recognise the L protein is also readily apparent in Fig. 5.5. Furthermore, the inability 
of the anti-preSl PAb 142 to recognise S is also apparent from the cell only 
expressing S showing no fluorescence. An attempt was made to triple-label samples 
showing the L, S and concanavalin-A fluorescent. However, satisfactory images 
could not be obtained due to both the unavailability of the appropriate antisera and 
fluorescent conjugates, and also due to channel overlap from fluorochromes with 
emission spectra overlapping that of other fluorochromes, resulting in areas of false 
positive colocalisation. However, it is reasonable to assume that the association of the 
S protein with the intracellular membranes is also present in the cells co-expressing 
the S and L proteins. The characteristic lattice distribution of S observed in the S- 
expressing cells is preserved upon coexpression of S and L, with the distribution of L 
conforming to that of S. To preclude the possibility that the expression of S was 
causing multinucleation in the cells, samples similar to that shown in Fig. 5.5 were 
analysed with the same antisera, with the inclusion of a propidium iodide-labelling 
step to allow identification of the nuclei of the cells. As shown in Fig. 5.6, S and L 
are distributed in a matrix-like pattern and they co-localise, thus confirming the above 
observations (panel A, C and D). Furthermore, there was no evidence of 
multinucleation as staining with propidium iodide showed the presence of a single, 
intact nucleus in the co-infected cell (panel D).
Similar observations were made in cells co-infected with vLx and vS. The association 
of the secretable form of the L protein (Lx) with the ERGIC marker and a widespread 
cytoplasmic distribution of Lx is shown in Fig. 5. IB. There was no marked change in 
the distribution of Lx in the cell co-infected with vLx and vS (Fig. 5.7, panel A, cell 
on the top left comer) from that seen in vLx-infected cell. However, as with L, Lx 
also co-localised with S (panel C) although the association of the S and Lx differed in 
comparison with L and S proteins seen in Figs. 5.5 and 5.6. Here, the Lx and S 
formed bodies throughout the cytoplasm, but did not appear to be conforming to the 
membrane association as seen in the S-Concanavalin-A (Fig. 5.2). The effect of the 
signal sequence located at the N-terminus of the Lx protein may be sufficient to
69
Fig. 5.4 Recognition of vM and vS by MAb 6B1.
Hepg2 cells were infected at a m.o.i. of 0.5 p.f.u per cell with, vLx, vM, vS, WR, or were mock- 
infected. At one hour post-infection, the cells were washed and incubated in DMEM for 24 hours. 
The coverslips were washed three times in PBS A and fixed in methanol at -20°C overnight. After 
fixing, the coverslips were washed twice with PBS A, then were permeablised by incubation with 
PBST for at least 30 minutes. The coverslips were incubated with MAb 6B1 for two hours in a 
volume of 200 pL. Unbound antibodies were removed by washing, and the coverslips were 
incubated in anti-mouse IgG-FITC for two hours. The coverslips were mounted and analysed with 
a NIKON Microphot immunofluorescent microscope.
Panel A: Wr-infected cells 
Panel B: vS-infected cells 
Panel C: vM-infected cells 
Panel D: vLx-infected cells 
Panel E: mock-infected cells
Fig. 5.5 Co-expression of L and S in HepG2 cells.
HepG2 cells were grown on glass coverslips in 24-well plates to about 60% confluence. The cells 
were coinfected with vL and vS at a m.o.i. of 0.5 p.f.u per cell. At 24 h post-infection, the 
coverslips were washed three times in PBS A and fixed in methanol at -20°C overnight. After 
fixing, the coverslips were washed twice with PBS A, then were permeablised by incubation with 
PBST for at least 30 minutes. The coverslips were incubated with a mixture of PAb 143 (at a 
dilution of 1:1000) and MAb 6B1 (at a dilution of 1:500) for two hours in a volume of 200 pL. 
Unbound antibodies were removed by washing, and the coverslips were incubated in a mixture of 
anti-mouse IgG-FITC and anti-rabbit Cy5 for two hours. The unbound secondary antibodies were 
removed by washing and the coverslips were mounted and analysed with a Zeiss Laser Scanning 
Confocal microscope.
Panel A: Cy5 fluorescence showing the intracellular distribution of vL.
Panel B: FITC fluorescence showing the intracellular distribution of vS.
Panel C: Merge. White arrow indicates areas where L and S are colocalised.
Fig. 5.6 Co-expression of L and S in HepG2 cells.
HepG2 cells were grown on glass coverslips in 24-well plates to about 60% confluence. The cells 
were coinfected with vL and vS at a m.o.i. of 0.5 p.f.u per cell. At one hour post-infection, the 
cells were washed and incubated in DMEM for 24 hours. The coverslips were washed three times 
in PBS A and fixed in methanol at -20°C overnight. After fixing, the coverslips were washed twice 
with PBSA, then were permeablised by incubation with PBST for at least 30 minutes. The 
coverslips were incubated with a mixture of PAb 143 (at a dilution of 1:1000) and MAb 6B1 (at a 
dilution of 1:500) for two hours in a volume of 200 pL. Unbound antibodies were removed by 
washing, and the coverslips were incubated in a mixture of anti-mouse IgG-FITC and anti-rabbit 
Cy5 for two hours. The unbound secondary antibodies were removed by washing. The coverslips 
were incubated with propidium iodide (1 mg/mL) for one minute to stain the nuclei, and were then 
washed three times in PBSA. The coverslips were mounted and analysed with a Zeiss Laser 
Scanning Confocal microscope.
Panel A: Cy5 fluorescence showing the intracellular distribution of vL.
Panel B: Propidium iodide staining the nucleus by intercalation with DNA, coloured blue.
Panel C: FITC fluorescence showing the intracellular distribution of vS.
Panel D: Merge. White arrow indicates areas where L and S are colocalised.
could not be obtained due to both the unavailability of the appropriate antisera and 
fluorescent conjugates, and also due to channel overlap from fluorochromes with 
emission spectra overlapping that of other fluorochromes, resulting in areas of false 
positive colocalisation. However, it is reasonable to assume that the association of the 
S protein with the intracellular membranes is also present in the cells co-expressing 
the S and L proteins. The characteristic lattice distribution of S observed in the S- 
expressing cells is preserved upon coexpression of S and L, with the distribution of L 
conforming to that of S. To preclude the possibility that the expression of S was 
causing multinucleation in the cells, samples similar to that shown in Fig. 5.5 were 
analysed with the same antisera, with the inclusion of a propidium iodide-labelling 
step to allow identification of the nuclei of the cells. As shown in Fig. 5.6, S and L 
are distributed in a matrix-like pattern and they co-localise, thus confirming the above 
observations (panel A, C and D). Furthermore, there was no evidence of 
multinucleation as staining with propidium iodide showed the presence of a single, 
intact nucleus in the co-infected cell (panel D).
Similar observations were made in cells co-infected with vLx and vS. The association 
of the secretable form of the L protein (Lx) with the ERGIC marker and a widespread 
cytoplasmic distribution of Lx is shown in Fig. 5. IB. There was no marked change in 
the distribution of Lx in the cell co-infected with vLx and vS (Fig. 5.7, panel A, cell 
on the top left comer) from that seen in vLx-infected cell. However, as with L, Lx 
also co-localised with S (panel C) although the association of the S and Lx differed in 
comparison with L and S proteins seen in Figs. 5.5 and 5.6. Here, the Lx and S 
formed bodies throughout the cytoplasm, but did not appear to be conforming to the 
membrane association as seen in the S-Concanavalin-A (Fig. 5.2). The effect of the 
signal sequence located at the N-terminus of the Lx protein may be sufficient to 
encourage the recmitment of S from the ER or the intracellular membranes and 
subsequent transport into the cytoplasm. As shown before, the anti-S MAb 6B1 failed 
to recognise vLx (Fig. 5.7, compare panel A and B cell on the bottom left).
Having established that L and S co-localised to the same compartment in co­
expressing cells, it was interesting to see if similar interaction between L or Lx and M 
existed. To examine this, HepG2 cells were co-infected with vL and vM or vLx and 
vM, fixed after 24 h, probed with anti-preSl PAb 143 and the anti S MAb 6B1, and
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VFig. 5.7 Co-expression of Lx and S in HepG2 cells.
HepG2 cells were grown on glass coverslips in 24-well plates to about 60% confluence. The 
cells were infected with both vLx and vS at a m.o.i. of 0.5 p.f.u per cell. At 24 h, post­
infection, the coverslips were washed three times in PBSA and fixed in methanol at -20°C 
overnight. After fixing, the coverslips were washed twice with PBSA, then were 
permeablised by incubation with PBST for at least 30 minutes. The coverslips were 
incubated with a mixture of PAb 143 (at a dilution of 1:1000) and MAb 6B1 (at a dilution of 
1:500) for two hours in a volume of 200 pL. Unbound antibodies were removed by washing, 
and the coverslips were incubated in a mixture of anti-mouse IgG-FITC and anti-rabbit Cy5 
for two hours. The unbound secondary antibodies were removed by washing and the 
coverslips were mounted and analysed with a Zeiss Laser Scanning Confocal microscope. 
Panel A: Cy5 fluorescence showing the intracellular distribution of vLx.
Panel B: FITC fluorescence showing the intracellular distribution of vS.
Panel C: Merge. White arrow indicates areas where Lx and S are colocalised.
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Fig. 5.8 Co-expression of L and M in HepG2 cells.
HepG2 cells were grown on glass coverslips in 24-well plates to about 60% confluence. The 
cells were infected with both vL and vM at a m.o.i. of 0.5 p.f.u per cell. At 24 h, post­
infection, the coverslips were washed three times in PBSA and fixed in methanol at -20°C 
overnight. After fixing, the coverslips were washed twice with PBSA, then were 
permeablised by incubation with PBST for at least 30 minutes. The coverslips were 
incubated with a mixture of PAb 143 (at a dilution of 1:1000) and MAb 6B1 (at a dilution of 
1:500) for two hours in a volume of 200 pL. Unbound antibodies were removed by washing, 
and the coverslips were incubated in a mixture of anti-mouse IgG-FITC and anti-rabbit Cy5 
for two hours. The unbound secondary antibodies were removed by washing and the 
coverslips were mounted and analysed with a Zeiss Laser Scanning Confocal microscope. 
Panel A: Cy5 fluorescence showing the intracellular distribution of vL.
Panel B: FITC fluorescence showing the intracellular distribution of vM.
Panel C: Merge. White arrow indicates areas where L and M are colocalised.
Fig. 5.9 Co-expression of Lx and M in HepG2 cells.
HepG2 cells were grown on glass coverslips in 24-well plates to about 60% confluence. The 
cells were infected with both vLx and vM at a m.o.i. of 0.5 p.f.u per cell. At 24 h, post­
infection, the coverslips were washed three times in PBSA and fixed in methanol at -20°C 
overnight. After fixing, the coverslips were washed twice with PBSA, then were 
permeablised by incubation with PBST for at least 30 minutes. The coverslips were 
incubated with a mixture of PAb 143 (at a dilution of 1:1000) and MAb 6B1 (at a dilution of 
1:500) for two hours in a volume of 200 pL. Unbound antibodies were removed by washing, 
and the coverslips were incubated in a mixture of anti-mouse IgG-FITC and anti-rabbit Cy5 
for two hours. The unbound secondary antibodies were removed by washing and the 
coverslips were mounted and analysed with a Zeiss Laser Scanning Confocal microscope. 
Panel A: Cy5 fluorescence showing the intracellular distribution of vLx.
Panel B: FITC fluorescence showing the intracellular distribution of vS.
Panel C: Merge. White arrow indicates areas where Lx and M are colocalised.
Panel D: the subtraction of fluorescent areas containing a single label results in the localised 
areas being demonstrable as a black-on-white image, with the white pixels indicating the 
presence of both fluors at similar intensities.
encourage the recruitment of S from the ER or the intracellular membranes and 
subsequent transport into the cytoplasm. As shown before, the anti-S MAb 6B1 failed 
to recognise vLx (Fig. 5.7, compare panel A and B cell on the bottom left).
Having established that L and S co-localised to the same compartment in co­
expressing cells, it was interesting to see if similar interaction between L or Lx and M 
existed. To examine this, HepG2 cells were co-infected with vL and vM or vLx and 
vM, fixed after 24 h, probed with anti-preSl PAb 143 and the anti S MAb 6B1, and 
analysed by confocal analysis. Consistent with the data shown in Fig. 5.4, MAb 6B1 
recognised M (Fig. 5.8, panel B), but not L (Fig. 5.8, panel A) or Lx (Fig. 5.9, panel 
A). The L protein as shown before was distributed evenly throughout the cytoplasm 
(Fig. 5.8, panel A), and in cells expressing L and M, it co-localised with the M protein 
(panel C). There was no major change in the distribution of either L or M in these 
cells. In cells infected with vLx only, the Lx protein showed the characteristic 
cytoplasmic distribution (Fig. 5.9, panel A). However, in the cell co-expressing Lx 
and M, both proteins colocalised, resulting in a dramatic change in the distribution of 
Lx (panels A and C). This distribution was similar to that seen in L- and S-expressing 
cells (Fig. 5.5) in that the proteins appeared to form a matrix-like pattern associated 
with internal membranes (Fig. 5.9, panels A and C). That the Lx and M proteins 
interact in co-expressing cells was further confirmed when fluorescence 
corresponding to single labels were subtracted resulting in apparent visualisation of 
the co-localised areas (Fig. 5.9, panel D).
5.4 Analysis of the interactions between L. Lx. M and S by imiminoprecipitation.
Confocal microscopy is a powerful technique used in the analysis of the intracellular 
distribution of proteins to gain valuable information on the localisation and 
colocalisation of the studied proteins with cellular compartments and/or other 
proteins. Whereas data obtained by confocal microscopy may indicate colocalisation 
of proteins on account of two or more fluorochromes localised in similar positions 
intracellularly, they do not necessarily constitute evidence of a direct interaction 
between the studied proteins. It may simply be that the studied proteins are co­
compartmentalised in the cell. To prove a direct physical interaction between two 
proteins, an assay to confirm the interaction must be employed. In this study,
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Fig. 5.10 MAb 6B1 recognises S but not L or Lx by immunoprecipitation.
HepG2 cells were grown in 60mm dishes and infected at a m.o.i. of 10 p.f.u. per cell 
with vL, vLx, vS, a mixture of vL and vS, a mixture of vLx and vS, WR or were mock- 
infected. At five hours post-infection, the cells were washed twice with PBSA and were 
radiolabelled with 35S-methionine. At 18 hours post-labelling, the cells were lysed, 
clarified and subjected to immunoprecipitation with MAb 6B1 (panel A) or PAb 143 
(panel B). The immune complexes were subjected to 10% SDS-PAGE and the 
radiolabelled proteins detected by autoradiography.
immunoprecipitation and co-immunoprecipitation techniques were used to explore the 
interaction between the surface antigens.
Radiolabelled proteins from HepG2 cells infected with the wild type vaccinia virus 
WR or r W  vL, vLx, or vS or co-infected with vL + vS or vLx + vS were 
immunoprecipitated with the anti-S MAb 6B1 or anti-preSl PAM43, and the immune 
complexes were analysed by SDS-PAGE. As shown in Fig. 5.10A, MAb 6B1 
specifically immunoprecipitated the two characteristic S bands of 26 and 28 kDa, 
from cells infected with vS. However, MAb 6B1 failed to precipitate L or Lx proteins 
from cells infected with vL or vLx. This result is consistent with the observation made 
in confocal microscopy analysis (Figs. 5.4 to 5.7), thus confirming that this 
conformation-sensitive anti-S MAb is unable to recognise the S domain of the L (or 
Lx) protein. This strongly indicates that S adopts a different conformation to the S 
domain of the L protein. There was relatively little reactivity of MAb 6B1 with either 
cellular (MI) or vaccinia virus proteins (WR) (Fig. 5.10A). As expected, the anti- 
preSl PAbl43 specifically immunoprecipitated both L and Lx proteins of 
approximately 42 kDa from cells infected with vL and vLx, respectively (Fig. 5.1 OB). 
A small amount of the 26 and 28 kDa S protein bands were also co-precipitated by 
PAbl43 from these cells. This is not unexpected as transcription and translation of the 
S gene is known to occur from the L ORF in heterologous expression systems as well 
as from the viral genome. Furthermore, the anti-preSl antiserum PAbl43 also co- 
immunoprecipitated both S products from cells co-infected with vL + vS or vLx + vS 
(Fig. 5.1 OB). The relatively larger quantities of S bands seen in the co-infected cells 
strongly indicated that S produced in trans as well as that supplied in cis can directly 
interact with the L and Lx proteins. The co-immunoprecipitation of S with L is 
consistent with the confocal microscopy data shown in Figs. 5.5 to 5.7, and is in 
agreement with previously published results (Bruss and Ganem, 1991). These data 
suggest that the surface antigens, while over-expressed, are correctly folded and 
capable of intermolecular interactions, presumably mediated by the disulphide 
linkages in the transmembrane regions of the S domains.
5.5 Discussion
The HBV surface antigens and core play a pivotal role in virus/subvirus assembly, 
morphogenesis, and secretion. The structures of the surface antigens remain poorly
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characterised due to the complex nature of conformation and transmembrane topology 
of these proteins. Understanding the biosynthesis, intracellular localisation, and 
maturation of these proteins in expressing cells should help shed light on the 
mechanisms involved in viral particle assembly. In this chapter, a detailed antigenic 
characterisation of the various HBV surface antigens was carried out using the 
immunological reagents described in Chapter 3.
To date, the biogenesis of HBV surface antigens has been studied largely by 
biochemical means. Surprisingly, very little information on the immunofluorescence- 
based direct visualisation of the intracellular distributions of these proteins exists. In 
this study, confocal microscopy was used to perform such an analysis. The results 
showed that L protein localised predominantly to the ERGIC compartment. The 
Western blot data presented in Chapter 3 showed that the L protein is not secreted. 
Taken together, these results are in agreement with the previously published 
observations that the L protein is retained in the ER (Cheng et al., 1986; Chisari et al., 
1987; Persing et al., 1986; Xu et al, 1997). The L protein has been shown to bud into 
the ER and is retained in this compartment as 20 nm intracellular particles, possibly 
by association with calnexin and other ER quality control proteins (Xu et al., 1997). 
In contrast, when forced through the secretory pathway by addition of a heterologous 
signal sequence at its N-terminus, the L protein is secreted as particles (Bruss and 
Vieluf, 1995; Gallina et al., 1995). Consistent with these observations, our Lx 
protein, which carries a vaccinia virus signal sequence, is efficiently secreted (Fig. 
3.3A). In keeping with its secretory characteristic, the intracellular distribution of Lx 
was markedly different from that of L. In contrast to L, the Lx protein was present 
throughout the cytoplasm.
The intracellular distribution of the M and S proteins was distinct from the L and Lx 
proteins in that both of these proteins co-localised with intracellular membranes, as 
defined by co-staining with ConA. The lectin Con A has a highly specific affinity for 
carbohydrates with terminal a-D-mannosyl and a-D-glucosyl residues present on 
glycoproteins. Thus, ConA specifically stains the glycoproteins present in internal 
membranes (mainly the ER) which have such sugar residues. Both M and S are 
synthesized as transmembrane proteins, and their translocation across the ER is
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mediated by signals of hydrophobic amino acids within the S domain (Eble et al, 
1986; Eble et al., 1990; Eble et al., 1987; Sheu and Lo, 1994). Both M and S are 
known to be secreted from expressing cells. It is not clear why the intracellular 
distribution pattern of M and S differs from that of Lx, but it is possible that Lx is 
secreted through a different secretion pathway.
In addition to examining the intracellular distribution of the HBV surface antigens, 
several anti-S MAbs were tested for antigen recognition. One set of MAbs, H I66, 
H10, and RF7 all recognised S but also L, Lx, and M proteins in confocal assays. 
MAb H I66 is known to recognise a linear epitope (amino acids 121-124) in S, 
whereas MAb H35 recognises a discontinuous epitope (amino acids 122 -  130 and 
166 -  175; (Chen et a l, 1996). In contrast with these MAbs, MAb 6B1 which is 
specific for a conformation-sensitive epitope in S recognised S and M, but not L (or 
Lx) in an immunofluorescence and immunoprecipitation assays, indicating structural 
differences in the S moiety of L from that in M and S. It is important to point out here 
that although all the surface antigens used here have been derived form the adw 
subtype of HBV, the S was obtained from a different patient serum. The M gene was 
subcloned from that encoding L and therefore originates from the same patient 
sample. Furthermore, amino acid sequence comparison has identified several variant 
amino acids between the S domain in L and S (see Appendix 2). However, the 
inability of MAb 6B1 to recognise the S domain in L or Lx is highly unlikely to be 
due to the presence of the variant amino acids in L because this MAb clearly 
recognised the M protein. Rather the data strongly indicate that there are discernible 
structural differences between the S domain of L, and that of M and S. Interestingly, 
in cells co-expressing L and S there was a dramatic change in the distribution of L. 
The L protein appeared to co-localise with S to intracellular membranes, indicating 
that it is no longer retained in the ER. The behaviour of the L protein when co­
expressed depends on the relative amounts of other surface antigens, however, a small 
portion of it is secreted (Cheng et al, 1986; Chisari et a l, 1987; Molnar-Kimber et 
al, 1988). In these confocal assays the S protein also co-localised with M and Lx 
proteins.
That there is a specific interaction between L (or Lx) and S was shown by 
immunoprecipitation assay where an anti-preSl PAb specifically co-precipitated the S
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proteins from cells infected with vL (or vLx) and vS. Other authors have shown 
immunoprecipitation and SDS-PAGE analysis that the surface antigens form 
heteromultimeric complexes upon co-expression (Cheng et al, 1986; Chisari et al., 
1987; Molnar-Kimber et al., 1988; Wunderlich and Bruss, 1996). A small amount of 
S synthesised by internal initiation from the L ORF encoded by vL was co- 
immunoprecipitated by the anti-preSl PAb. The failure of MAb 6B1 to recognise 
these S products in both immunoprecipitation and immunofluorescence is likely due 
to their very low levels of expression in cells.
It is possible the S domain in L protein has a dramatically different topology to the S 
protein, but presumably, the ability to interact with S must be conserved in order to 
retain the ability to form virions. It is also worth considering that the insertion of the 
preSl domain into the lipid bilayer at Gly2 via the myristic acid moiety, which is 
necessary for infectivity (Bruss et al., 1996b) may affect the spatial arrangement of 
the transmembrane regions, therefore contributing to a difference in the conformation 
of S and L. It is also feasible that the arrangement of the alpha helices in S and L 
differs, but the association of the disulphide linkages forming the intermolecular 
bonds remains conserved to allow oligomerisation of the envelope proteins. The 
observation of Lx interacting with S may indicate that the structure of the Lx protein 
is similar to that of the L protein, although it may be possible that the extra-luminal 
domains of the Lx protein whilst undergoing processing in the ER are less abundant 
than those in the L protein. Furthermore, it can be seen from the Figs. 5.2 and 5.4 that 
the recognition of S by MAb 6B1 occurs even when the S and L proteins are 
interacting. This indicates that the binding site of the MAb 6B1, even though 
unidentified, remains exposed and intact when the S protein is interacting with the L 
or Lx proteins.
To my knowledge, this is the first report which describes an immunological reagent 
capable of selectively discriminating S, and the S domain of M, from that of the L 
protein. Numerous studies on the biosynthesis and maturation of HBV surface 
antigens have been performed over the years, leading researchers to propose topology 
models of these proteins. However, several important aspects are unclear. The 
availability of MAb 6B1 with its unique/novel characteristics should further facilitate 
the study of the conformational nature of these proteins, without the use of potentially
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disruptive techniques such as tagging with heterologous epitopes or fluorescent 
protein domains into the surface antigens.
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Chapter 6
Investigation of the interaction between HBV core and L proteins.
The encapsidation of hepadnavirus pregenomic RNA depends on the formation of a 
ribonucleoprotein (RNP) complex with the viral polymerase and certain cellular 
factors that include the heat shock protein 90 (Hsp90) (Hu and Seeger, 1996). This 
multi-component complex assembles together with HBV core to form nucleocapsids 
which in turn are enveloped at the ER by docking to the preS regions of viral surface 
antigen (Bruss and Ganem, 1991; Dyson and Murray, 1995; Ostapchuk et al, 1994; 
Prange and Streeck, 1995). However, the process of hepadnaviral morphogenesis 
remains poorly understood, and in particular there is little data concerning the in vivo 
interactions of the structural proteins in the processes of morphogenesis. Previous 
data based on observations from in vitro studies has suggested an interaction of the 
core protein with the L protein (see Introduction), but there is very little in vivo 
information to support the validity of these observations. Studies of the in vitro L- 
core interaction have suggested a synergistic interaction of core with both the preSl 
domain and the S domain of the L protein (Tan et al, 1999). Using deletion analysis, 
and short peptide mimotopes corresponding to the L protein in an in vitro core­
binding assay, Tan et. a l (1999) identified two peptides that were capable of binding 
the core protein. One of the peptides corresponded to a region within (amino acids 
24-119) of the L and the second to a region (amino acids 191-322) in the S domain. 
Furthermore, the dissociation constants of these peptides to the core protein were 
different, with the preSl-specific peptide binding strongly, where the S-specific 
peptide bound relatively weakly to the core. Furthermore, Tan et. a l  suggest that 
both the preSl peptide region and the S peptide region bind to the core protein a 
stronger bond and this is the evidence of a synergistic interaction. Whether the 
peptide in the S domain of HBsAg and M protein is capable of binding to the core 
protein in vivo remains unclear.
Although considerable benefit can be derived from data obtained from in vitro 
studies, in vivo analysis often results in data more likely to reflect the nature of the 
interactions within the infected cell. This work was undertaken as part of a study of 
the localisation of the HBV surface antigens within the cell, when expressed
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Figure 6.1 Colocalisation of core and L in HepG2 cells.
H epG 2 cells on glass coverslips in 24-w ell plates were coinfected at an m .o.i. o f  0.5 p.f.u./cell 
w ith rVVs vL and v5D. At 24 hours post-infection, the cells were fixed in m ethanol at -20°C, 
then perm eablised in PBST. The cells were probed with M Ab RC109 (anti-L) and PAb anti­
core for two hours at room  tem perature, then were w ashed in PBST. The coverslips were 
incubated w ith anti-m ouse FITC and anti-rabbit IgG -C y5, and the coverslips w ere m ounted 
and exam ined by confocal m icroscopy.
Panel A: cells expressing vL stained with M Ab RC109 and anti-m ouse IgG -FITC .
Panel B: cells expressing core stained w ith PAb anti-core and anti-rabbit IgG -cy5, coloured 
red
Panel C: m erge. W hite arrow  shows colocalised areas o f  core and L.
Figure 6.2 Colocalisation of core in H5 cells expressing core and L.
H5 cells on glass coverslips in 24-well plates were coinfected at an m.o.i. o f  0.5 p .f.u ./cell w ith 
vL and v5D. At 24 hours post-infection, the cells were fixed in m ethanol at -20°C, then 
perm eablised in PBST. The cells were probed with M Ab RC109 (anti-L ) and PA b anti-core for 
tw o hours at room  tem perature, then were washed in PBST. The coverslips were incubated with 
anti-m ouse FITC and anti-rabbit IgG -Cy5, and the coverslips w ere m ounted and exam ined by 
confocal m icroscopy.
Panel A: cells expressing core stained w ith PAb anti-core and anti-rabbit IgG -cy5, coloured red. 
Panel B: cells expressing vL stained with M Ab RC109 and anti-m ouse IgG -FIT C .
Panel C: m erge. W hite arrow  shows colocalised areas o f  core and L.
Panel D: the subtraction o f  fluorescent areas containing a single label results in the localised 
areas being dem onstrable as a black-on-w hite image, w ith the w hite pixels indicating the 
presence o f  both fluors at sim ilar intensities.
Figure 6.3 Colocalisation of core and L in HeLa cells.
H eLa cells on glass coverslips in 24-w ell plates were coinfected  at an m .o.i. o f  0.5 p.f.u ./cell 
w ith vL and v5D. At 24 hours post-infection, the cells w ere fixed in m ethanol at -20°C , then 
perm eablised in PBST. The cells were probed w ith PAb 143 (anti-L) and M A b 2A23 anti-core 
for two hours at room  tem perature, then were w ashed in PBST. The coverslips w ere incubated 
w ith anti-m ouse FITC and anti-rabbit Cy5, and the coverslips w ere m ounted and exam ined by 
confocal m icroscopy.
Panel A: cells expressing vL stained w ith PAb 143 and anti-m ouse IgG -FIT C , coloured red. 
Panel B: cells expressing core stained with M Ab 2A23 and anti-rabbit IgG -cy5 coloured green 
Panel C: m erge. W hite arrow  shows colocalised areas o f  core and L.
Figure 6.4 Intracellular distribution of Core and L in H5 cells.
H5 cells in 6-well plates were coinfected w ith w ild-type vaccinia strain W R at a m.o.i 
o f  5 p.f.u/cell and incubated for 18 hours at 37°C. The cells were w ashed three tim es 
with PBSA and scraped into Beem  capsules and centrifuged at 400 r.p.m . in a B eckm an 
benchtop centrifuge. The supernatant was discarded, and the cell pellet was fixed by 
the addition o f  400 pL o f  2.5 % glutaraldehyde and then em bedded and perm eated in 
4%  gelatin  at 37°C. The cell pellets were rem oved from  the capsules and cryo- 
sectioned into 100 pM  sections, were transferred onto N ickel grids and labelled with 
prim ary antibodies (PAb 143 anti-L , and M Ab 2A23 anti-core), and secondary 
antibody-gold  conjugates anti-m ouse IgG -5nm  gold, and anti-rabbit IgG -15nm  gold. 
The sam ples were visualised with a JOEL 100S electron m icroscope.
Figure 6.5 Intracellular distribution of Core and L in H5 cells.
H5 cells in 6-well plates were coinfected w ith vL and v5D virus at a m .o.i o f  5 p.f.u/cell and 
incubated for 18 hours at 37°C. The cells were w ashed three tim es w ith PB SA  and scraped 
into Beem  capsules and centrifuged at 400 r.p.m . in a Beckm an benchtop centrifuge. The 
supernatant was discarded, and the cell pellet was fixed by the addition o f  400 pL  o f  2.5 % 
glutaraldehyde and then em bedded and perm eated in 4%  gelatin  at 37°C. The cell pellets 
were rem oved from  the capsules and cryo-sectioned into 100 pM  sections, were transferred 
onto N ickel grids and labelled with prim ary antibodies (PAb 143 anti-L , and M A b 2A23 
anti-core), and secondary antibody-gold conjugates anti-m ouse IgG -5nm  gold, and an ti­
rabbit IgG -15nm  gold. The sam ples were visualised with a JOEL 100S electron m icroscope.
singularly and upon co-expression with HBV core. Here, a detailed intracellular 
analysis of the interactions of the surface antigens with core protein has been 
performed.
6.1 Intracellular localisation of HBV core protein
The distribution of HBcAg produced in HepG2 cells infected with v5D was assessed 
and compared with reported data. The core protein from v5D can be seen stained 
with a polyclonal antibody in cells in Fig. 3.3 panel E, and appears ubiquitously 
distributed throughout the cytoplasm and nucleus, with weaker staining present in the 
latter, but no staining of the nucleoli. This behaviour of core is in agreement with that 
observed by others (Aiba et al., 1997).
6.2 Coexpression of L and core.
As reported in Chapter 5, the HBV L protein when expressed using recombinant 
vaccinia virus in mammalian cells is retained in the ERGIC compartment. The 
intracellular localisation characteristics of HBV L and core proteins when co­
expressed or expressed individually were examined by confocal microscopy using 
appropriate antibodies. HepG2 cells were co-infected with recombinant vaccinia virus 
vL and v5D expressing HBV L and core proteins, respectively. The cells were fixed 
and analysed by indirect immunofluorescence confocal microscopy using anti-L MAb 
RC109 and anti-core polyclonal antibodies. As shown in Fig. 6.1 (panel B), in cells 
infected with v5D alone, the core was distributed throughout the cytoplasm and the 
nucleus with roughly equal intensity. In co-infected cells, the distribution pattern of L 
was similar to that seen previously (see above) it co-localised with the ERGIC 
compartment. In contrast, in co-infected cells the intracellular distribution of core had 
changed; it was not present in the nucleus but it co-localised with L (Fig. 6.1, panels 
B and C). These results indicate that L influences the intracellular localisation of core 
such that it co-localises with L in co-expressing cells, and this may occur due to a 
direct interaction between the two proteins. This redistribution of the core protein 
when co-expressed with the L protein was evident not only in HepG2 cells as shown 
above (Fig. 6.1), but also in the other human hepatocyte cell line H5, and in HeLa 
cells (Figs. 6.2 and 6.3, respectively). This indicated that the redistribution of core in 
the presence of L is not restricted to a particular cell type.
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Whereas the confocal data shows the colocalisation of the core and L protein clearly, 
this observation alone is insufficient to confirm the existence of the L-core protein- 
protein interaction. In order to clarify the presence of the interaction in vivo, a 
different method was employed, which would allow immunological detection by 
electron microscopy (EM) of the proteins in cryo-sectioned. Briefly, the H5 cells were 
infected with the wild type vaccinia virus strain WR or co-infected with the 
recombinant viruses vL and v5D in 6-well plates at a m.o.i of 5 p.f.u./cell and 
incubated for 18 hours at 37°C. The cells were washed three times with PBSA and 
scraped into Beem capsules and centrifuged at 400 rpm in a Beckman benchtop 
centrifuge. The supernatant was discarded, and the cell pellet was fixed by the 
addition of 400 pL of 2.5 % glutaraldehyde (EM grade, double distilled, TAAB, 
Amersham, UK), and stored at 4°C prior to processing. The cell pellet was then 
embedded and permeated in 4% gelatin (TAAB, Amersham, UK) at 37°C. The cell 
pellets were removed from the capsules and sectioned into 100 pM sections, 
transferred onto Nickel, Copper or gold grids, and labelled with primary antibodies 
(PAb 143 anti-L, and MAb 2A23 anti-core) followed by secondary antibody 
conjugated to gold particles of 10 or 15 nm. The samples were stained with vanadium 
and visualised in a JOEL 100S electron microscope. As shown in Fig. 6.4, both the 
anti-L PAb 143 and the anti-core MAb 2A23 bound to proteins in the cytoplasm of 
cells infected with the WR virus. The use of the WR-infected cells as a negative 
control was essential to exclude the possibility of misinterpretation of binding 
specificities of the primary or secondary antibodies. The electron micrograph in Fig.
6.4 clearly shows a large amount of non-specific binding as evident by the areas of 
gold labelling. Similar pattern of gold distribution was also seen in cells co-infected 
with vL and v5D (Fig. 6.5). A close comparison of electron micrographs shown in 
Figs. 6.4 and 6.5 showed that there is little discernible difference between them. 
During the course of this series of experiments, a large number of experimental 
conditions were employed; antibodies were titred for optimal signal to background 
ratio, and a variety of embedding techniques were used. The experiments shown in 
Figs. 6.4 and 6.5 represent the optimal results obtainable in this system. The relatively 
similar distributions of the gold particles seen in these figures unfortunately prevent 
any conclusions being reached.
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Figure 6.6 Colocalisation of core and Lx in HepG2 cells.
HepG2 cells on glass coverslips in 24-w ell plates were coinfected at an m .o.i. o f  0.5 p.f.u./cell 
w ith vLx and v5D. At 24 hours post-infection, the cells were fixed in m ethanol at -20°C, then 
perm eablised in PBST. The cells were probed with M Ab 109 (anti-L) and Pab anti-core for two 
hours at room  tem perature, then were washed in PBST. The coverslips w ere incubated w ith 
anti-m ouse FITC and A nti-R abbit Cy5, and the coverslips were m ounted and exam ined by 
confocal m icroscopy.
Panel A: cells expressing v5D stained with PAb anti-core and anti-rabbit IgG -cy5, coloured 
red.
Panel B: cells expressing vLx stained w ith M Ab 109 and anti-m ouse IgG -FIT C .
Panel C: m erge.
Panel D: the subtraction o f  fluorescent areas containing a single label results in the localised 
areas being dem onstrable as a black-on-w hite im age, with the w hite pixels indicating the 
presence o f  both fluors at sim ilar intensities.
Figure 6.7 Colocalisation of core and Lx in H5 cells.
H5 cells on glass coverslips in 24-w ell plates were coinfected at an m .o.i. o f  0.5 p.f.u./cell w ith 
vLx and v5D. At 24 hours post-infection, the cells were fixed in m ethanol at -20°C, then 
perm eablised in PBST. The cells were probed with M Ab RC109 and PA b anti-core for two 
hours at room  tem perature, then were w ashed in PBST. The coverslips w ere incubated with 
anti-m ouse FITC and anti-rabbit Cy5, and the coverslips were m ounted and exam ined by 
confocal m icroscopy.
Panel A: cells expressing v5D stained w ith PAb anti-core and anti-rabbit IgG -cy5, coloured red. 
Panel B: cells expressing vLx stained w ith M Ab 109 and anti-m ouse IgG -FIT C  
Panel C: m erge.
Figure 6.8 Colocalisation of core and Lx in HeLa cells.
H eLa cells on glass coverslips in 24-well plates w ere coinfected at an m .o.i. o f  0.5 p.f.u./cell 
w ith vLx and v5D. At 24 hours post-infection, the cells were fixed in m ethanol at -20°C, then 
perm eablised in PBST. The cells were probed w ith M Ab RC 109 and PAb anti-core for two 
hours at room  tem perature, then were washed in PBST. The coverslips w ere incubated w ith 
anti-m ouse FITC and anti-rabbit Cy5, and the coverslips w ere m ounted and exam ined by 
confocal m icroscopy.
Panel A: cells expressing v5D stained with PAb anti-core and anti-rabbit IgG -cy5, coloured 
red.
Panel B: cells expressing vLx stained with M Ab 109 and anti-m ouse IgG -FIT C .
Panel C: m erge.
Panel D: the subtraction o f  fluorescent areas containing a single label results in the localised 
areas being dem onstrable as a black-on-w hite im age, with the w hite pixels indicating the 
presence o f  both fluors at sim ilar intensities.
Figure 6.9 Intracellular distribution of Core and Lx in H5 cells.
H5 cells in 6-well plates were coinfected w ith vLx and v5D virus at a m .o.i o f  5 p.f.u/cell 
and incubated for 18 hours at 37°C. The cells were w ashed three tim es w ith PBSA and 
scraped into Beem  capsules and centrifuged at 400 r.p.m . in a B eckm an benchtop centrifuge. 
The supernatant was discarded, and the cell pellet was fixed by the addition o f  400 pL o f 
2.5 % glutaraldehyde and then em bedded and perm eated in 4%  gelatin  at 37°C. The cell 
pellets were rem oved from the capsules and cryo-sectioned into 100 pM  sections, were 
transferred onto N ickel grids and labelled w ith prim ary antibodies (PA b 143 anti-L , and 
M Ab 2A23 anti-core), and secondary antibody-gold  conjugates anti-m ouse IgG -5nm  gold, 
and anti-rabbit IgG -15nm  gold. The sam ples were visualised w ith a JOEL 100S electron 
m icroscope.
Figure 6.10A Failure of recognition of L-core with RC28.
HepG 2 cells on glass coverslips in 24-well plates were coinfected at an m .o.i. o f  0.5 p.f.u./cell w ith 
vL and v5D. A t 24 hours post-infection, the cells were fixed in m ethanol at -20°C, then 
perm eablised in PBST. The cells were probed with M A b RC28 (anti-L ) and PA b (anti-core) for two 
hours at room  tem perature, then were w ashed in PBST. The coverslips w ere incubated w ith anti­
m ouse FITC and anti-rabbit Cy5, and the coverslips were m ounted and exam ined by confocal 
m icroscopy.
Panel A: cells expressing v5D stained with PAb anti-core and anti-rabbit IgG -cy5, coloured red. 
Panel B: cells expressing vL stained with M Ab RC28 and anti-m ouse IgG -FIT C .
Panel C: m erge.
VB
Figure 6.10B Failure of recognition of Lx-core with RC28.
HepG 2 cells on glass coverslips in 24-well plates were coinfected  at an m .o.i. o f  0.5 p.f.u./cell w ith 
vLx and v5D. At 24 hours post-infection, the cells were fixed in m ethanol at -20°C, then 
perm eablised in PBST. The cells were probed w ith M A b RC28 (anti-L) and PA b (anti-core) for two 
hours at room  tem perature, then were washed in PBST. The coverslips were incubated with anti­
m ouse FITC  and anti-rabbit Cy5, and the coverslips were m ounted and exam ined by confocal 
m icroscopy.
Panel A: cells expressing v5D stained with PAb anti-core and anti-rabbit IgG -cy5, coloured red. 
Panel B: cells expressing vLx stained with M Ab RC28 and anti-m ouse IgG -FITC .
Panel C: m erge.
6.3 Co-expression of Lx and core.
The immuno-staining of the cells expressing the secretory form of L (Lx) with the 
ERGIC MAb p53 showed a distribution of Lx clearly contrasting with that of L 
protein as described in Chapter 5 To examine the intracellular distribution of core 
when co-expressed with Lx, HepG2 cells were co-infected with recombinant vaccinia 
viruses, vLx and v5D. The infected cells were probed with the anti-core polyclonal 
antisera and the anti-L MAb RC28 or the MAb RC109, or anti-L PAb 143 and an 
anti-core MAb-2A23 (see figure legends for details of antisera, and appendix 1). The 
distribution of Lx appeared similar to that observed in cells expressing Lx alone, 
whereas the localisation of core changed to a punctate appearance in comparison with 
that found with vL and core (see Fig. 6.1, 6.2 and 6.3), but was also found to be in the 
nucleus of co-expressing cells (Fig. 6.6). It was found necessary to analyse the 
confocal images with an algorithm (Zeiss) that can be used to exclude dissimilar 
fluorescent intensities from images, therefore allowing viewing of similar intensities, 
represented here in this work as panel D (Fig. 6.6). The white areas in the panels 
labelled correspond to areas of similar fluorescent intensity for both the FITC channel 
and the Cy5 channel, enabling small areas of fluorescence to be depicted against a 
suitably contrasting background. The small nature of these bodies found upon the 
coexpression of the core and Lx proteins is clearly visible in panel D of Fig. 6.6. The 
punctate distribution of core in the Lx and core-expressing cells differs markedly from 
the distribution of core when expressed singularly. In these images it has been 
possible, by using a carefully controlled multiplicity of infection, to obtain images 
that have unstained cells, singularly expressing cells and co-expressing cells in one or 
more cell types in Figs. 6.1, 6.2, 6.3 and 6.7. Thus, a comparison of the intracellular 
distribution of the proteins is possible for each of the protein combinations studied, as 
is the comparison with mock-infected cells in the images. Identical results were 
obtained in H5 and HeLa cells, indicating that the changes in the distribution of core 
in the presence of Lx is not cell-type dependent (Figs. 6.7 and 6.8, respectively). The 
observation that core co-localises with Lx (and L, see Figs. 6.1 to 6.3) again indicates 
an existence of a direct protein-protein interaction. As before, an attempt was made to 
confirm this interaction by immune-labelling cryo-sectioned cells and EM. H5 cells 
were co-infected with recombinant vaccinia viruses vLx and v5D, cryo-sectioned, 
probed with anti-L PAb 143 and anti-core MAb 2A23, and analysed by EM as
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Figure 6.11 HepG2 cells expressing both core and M.
HepG 2 cells on glass coverslips in 24-w ell plates were coinfected at an m .o.i. o f  0.5 p .f.u ./cell w ith 
vM  and v5D. At 24 hours post-infection, the cells were fixed in m ethanol at -20°C, then 
perm eablised in PBST. The cells were probed with M Ab 2-F2-12 (anti-M ) and PA b anti-core for 
two hours at room  tem perature, then were washed in PBST. The coverslips were incubated with 
anti-m ouse FITC and anti-rabbit Cy5, and the coverslips w ere m ounted and exam ined by confocal 
m icroscopy.
Panel A: staining o f  core with PAb anti-core, with anti-rabbit-IgG -cy5 fluor.
Panel B: staining o f  M protein with M Ab 2F2-12, w ith anti-m ouse-IgG -FIT C .
Panel C: m erge. W hite arrow  shows cell expressing core and M, w ith no co localised  areas. W hite 
star is situated next to a cell exhibiting CPE due to the rVV infections.
Figure 6.12 HepG2 cells expressing core and vHBsAg.
HepG2 cells on glass coverslips in 24-well plates were coinfected at an m .o.i. o f  0.5 p.f.u./cell 
with vH B sA g and v5D. At 24 hours post-infection, the cells were fixed in m ethanol at -20°C, 
then perm eablised in PBST. The cells were probed w ith M Ab 6B1 (anti-H B sA g) and PAb anti­
core for two hours at room  tem perature, then were w ashed in PBST. The coverslips were 
incubated w ith anti-m ouse FITC and anti-rabbit Cy5, and the coverslips were m ounted and 
exam ined by confocal m icroscopy.
Panel A: staining o f  core w ith PA b anti-core, w ith anti-rabbit IgG -cy5.
Panel B: staining o f  S protein w ith M A b 6B1, w ith anti-m ouse IgG -FIT C .
Panel C: m erge.
described in Figs. 6.4 and 6.5. Gold particles of both sizes were found throughout the 
cytoplasm of cells (Fig. 6.9). As this pattern of gold distribution is similar to that 
found in wild type WR-infected cells (Fig. 6.4), it was concluded that the high levels 
of non-specific binding to proteins by antibodies preclude any firm interpretations of 
the data.
HepG2 cells co-infected with (A) vL and v5D, and (B) vLx and v5D were also probed 
with and anti-L MAb RC28 and anti-core PAb and the bound antibodies were 
detected using appropriate secondary antibody conjugates which were then analysed 
by confocal microscopy. As expected, both MAb RC28 and the anti-core PAb 
recognised the respective proteins with their characteristic distribution in cells (Fig. 
6.10A and 6.1 OB). Interestingly, MAb RC28 failed to recognise the portion of L or 
Lx that had co-localised with core -  in fact, as opposed to the data shown in Figs. 6.6 
to 6.8 where the anti-L MAb RC109 was used to detect Lx, there was a complete 
absence of any colocalisation of the two fluorochromes when probed with MAb RC28 
(Fig. 6.IOC). This effect was evident only with MAb RC28, as RC109 (and the other 
anti-L MAbs RC9 and RC152 were able to recognise the L or Lx protein co-localised 
with core.
6.4 Co-expression of Core with M and S.
It was previously shown that both HBV antigens M and S associate with cytoplasmic 
membranes (see Chapter 5). Here, the intracellular distribution of core and M or core 
and S in co-expressing cells was examined. HepG2 cells were co-infected with rVVs 
vM and v5D or vS and v5D, immunolabelled with appropriate primary and secondary 
antibodies, and analysed by confocal microscopy. As shown in Figs. 6.11 and 6.12, 
the distribution of core protein throughout the cells expressing core alone was 
comparable with those observed in cells co-expressing core and either M or S. There 
was no colocalisation of core with either the M or S protein.
6.5 Discussion
The association of the viral envelope with the nucleocapsid is an area of much study 
in many laboratories, and the mechanisms governing viral assembly and 
morphogenesis still remain unclear. In the work described in this chapter, the 
intracellular distribution of core when co-expressed with the surface antigens has been
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analysed. This was undertaken to enhance our understanding of the processes 
involved in hepadnaviral assembly and morphogenesis.
Existing models of hepadnaviral morphogenesis suggest the core and surface antigens 
associate as the assembled core passes in to the lumen of the ER and obtains an 
envelope of the surface antigens (Bottcher et al., 1998; Bruss and Ganem, 1991; Bruss 
and Vieluf, 1995). An in vitro binding assay using synthetic peptides was used to 
identify two interaction sites on the L protein: one site on the preS 1 domain, and one 
site on the S domain (Poisson et al., 1997; Tan et al., 1999). Tan et. al. suggested a 
synergistic interaction with the two binding sites forming a strong interaction with the 
core protein. Also, it has been shown that the N-terminal 5/6 of the preSl domain of L 
is dispensable for virion assembly (Bruss and Thomssen, 1994), and that the 
extraluminal preS 1 domains of L when embedded in the ER are capable of binding 
the pre-formed nucleocapsid (Ostapchuk et al., 1994); (Bruss and Vieluf, 1995).
The data presented here show that the expression of L with core results in the 
redistribution of core from the nucleus and most of the cytoplasm, and colocalisation 
with the L protein. As the intracellular distribution pattern of L in co-expressing cells 
remained the same as that found in cells expressing L alone and as L is known to 
reside in the ERGIC compartment (Xu et al., 1997), it is reasonable to conclude that 
core is co-localised with L in the ERGIC compartment.
The preSl domain has been reported to interact with core (Bruss and Thomssen, 
1994; Bruss and Vieluf, 1995; Poisson et al., 1997), and the data presented here is in 
agreement with these findings. Furthermore, there is evidence from in vitro studies 
that shows there is a region of S that is involved in binding to core (Poisson et al., 
1997); (Tan et al, 1999). There remains uncertainty regarding the minimal 
requirements for an interaction between the viral envelope proteins and the core. 
Although the intracellular distribution of L upon co-expression with core cannot be 
proven to be residing in the ERGIC in these images, due to the unavailability of 
suitable antisera for triple-labelling of these samples, it is reasonable to assume that 
the localisation of L to the perinuclear compartment in these samples is similar to that 
observed earlier as part of the characterisation of the L expression system, and from 
the results of others. The apparent effect of L on the distribution of core can be seen
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readily from the confocal images, but there is no indication of the minimal 
requirements for this effect. The association of Lx with core remains unclear. The 
data presented here clearly shows that core, when co-expressed with Lx, has a 
widespread cytoplasmic and punctate appearance, with a large proportion of core still 
residing in the nucleus. The appearance of the co-localised core-Lx is similar to that 
of the Lx protein alone, thus, it could be possible that Lx is influencing the 
distribution of core. The results from the electron microscopic analysis of the infected 
cells are insufficiently clear to enable any firm conclusions about the precise location 
of the proteins, and whether the proteins are directly interacting, to be drawn from this 
work.
During the course of this work, extensive efforts were made to co-immunoprecipitate 
core and L or Lx from the cytoplasm of infected cells, and from the medium of 
infected cells. Although it is clear that L and Lx proteins can be readily 
immunoprecipitated by the specific antisera generated in this work (see Chapter 3), it 
proved impossible to co-immunoprecipitate core with any of the surface antigens 
from co-expressing cells.
It was observed that both L and its secretory form of L (Lx) is localised in the 
cytoplasm and in seemingly punctate bodies, and that core colocalised with these 
proteins in co-expressing cells (Figs. 6.1 to 6.3 and 6.6, to 6.8). Interestingly, that both 
L and Lx co-localised with core was detectable with anti-L MAbs RC9, RC109, and 
RC152, but not RC28. The failure of RC28 to recognise Lx when complexed with 
core may be explained by the Lx-core complex having different properties in 
comparison with the L-core, further strengthening the argument for the chief 
interaction between the two proteins being between the preSl domain and the core. 
On account of it being forced through the secretory pathway, the Lx protein is likely 
to be different from the L protein in terms of its tertiary structure and/or post- 
translational processing, e.g. glycosylation. Moreover, it is possible that both L and 
Lx undergo conformational change when bound to core and this together with the 
possible differences in the tertiary structure and/or glycosylation may mask or impede 
the binding of RC28 to the preSl domain of Lx. It is possible that studying the 
interaction of the preSl domain, in the presence and absence of RC28, with the core 
particle could enhance our understanding of the hepadnaviral assembly process.
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Delineation of the structural arrangement of the preS 1 domain bound to core may give 
insights into the scaffolding function of the L protein, and possibly allow the 
evaluation of the RC28 MAb as a means by which the hepadnaviral assembly process 
could be impeded.
It is interesting to note that the epitopes recognised by our anti-L MAbs RC9, RC28, 
RC109, and RC152 all map to similar regions (amino acid residues 15 to 35) of the 
preSl domain (see Fig. 3.15). The inability of RC28 to recognise Lx-core complex (at 
least in this immunofluorescence assay) indicates that the amino acid residues in this 
region of the preSl domain may play a critical role in L-core interaction. 
Furthermore, it is impossible to tell the orientation on the preSl domain the RC28 
MAb binds. The preSl domain must be considered as a three-dimensional molecule, 
and it remains possible that the MAb RC28 binds to the preS21 domain in a different 
orientation in comparison with the other MAbs generated here.
Having established a change in the intracellular distribution of core when co­
expressed with L or Lx, it was therefore of interest to investigate the ability of M and 
S to bind and influence the behaviour of the core protein in the absence of L. In Figs. 
6.11 and 6.12 it is clear that the core protein did not colocalise with the M or S protein 
in our expression systems, leading to the suggestion that the chief requirement for the 
interaction of the envelope proteins with the core is the presence of the preS 1 domain. 
The presence of the second, weaker binding site on the S domain of M and S as 
described by Tan et. al. appears to be insufficient for recruitment of core protein to 
the site of localisation of the smaller surface antigens at least in immunofluorescence 
assay.
The requirement of HBV M for virion morphogenesis and infectivity has yet to be 
proven (Le Seyec et al., 1998), and therefore it is of no surprise that there seems to be 
no effect on core due to the presence of M. The functional relevance of M to the life 
cycle, infectivity and morphogenesis of the human Hepadnaviruses remains unclear.
The failure of S and M to influence the localisation of core is interesting when 
considering the evidence from in vitro studies. Recently, Tan et. al. have shown two 
components of the surface antigen are involved in binding to the core protein. The
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two interaction sites are purported to act synergistically in the association of the core 
and large surface antigen. Here we have explored the potential of the small surface 
antigen alone to affect the intracellular retention and localisation of the core protein, 
and we find there is insufficient interaction between the S and core proteins to result 
in any change in intracellular retention or localisation. This observation may be 
explainable by the binding site in the S domain responsible for binding core being 
insufficiently avid to bind to the core protein in the absence of the preSl domain. 
Alternatively, the interaction site of S may not be in the appropriate orientation or 
conformation due to the established topological differences between the L and S 
proteins (Ostapchuk et al, 1994). It is also possible that the structure of S is different 
to the structure of the S domain of L (see Chapter 6) and that the synergistic 
interaction of the two domains of L is dependant on the conformation of the L protein 
in exposing the available binding epitopes in a manner which may enable efficient 
binding of core.
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Chapter 7
Ligand binding assays
The mechanisms of HBV attachment and entry into the target cell are poorly 
understood. The delineation of this initial step in infection process remains a goal 
common to many laboratories. As with other viruses, infection with HBV is thought 
to initiate by specific binding to cell surface structures via one or more viral envelope 
proteins. There is no effective in vitro cell culture systems for propagation of HBV 
and this has hampered studies on understanding the mechanisms involved in this 
process.
The identification of cellular receptors for the L protein of HBV has so far been 
difficult to achieve. Although there is a body of literature that contains some putative 
receptor identities (Alberti et al., 1987; Atkins et al., 1997; Budkowska et al., 1993; 
Dash et al, 1992; Franco et a l, 1992; Itoh et a l, 1992; Leenders et a l, 1990), there 
remains little evidence to support the role of these proteins in the natural infection.
More recently, progress has been made with the identities of putative cellular 
receptors and the possible mechanisms of entry utilised by the Hepadnaviruses 
(Harvey et a l, 1999; Klingmuller and Schaller, 1993; Qiao et al, 1994). However, 
there remains sparse evidence that the proteins identified in the literature are involved 
in hepadnaviral tropism, therefore workers in the field remain engaged in endeavours 
to identify the cellular receptors for HBV. As a starting point in the study of the 
interaction of the virion with the host cell, the author chose to investigate the binding 
of the preSl domain of HBV to cultured cells. The preSl domain was chosen, 
because this protein is the region of the L protein which is purported to be involved in 
the initial binding of the virus to the hepatocyte (Mabit et a l, 1996; Neurath et a l, 
1988; Petit et a l, 1992). Thus, a series of experiments were designed and executed to 
explore the binding events of the L protein.
7.1. Binding of preSl domain to hepatocvtes.
Flow cytometry was used as a tool by which the interaction of the preS 1 domain with 
the cell surface could be explored. The assay involved incubation of hepatocytes with
85
ooo
oN
lOOx 21-47
c
30
»
MAb C trl
5ug preSl 20 ug preSl
0 ug preSlo
O
FL1-H F L I-H
O -f
wtr
C  ■
30
°oJ
MAb C trl
5ug preSl
0 ug preSlo_
Figure 7.1 HBV preSl domain binding to HepG2 and BHK cells
HepG 2 cells and B H K  cells at near confluence were dissociated from  the m onolayers, w ashed in 
FPBS and incubated w ith the p reS l dom ain in the presence and absence o f  a potentially 
inhibiting peptide 21-47. U nbound ligand w as rem oved by w ashing, the cells were then 
incubated with prim ary antibody RC28, w ashed, then incubated w ith anti-m ouse IgG -FIT C . The 
cells were analysed for fluorescence in FL1 in a BD FA CScan.
Panel A: HepG2 cells incubated w ith 5 and 20 ug o f  p reS l dom ain.
Panel B: HepG2 cells incubated with 20 ug o f  preS l dom ain and lOOx m olar excess o f  peptide 
21-47.
Panel C: BHK cells incubated w ith 5 and 20 ug o f  p reS l dom ain.
purified preSl domain for 1 h at room temperature. Following washing, cells were 
then incubated with MAbs to preSl again for 1 h at room temperature. Cells were 
washed, incubated with an anti-mouse IgG-FITC conjugate as above, washed and the 
bound fluorochrome detected by Fluorescent Activated Cell Sorting (FACS). In order 
to establish which of the monoclonal antibodies generated in this work were active in 
FACS assays, they were evaluated as hybridoma supernatants in a pilot experiment. 
The use of MAbs in the form of hybridoma supernatant in these assays resulted in 
unwanted background reactivity in some of the samples, and necessitated the 
production of one monoclonal in serum-free conditions and subsequent affinity 
purification to obtain an antibody giving rise to negligible background in these assays. 
The supernatants from RC9, RC109 and RC152 showed little reactivity in these 
assays and it was therefore decided to use a purified preparation of RC28 (chapter 3) 
in FACS assays.
To test if the bacterially produced and purified preSl domain bound to the plasma 
membrane, HepG2 or BHK cells were incubated with 5 and 20 pg of preS 1 and the 
bound ligand detected using MAb RC28 as described above. As shown in Fig. 7.1, 
panel A, there was a shift in population of fluorescing cells that were incubated with 
preS 1; the fluorescence intensity obtained at two different concentration of the ligand 
remained the same. In contrast, the preSl domain failed to bind BHK cells (Fig. 7.1, 
panel C), indicating binding of the ligand to the human cells used heere. The level of 
autofluorescence in these cells is low and was used to set the operating parameters for 
this cell line in the FACScan instrument. Cells treated with a control antibody 
exhibited a low level of fluorescence due to the presence of fluorescent molecules 
normally present within living cells (autofluorescence). The level of fluorescence of 
cells incubated with the anti-mouse IgG-FITC in the absence of ligand, and with a 
non-specific primary antibody (MAb H53 directed against the S protein of HBV) of 
the IgG la  subtype was low, and can be seen in the samples labelled ‘MAb Ctrl’ in 
Fig. 7.1, panel A. Clearly, there is little fluorescence due to the binding of IgG la 
molecules (which is the same subtype as MAb RC28) on the plasma membrane. The 
specificity of preSl binding to HepG2 was demonstrated by pre-incubating the cells 
with a 100-fold molar access of a synthetic peptide (peptide 21-47) corresponding to 
the amino acids 21 to 47 of preSl. As shown in Fig. 7.1 panel B, the binding of the
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Figure 7.2A-C HBV preSl domain binding to non-hepatocyte cells
COS7 cells at near confluence were dissociated from  the m onolayers, w ashed in FPBS and 
incubated with the p reS l dom ain. CEM 4 and C C R F-C EM 4 cells were taken from  suspension 
culture, washed in FPBS and incubated with the p reS l dom ain. U nbound ligand w as rem oved 
by w ashing, the cells were then incubated w ith prim ary antibody RC28, w ashed, then incubated 
w ith anti-m ouse IgG -FITC. The cells were analysed for fluorescence in FL1 in a BD FA CScan. 
Panel A: COS7 cells incubated w ith 20 ug o f  preS l dom ain.
Panel B: CEM 4 cells incubated with 20 ug o f  p reS l dom ain.
Panel C: CCRF-CEM 4 cells incubated with 20 ug o f  p reS l dom ain.
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Figure 7.2D-E HBV preSl domain binding to hepatocyte-derived cell lines.
H5 and H16 cells at near confluence were dissociated from the m onolayers, w ashed in FPBS 
and incubated w ith the p reS l dom ain in the absence or presence o f  lOOx m olar excess o f  
peptide 21-47. U nbound ligand was rem oved by w ashing, the cells were then incubated w ith 
prim ary antibody RC28, w ashed, then incubated w ith anti-m ouse IgG -FIT C . The cells were 
analysed for fluorescence in FL1 in a flow cytom eter.
Panel D: H5 cells incubated with 20 ug o f  p reS l dom ain in the presence or absence o f  peptide 
21-47.
Panel E: H16 cells incubated with 20 ug o f  p reS l dom ain in the presence or absence o f  
peptide 21-47.
ligand to cells was completely abrogated in the presence of peptide, indicating that 
preSl bound specifically to a receptor(s) on HepG2 cells. The amino 21 to 47 of 
preSl has previously been shown to be the region involved in receptor recognition 
(Gerlich et al., 1993).
Having established that the preSl domain bound to HepG2 and not BHK cells, 
experiments were conducted in order to assess the binding of this ligand to a variety 
of cell lines of human hepatocyte origin, human non-hepatocyte origin, and non­
human origin. COS-7 (African green monkey kidney cell line), CCRF-CEM4 and 
CEM4 (both of human lymphocyte origin and phenotypically similar), and H5 and 
H I6 (both derived from primary human hepatocyte and described in Chapter 4) were 
used to examine the plasma membrane binding of the preSl domain in FACS assays. 
From comparison of the fluorescence intensities in the cells incubated with ligand, 
primary and secondary antibodies with the cells incubated with the control H53 MAb 
(Fig. 7.2, panels A-C), it was clear that there was no binding of the preSl domain to 
the plasma membranes of the COS-7, CEM-4 and CCRF-CEM4 cell lines. However, 
there was clearly preSl binding demonstrable on the plasma membranes of the H5 
and H I6 cell lines, represented by an order of magnitude increase in fluorescence in 
the samples incubated with 20pg of the preSl domain (green line) (Fig. 7.2, panels D 
and E). The affinity of the preSl domain to H5 and H16 cells was higher than that on 
HepG2 cells, as judged by the relative shift in fluorescence peaks seen in these 
samples (compare Fig. 7.1 panels A and B to Fig. 7.2 panels D and E). As in Fig. 7.1, 
inhibition of preSl binding to H5 and H I6 cells was attempted by pre-incubating the 
cells with the peptide 21-47 prior to incubation with the preSl domain. In Fig. 7.2 
panel D, it was observed that the fluorescent intensity of the cells pre-incubated with 
the peptide 21-47 is similar to that of the MAb control (ctrl) cells, indicating that the 
preSl interaction of preSl with cell surface protein(s) on H5 cells occurs via amino 
acids 21-47. However, when H I6 cells are used in similar experiments, (Fig. 7.2, 
panel E) there is no comparable inhibition of the binding of the preSl domain to the 
plasma membrane by pre-incubation with the 21-47 peptide. The control experiments 
show low levels of autofluorescence and non-specific binding of the MAb RC28 for 
these assays (Fig. 7.2 panels A to E, samples labelled MAb Ctrl) which is in keeping 
with the results depicted in Fig. 7.1. The results presented in Figs. 7.1 and 7.2
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Figure 7.3 HepB3 binding to HepG2, COS7 and H5 cells.
H epG 2, CO S7 and H5 cells at near confluence were dissociated from  the m onolayers, washed 
in FPBS and incubated with the Hepagene protein in the presence and absence o f  the preS l 
dom ain for inhibition. Unbound ligand was rem oved by w ashing, the cells w ere then 
incubated w ith prim ary antibody H53, w ashed, then incubated w ith anti-m ouse IgG -FITC. 
The cells were analysed for fluorescence in FL1 in a flow  cytom eter.
Panel A: HepG2 cells incubated with HepB3 and preS l dom ain.
Panel B: COS7 cells incubated with HepB3 and p reS l dom ain.
Panel C: H5 cells incubated w ith HepB3 and p reS l dom ain.
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Figure 7.4A-B Assessment of vLx protein binding to H5 cells.
Panel A: To assess the level o f  binding o f  the Lx preparation the cell line H5 was grow n to near 
confluence, dissociated from the m onolayer, w ashed in FPBS and incubated with increasing 
am ounts o f  the vL x-enriched preparation. The unbound ligand was rem oved by w ashing and the 
cells w ere then incubated w ith M Ab RC28. The unbound RC28 was rem oved by w ashing and the 
bound com plexes labelled with anti-m ouse-IgG -FITC .
Panel B: The preparation o f  the Lx protein from the m edium  o f  vL x-infected  BH K  cells. The 
infected cell supernatant was clarified and overlaid onto a 20%  sucrose cushion in a SW 28 rotor, 
at 28K r.p.m . for 4 hours. The pellet was resuspended, overlaid on a 15-45% sucrose gradient, 
centrifuged a TST41 rotor at 40K r.p.m . for four hours and then fractionated from  the top in 1 mL 
fractions. The fractions were then analysed by SD S-PAG E on a 10% acrylam ide gel, follow ed 
by w estern blotting w ith M Ab RC28 and the im m une com plexes were visualised by 
chem ilum inescence. It should be noted that the proteins visible by the w estern blot in this figure 
were indiscernible by coom assie blue staining o f  the fractions analysed by SD S-PAG E, hence the 
use o f  w estern b lotting to dem onstrate the presence o f  Lx proteins.
demonstrated that the preSl domain is capable of binding specifically to cells of 
human hepatic origin.
7.2. Binding of HepB3 and Lx protein to hepatocvtes.
In addition to the preS 1 domain, two other ligands in the form of HepB3 particle 
preparation (kindly donated by Medeva, UK) and a partially purified Lx protein were 
also tested for their ability to bind cells in FACS assay. The FlepB3 preparation 
contains a mixture of particles composed of the S protein with an inserted region of 
the preSl domain. HepG2, COS-7, or H5 cells were incubated with HepB3 particles 
alone or with the preSl domain, and the bound particles were detected using anti-S 
MAb H53. As shown in Fig. 7.3 panels A to C, the particles bound to all the cell lines 
tested. Furthermore, the preS 1 domain failed to block binding of HepB3 particles to 
cells. These results are in contrast to the preSl domain, which was shown to bind 
specifically to human hepatocytes and not COS-7 cells (Figs. 7.1 and 7.2). It should 
be noted that the shift in the fluorescing cells seen in Fig. 7.3 is not due MAb 53 
binding non-specifically to cells, as this MAb does not produce background 
fluorescence (Figs. 7.1 and 7.2). Thus, it would appear that the shift in fluorescence 
seen in Fig. 7.3 is due to recognition by MAb H53 of cell-bound HepB3 articles. The 
conclusions that can be drawn from the failure of the preSl domain to inhibit the 
binding of the HepB3 particles are that either the HepB3 particles are binding non- 
specifically to the plasma membranes of cells, or that the binding is specific and is 
mediated through the S domain of the particles. In either case, the HepB3 particle is 
unsuitable for investigation of the binding of the preS 1 domain to cells.
To test the ability of the Lx protein to bind to H5 cells, it was first partially purified as 
described in Fig. 7.4 (panel B). However, the yield of the protein was very low 
suggesting that a major effort outside the author’s remit was required to produce the 
Lx protein in large quantities and to develop appropriate purification protocols. 
However, the small quantities of the partially pure Lx generated as described in Fig.
7.4 (panel B) was used in FACS assays which showed that there was a small increase 
in fluorescent intensity of the H5 cells when incubated with increasing amounts of the
Figure 7.5. Confocal-based assay to assess Lx binding to plasma membranes of HepG2, 
COS7 and H5 cells.
H epG 2, CO S7 and H5 cells were grow n in 24-well plates on glass coverslips for three days, 
then w ere incubated with the Lx preparation, a W R -derived preparation, or m ock antigen, in 
D M EM  for one hour at 4°C. The unbound antigens were w ashed w ith DM EM  and the cells 
were incubated w ith M Ab RC28 for one hour. A fter w ashing, the cells were labelled with 
anti-m ouse-IgG -FITC  and were exam ined for fluorescence w ith a Zeiss L aser Scanning 
Confocal m icroscope.
Panels A and D: COS7, and HepG2 cells, respectively, w ith W R-derived purified  protein. 
Panels B and E: COS7, and HepG2 cells, respectively, w ith m ock antigen.
Panels C and F: COS7, and HepG2 cells, respectively, w ith purified Lx protein.
Figure 7.5. Confocal-based assay to assess Lx binding to plasma membranes of HepG2, 
COS7 and H5 cells (continued).
G: H5 cells, w ith W R -derived purified protein.
H: H5 cells, and HepG 2 cells, w ith m ock antigen.
I: H5 cells, and HepG2 cells, w ith purified Lx protein.
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Figure 7.6A. Scanning Electron Microscopy-based assay to assess preSl domain binding 
to plasma membranes of COS7 cells.
COS7 cells were grow n in 24-w ell plates on glass coverslips for th ree days, then were 
incubated w ith p reS l dom ain, or m ock antigen, in D M EM  for one hour at 4°C. The unbound 
antigens were w ashed w ith D M EM  and the cells w ere incubated w ith M A b RC28 for one 
hour. A fter w ashing, the cells were incubated with anti-m ouse-IgG -30 nm . gold conjugate, 
washed and fixed in 2.5%  glutaraldehyde. The cells were dehydrated  in ethanol, dried by 
critical-point d isplacem ent w ith CO2 and coated w ith carbon. The sam ples w ere analysed by 
secondary electron detection (panels A and D), by back-scatter analysis (panels B and E) and 
by reverse back-scatter (panels C  and F).
Figure 7.6B. Scanning Electron Microscopy-based assay to assess preSl domain binding 
to plasma membranes of HepG2, cells.
HepG 2 cells were grow n in 24-well plates on glass coverslips for three days, then were 
incubated w ith p reS l dom ain, or m ock antigen, in DM EM  for one hour at 4°C. The unbound 
antigens w ere w ashed with DM EM  and the cells were incubated w ith M A b RC28 for one 
hour. A fter w ashing, the cells were incubated with anti-m ouse-IgG -30 nm . gold conjugate, 
w ashed and fixed in 2.5%  glutaraldehyde. The cells were dehydrated  in ethanol, dried by 
critical-point displacem ent w ith CO 2 and coated with carbon. The sam ples were analysed by 
secondary electron detection (panels A and D), by back-scatter analysis (panels B and E) and 
by reverse back-scatter (panels C and F).
Figure 7.6C. Scanning Electron Microscopy-based assay to assess preSl domain binding 
to plasma membranes of H5 cells.
H5 cells were grown in 24-w ell plates on glass coverslips for three days, then w ere incubated 
w ith preS l dom ain, or m ock antigen, in D M EM  for one hour at 4°C. The unbound antigens 
were washed with DM EM  and the cells were incubated w ith M Ab RC28 for one hour. After 
washing, the cells were incubated w ith anti-m ouse-IgG -30 nm. gold conjugate, w ashed and 
fixed in 2.5%  glutaraldehyde. The cells were dehydrated  in ethanol, dried by critical-point 
displacem ent with C O 2 and coated w ith carbon. The sam ples were analysed by secondary 
electron detection (panels A and D), by back-scatter analysis (panels B and E) and by reverse 
back-scatter (panels C and F).
Lx preparation. Due to the small amount of Lx protein recovered from the infected 
vLx cells, it was possible only to evaluate binding, but not specificity by inhibition in 
these experiments.
An attempt was also made to investigate the binding of the Lx protein preparation to 
the plasma membrane of HepG2, H5 and COS-7 cells by confocal microscopy. In 
this experiment, the cultured cells were incubated with the Lx protein preparation, a 
mock antigen, or a preparation obtained from the medium of WR-infected cells and 
then probed with the MAb RC28 and anti-mouse IgG-FITC, then fixed and analysed 
for fluorescence. In Fig. 7.5, panels A-I, the images of the plasma membrane 
fluorescence from HepG2, H5 and COS-7 cells are shown. There was fluorescence 
discernible from all of the plasma membranes of the cells in each panel. The 
fluorescent images showed no localisation on the plasma membranes that are found 
only in the cells incubated with the Lx preparation. Furthermore, there was no 
discernible difference in the intensity of the fluorescence of the plasma membranes 
between the cell lines, or within the same cells incubated in the presence or absence of 
a ligand. It should be noted that during the course of this experimentation, the 
parameters used in the controlling software for the Laser Scanning Confocal 
Microscope remained constant throughout. The use of constant amplification and 
laser excitation parameters was intended to allow any discernible difference in the 
intensities of the plasma membrane fluorescence to become visible from examination 
of the image. However, it was the case here that there was no discernible difference 
between any of the images obtained.
It was apparent from the results obtained by flow cytometry, that the preS 1 domain 
and Lx bound specifically to the plasma membrane of the HepG2 and H5 cell lines. 
The confocal assay used here (Fig. 7.4) to examine the plasma membrane binding of 
the Lx protein yielded no useful results, so the author utilised Scanning Electron 
Microscopy in order to attempt the visualisation of the preSl domain to the plasma 
membrane of the HepG2 and H5 cell lines. Due to the larger increase in the 
fluorescent intensity of the HepG2 and H5 cells when incubated with the presl 
domain, in comparison with those incubated with the Lx preparation, it was prudent to 
examine the preSl domain binding to the plasma membrane of cells in these 
experiments. The incubation of the cells with the preSl domain was performed on
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glass coverslips in 24-well plates and probed with MAb RC28, followed by anti­
mouse IgG-gold conjugate (30nm). The samples were analysed for secondary electron 
detection, backscatter and reverse backscatter in a JEOL SEM T100. The results 
shown in Figs. 7.6 A to C show secondary electron detection (panel A), backscatter 
(panel B) and reverse backscatter (panel C). The negative control samples were 
incubated with mock antigen (PBSA) and then probed with the same primary and 
secondary antisera and analysed for secondary electron detection (panel D) 
backscatter (panel E) and reverse backscatter (panel F). The morphology of the COS- 
7 cell chosen for Fig. 7.6 is clearly apparent from the image in panel A and was 
typical of the COS-7 cells grown in this laboratory. Visualisation of the gold 
conjugate is readily apparent in panel B (white spots) and also in panel C (dark spots). 
The presence of the gold conjugates on the plasma membranes of COS-7, H5 and 
HepG2 cells is clearly visible in these figures. However, the negative controls for 
these experiments showed similar amounts of gold conjugate labelling on the plasma 
membranes of all the cells analysed in these experiments (panels D, E and F). The 
absence of any indication of binding of the preSl domain to the plasma membrane 
may be due to one or more factors; it is possible that there is poor recognition of the 
MAb RC28 by the anti-mouse -gold conjugate: it may also be possible that the 
expression of MHC proteins on the plasma membrane of the cells binds the anti­
mouse-gold conjugate, leading to a ubiquitous signal on all cells. This data contrasts 
with the data obtained from the cytometry experiments described earlier in this 
chapter.
7.3 Discussion.
The binding of the preS 1 domain to hepatocytes and non-hepatocyte-derived cell lines 
has been investigated by flow cytometry. It has been shown that the preSl domain 
binds to established and novel human hepatocyte cell lines, and binds specifically to 
HepG2 cells, and H5 cells. There was little or no binding of the preSl domain to 
COS-7 cells, CEM-4 or CCRF-CEM4 cells in these assays. The demonstration of 
specific and inhibitable binding of the preSl domain to established cell lines and to 
one of our novel cell lines, and the absence of binding to non-human and non-hepatic 
cell lines implies that the use of the preS 1 domain for studying the interaction of the L 
protein with the plasma membrane proteins of the cell is appropriate for these types of 
investigation. The results are in agreement with previously published data that
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implicates preSl regions in binding to cell surface receptor. From the results 
described in this chapter it would appear that the preSl domain recognises a human 
hepatocyte specific receptor(s). It is intriguing to note that the preSl domain bound 
much more efficiently to H5 cells compared to HepG2, and moreover this binding 
was subject to dose-dependent inhibition by peptide 21-47 implicating this region in 
receptor recognition. Thus, the FACS-based assay developed in this study, together 
with the availability of a novel human hepatocyte cell line H5 would provide a basis 
to identify and clone the receptor(s) for preS 1.
The absence of any meaningful results from the confocal microscopy-based and 
scanning electron microscopy-based assays for the binding of the preS 1 domain to the 
plasma membranes demonstrates the difficulties associated with these assays. Clearly 
more work is required to eliminate the occurrence of high background presumably 
due to non-specific binding of primary and/or secondary antibodies or appropriate 
detection reagents to cells in these assays.
The demonstration of specific binding of HBV ligands to plasma membrane proteins 
has been notoriously difficult and has severely hampered progress in this field. It 
remains possible that the use of recombinant proteins such as the preSl domain used 
here represents a sub-optimal assay system for investigation of the early events 
involved in receptor binding. The current regulations restricting workers to category 
three containment for use of viable HBV prevented the author investigating the early 
stages of infection of hepatocytes by HBV. Thus, the only avenue of investigation is 
to examine the early stages of the infection process is to use recombinant proteins 
instead of the infectious agent. A useful avenue of investigation would be to examine 
the binding of purified HBV in the presence and absence of inhibitory agents such as 
the preSl domain and purified S from the serum of infected patients. However, in 
experimental investigation to identify the receptor for the L protein, it would be useful 
to use the preSl domain to study the interaction of the protein of the L protein 
purported to be involved in the initial steps of binding to the plasma membrane 
proteins. It is likely that the S protein is involved in binding to annexin V on the 
plasma membrane, and the presence of the S domain in the L protein could lead to 
confusion in interpretation of results. Thus, the use of the preS 1 domain in order to 
identify the cellular receptor for the L protein is a sound strategy, and has been used
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to good effect in the search for the DHBV receptor (Breiner et al., 1998) and 
subsequent characterisation of the ligand-receptor complex (Urban et al., 1999).
Chapter 8 
Conclusion.
In this study, the various roles played by the HBV surface antigens (S, M and L) in 
virus infection, assembly and morphogenesis has been investigated. To carry out this 
work, it was essential to generate a wide range of reagents. The surface antigens were 
expressed using a recombinant vaccinia virus and bacterial system. The bacterially 
expressed preS 1 domain of the L antigen was used to generate a panel of MAbs and 
PAbs. The antibodies generated in house and those obtained from elsewhere were 
used to confirm the expression of viral proteins by recombinant vaccinia virus 
system. A detailed analysis of the antigenicity of the HBV surface antigens and core 
was undertaken to confirm that the intracellular behaviour of the expressed proteins 
was in keeping with the previously published data. The reactivities of the MAbs and 
PAbs were characterised in detail in ELISA, Western Blot, immunofluorescence and 
immunoprecipitation assays. Comprehensive analysis of the reactivities of the 
antibodies directed against the L protein has shown that all of the anti-preS 1 MAbs 
generated here are reactive to amino acids 15-35 of the preSl domain. Furthermore, a 
previously uncharacterised anti-S MAb, 6B1, was shown to recognise a 
discontinuous epitope in S and this MAb was used to generate new data concerning 
the antigenicity and conformation of the surface antigens. These antisera have been 
instrumental in the work described in Chapters 5, 6 and 7.
Given the hepatotropic nature of HBV and its inability to replicate efficiently in 
existing hepatocyte cell lines, the potential value of stable hepatocyte cell lines as a 
HBV research tool cannot be underestimated. The inability of HBV to replicate 
efficiently in culture is likely due to the lack of certain liver-specific functions in cells 
cultured in vitro. There is a considerable interest in generating novel hepatocyte cell 
lines as their relevance to hepatotropic virus research is obvious. Furthermore, the 
applicability of these lines on a wider scale to the biotechnology industry, e.g. for
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examination of the metabolism and toxicity of compounds (which has so far seen 
HepG2 used as a preferred cell line) is immense. In this study, the novel hepatocytes 
(H5 and H I6) generated in-house from a healthy human liver were characterised 
partially for expression of certain cellular markers. The analysis of intracellular 
markers such as cytokeratins 8 and 18, alpha-1-anti-trypsin and alpha-fetoprotein has 
lead the author to suggest that these novel cell lines (H5 and H I6) are likely to have 
retained salient phenotypic markers of hepatocyte differentiation. The retention of 
these markers shows there is some likelihood that these cell lines are representative of 
the phenotype found in hepatocytes in the healthy liver. However, further evaluation 
of the appropriate proteins and mRNAs in the H5 and H16 cell lines is required to 
confirm the hepatocyte phenotype. This work was not done here as it was considered 
to be outside the scope of this project. The novel cell lines H5 and HI 6, as well as the 
well-characterised HepG2 and Huh7 cells were used in the work described in 
Chapters 5, 6 and 7. Overall, the results obtained are promising and suggest that these 
cell lines should be assessed for the ability to support infection and replication by 
HBV (and HCV) as soon as is practicable.
The structure of the surface antigens was evaluated immunologically to shed light on 
the conformation and transmembrane topology of these proteins. The anti-S MAb 
6B1 that reacts with a conformational epitope present on S interestingly fails to 
recognise L. Thus, recognition of S, but not the S domain of L, in both 
immunofluorescence and immunoprecipitation by this MAb is evidence to suggest 
that there are significant differences present in structure of the S domains of the S and 
L proteins. Furthermore, the recognition of M by the MAb 6B1 is demonstrated, 
suggesting that the L protein has differently structured S domains than the M and S 
proteins. Current computer generated models of HBV surface antigen topology 
depict no overall differences in the structure of the S domain of L and M to HBsAg 
(see Introduction, Fig. 1.3). However, biochemical evidence to support this 
hypothesis has been lacking. In this study, using a novel MAb it has been shown 
experimentally for the first time the existence of structural differences between the S 
domain of L and the S protein. It would seem plausible that the MAb 6B1 epitope on 
S is masked by the preS domains of L, accounting for non-recognition of L, but given 
the dual topology of the L protein it is likely that at least 50% of S epitopes would be 
exposed for recognition by MAb 6B1. However, 6B1 does not recognise L at all,
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clearly pointing to recognition of a structurally different S domain in L. Clearly, 
further experiments are required to ascertain where the differences may lie.
The MAb 6B1 has also been valuable in studying the intracellular distribution and 
behaviour of the L and S (and Lx and S, and M and S). It was shown that the 
intracellular retention of the L protein in the ER/ERGIC is abrogated by the 
expression of S, resulting in a membrane-associated complex of proteins distributed 
throughout the cell. The expression of Lx and S results in a wide distribution of 
tightly co-localised proteins throughout the cytoplasm, with S no longer associating 
with the intracellular membranes. Furthermore, to confirm both of these 
observations, anti-L antisera have been used to demonstrate the co- 
immunoprecipitation of L with S, and Lx with S. Taken together, these results 
clearly indicate that L and S specifically interact with each other. Wunderlich and 
Bruss (1996) demonstrated multimerisation between S and L, indicating that this 
event may potentially mediate budding of HBV particles. Thus, the author 
demonstrates in Chapter 5 the existence of a novel reagent capable of distinguishing 
between surface antigens, and analyses the intracellular behaviour of the proteins 
when expressed singularly or co-expressed.
The intracellular interactions of the surface antigens with core have been investigated 
using the reagents generated and described in Chapter 3. The expression and 
distribution of the core protein in hepatocytes and other cell lines when co-expressed 
with surface antigens has generated new data concerning the morphogenesis of HBV. 
The results presented here show that expression of core results in a nuclear and 
cytoplasmic distribution, but upon co-expression with L, the core protein is tightly 
retained in the ER/ERGIC, the same compartment known to retain the L protein (as 
demonstrated in Chapter 6). Redistribution of core is not observed when co-expressed 
with either M or S. This information adds useful data to the existing literature base. 
Recent reports have shown in vitro interactions between the S domain and core, and 
the preSl domain and core. However, data presented here show that the presence of 
M or S alone is insufficient to redistribute the core indicating a lack of, or a weak 
intracellular interaction between the proteins. The lack of recognition by MAb RC28 
of L bound to core points to involvement of the epitope on the preSl in the 
interaction of the core. Taken together, these results lead the author to reason that the
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predominant influence in the association of the envelope with the core is due to the 
presence of the preSl domain of L. However, it is possible that the structure of the S 
domain in L is disposed to interaction with the core protein, since this domain in L 
has been shown in this study to be conformationally different from HBsAg. The 
association of core with Lx is also demonstrated throughout the cytoplasm of co­
expressing cells, suggesting that although the Lx protein is not retained intracellularly 
in the same manner as L, the Lx retains the ability to colocalise and interact with core 
within the cytoplasm.
The investigations of the binding of the HBV-derived ligands to the cell lines 
described in Chapter 7 have shown several new findings. The binding of the preSl 
domain to the plasma membrane of human hepatocytes (HepG2 and H5) has been 
shown to be specific and inhibitable. There was an absence of binding to cells of 
lymphoblastic origin (CEM 4) and non-human cell lines (COS-7). Inhibition of the 
preSl domain by the 21-47 peptide is in keeping with the inhibition of binding of the 
virus to immobilised plasma membrane proteins described in the literature. That the 
preS 1 domain binds in a similar manner to HBV to the plasma membrane of HepG2 
and H5 cells, suggests that this ligand is a suitable substitute for L and could be 
utilised in the search for the cellular receptor for HBV. The differences between the 
H5 and H I6 cell lines are of considerable interest. Both cell lines were derived from 
a healthy liver donor and have been immortalised and partially characterised 
indicating a high likelihood of retention of a hepatocyte phenotype. The inability of 
the H I6 cell line to bind the preSl domain in the same manner as the H5 and HepG2 
cell lines may indicate that there is a difference in expression of an as yet unidentified 
receptor or co-receptor in these cell lines. Alternatively, the difference in binding of 
the preSl domain to H16 may indicate that this cell line has differentiated over time 
to a non-hepatocytic phenotype. Thus, the importance of a detailed analysis of the 
H5 and H I6 cell lines should offer considerable insight into the hepatocyte-specific 
binding of the HBV surface antigens. It is conceivable that expression of a co­
receptor for the preSl domain is occurring in only one of these novel cell lines and 
that the true retention of an hepatocyte phenotype may be responsible for expression 
of this co-receptor.
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This research presented here has generated novel information concerning HBV 
surface antigen structure, virion morphogenesis and receptor binding. Additionally, a 
comprehensive array of novel reagents has been generated and characterised, many of 
which hold a great deal of promise for future HBV research in this laboratory.
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Appendix 1
The hybridoma supernatants from MAbs RC9, RC28, RC109, RC152 were used at a 
dilution of 1:1000 for indirect immunofluorescence.
PAbs 142 and 143 were used at a dilution of 1:4000 for indirect immunofluorescence. 
MAb 6B1/1 (obtained from Dr. Connal McCaughey, Queen's university of Belfast) 
was used at a dilution of 1:100 for indirect immunofluorescence.
Anti-p53 MAb 91/93 was used at 1:100.
Anti-human serum albumin (Sigma) was used at 1:50.
Anti-human alpha-1-antitrypsin (Sigma) was used at 1:100.
Anti-apolipoprotein (Calbiochem) was used at 1:200.
Anti-human plasminogen (Sigma) was used at 1:100.
Concanavalin-A-FITC (Sigma) was used at 1:200.
MAbs H I66, H35, RF7 and H53 used at 1:100 for immunofluorescence. These 
antibodies were obtained from the laboratory of Dr. W. F. Carman. Relevant 
literature concerning the reactivities of these antisera can be found in Chen et. al 
(1996). Anti-Annexin V MAb was also obtained from Dr. Carman’s laboratory and 
was used at 1:50.
MAb 18/7 was kindly donated by Prof. W. H. Gerlich (Geissen, Germany) and was 
used at a dilution of 1:1000.
MAb 2-12F2 was kindly donated by Prof. W. H. Gerlich (Geissen, Germany) and was 
used neat.
MAb 2A23 was obtained from the Institute of Immunology, Osaka, Japan, and was 
used at 1:100.
Anti-mouse-IgG-FITC (Sigma) was used at a concentration of 1:100, anti-rabbit IgG- 
FITC (Sigma) was used at 1:100, anti-rabbit-IgG-cy5 (Amersham) was used at 1:200, 
and anti-mouse-IgG-cy5 (Amersham) was used at 1:100.
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AT C T CT  CCA C C A C T A AGA GAC AGT  3 8 4
S T A F H Q A L  1 2 0
T CT  ACA GCA T T C  CAC CAA GCT  C T A 4 3 2
Y F P A G G S  S 1 3 6
T AT T T T  CCT  GCT  GGT GGC T CC AGT  4 8 0
T I A S H I S S  1 5 2
ACT  AT T  GCC T CT  CAC AT C  T C G T C A 5 2 8
r*-s
A P N M E N I T  1 6 8
GCA CCG AAC AT G GAG AAC AT C  AC A 5 7  6
V L Q A G F F L  1 8 4
GT G T T A CAG GCG GGG T T T  T T C  T T G 6 2 4
Q S L D S W W T  2 0 0
CAG AGT  CT A GAC T CG T GG T GG AC T  6 7 2
P V C P G D N S  2 1 6
CCC GTG T GT CCT  GGC C T A AAT  T C G 7 2 0
P O S C P P T C  2 3 2
CCA AT C TCC T GT  CCT  C C A AC T  T GT  7 6 8
R R F I I F L F  2 4 8
CGG CGT T T T  A T C  A T A  T T C  C T C  T T C  8 1 6
I L L L C L I F L L V L L D Y Q 2 6 4
ATC CTG CTG CTA TGC CTC ATC TTC TTG TTG GTT C T T C T G GAC TAT CAA 8 6 4
G M L P V C P L I P G S S T T S 2 8 0
GGT ATG TTG CCC GTT TGT CCT CTG A T T CCA GGA TC C T C G ACC ACC AGT 9 1 2
T G P C K T C T T P A Q G N S M 2 9 6
ACG GGA CCC TGC AAA ACC TGC ACG ACT CCT GCT CAA GGC AAC TCT A T G 9 6 0
Y P S C C C T K P S D G N C T C 3 1 2
TAT CCC TCA TGT TGC TGT ACA AAA CCT TCG GAC GGA A A T TGC ACC TGT 1 0 0 8
I P I P S S W A F A K Y L W E W 3 2 8
A T T CCC ATC CCA TCA TC T TGG GCT TTC GCA AAA TAC C T A TGG GAG TGG 1 0 5 6
A S V R F S W L S L L V P F V Q 3 4 4
GCC TCA GTC CGT TTC TC T TGG CTC AGT TTA CTA GTG C C A T T T GTT CAG 1 1 0 4
W F V G L S P T V W L S A I W M 3 6 0
TGG T TC GTA GGG C T T TCC CCC ACT GTC TGG CTT T C A G C T A T A TGG A T G 1 1 5 2
M W Y W G P m L Y N I L S P F I 3 7 6
ATG TGG TAT TGG GGG CCA AAT CTG TAC AAC ATC T T G A G T CCC T T T A T A 1 2 0 0
P L L P I F F C L W V Y I - 3 8 9
CCG CTG TTA CCA A T T TTC T T T TGT C T T TGG GTA TAC A T T TAA A C CCTAA CC 1 2 5 1
AA GCTT 1 2 5 7
H in d l l l
The nucleotide sequence o f  the ORF encoding the secretory form  o f  HBV  (subtype adw ) 
L (Lx). The am ino acid sequence in blue box represents the secretory  signal sequence o f 
the vaccinia virus 35 kDa polypeptide. The translational start sites o f  HBV  L, M and S 
are show by an arrow. The amino acid sequence is num bered from the initiating 
m ethionine o f  the L protein. The nucleotide sequences encoding  HBV preS l dom ain, L
and M were derived by subcloning or PCR from that o f  Lx (see M ethods and M aterials,
section .....). The relevant restriction enzym e sites used in cloning  are shown. The am ino 
acid sequence highlighted in burgandy represent the 21 to 47 region o f  the p reS l dom ain 
involved interaction with a putative receptor. Com parison o f  the am ino acid sequence o f  
our L w ith those in the Sw issProt database identified several unique residues at variant 
and invariant positions. These are highlighted in red or green, respectively.
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